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 HIV-1 is an enveloped RNA virus that recruits cellular machinery to facilitate 
virus budding.  HIV-1 Gag, the structural protein that drives the assembly and budding 
processes, binds directly to two cellular factors, TSG101 and ALIX.  Both TSG101 and 
ALIX are proteins in the endosomal sorting complexes required for transport (ESCRT) 
pathway and are required for inward vesicle formation at late endosomes or 
multivesicular bodies (MVBs).  Most ESCRT proteins are subunits one of five hetero-
oligomeric complexes named ESCRT-0, ESCRT-I, ESCRT-II, ESCRT-III, and the VPS4 
AAA ATPases (vacuolar protein sorting), which are sequentially recruited to sites of 
vesicle formation and virus budding.  TSG101 is a member of the ESCRT-I complex and 
is involved in recognition of cargos and recruitment of ESCRT-II.  ESCRT-II recruits 
ESCRT-III, which is composed of charged multivesicular body proteins (CHMPs) that 
coassemble to form a lattice on the surface of endosomal membranes.  ALIX interacts 
with proteins in both ESCRT-I and ESCRT-III, but is not a constitutive member of either 
complex.  ESCRT-III proteins bind directly to the VPS4 AAA ATPases, which are the 
only known enzymes in the pathway.  ATP hydrolysis by the VPS4 ATPases releases all 
assembled ESCRT machinery, allowing multiple rounds of vesicle formation or viral 
egress.  This thesis focuses on the identification and characterization of components of 
the human ESCRT protein network involved in HIV-1 budding. 
 iv 
Chapter 2 describes my contribution to the identification of the protein network 
involved in HIV-1 budding.  Discovery of new protein-protein interactions in the ESCRT 
pathway defined bridges between complexes that act early in the pathway and those that 
act late.  Chapter 3 describes the role of ESCRT-I in HIV-1 budding.  Specifically, I 
identified four previously unknown subunits of human ESCRT-I (VPS37A-D) and 
characterized the biochemistry of VPS37B.  Finally, Chapter 4, Appendix and Appendix 
B describe the interaction between the CHMPs of ESCRT-III and the VPS4 MIT 
domains.  My contribution to these sections was the identification of the regions of 
required for the complex interactions.  Specifically, I identified a C-terminal motif found 
in CHMP 1-3 that binds the VPS4 MIT domains.  Structural studies of the 
VPS4B/CHMPB complex revealed that the CHMP2B peptide binds to the antiparallel 
three helix bundle of the VPS4B MIT domain between helices two and three, and 
suggested two plausible models for the complex.  Overall, the data presented here support 
the model that HIV-1 usurps the human ESCRT pathway to enable virus budding, and 
help to define the interactions that allow this pathway to facilitate MVB vesicle formation 
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HIV and AIDS Prevalence 
 
 Acquired immune deficiency syndrome (AIDS) is one of the most devastating 
diseases to affect the world today.  In 1981, five patients in Los Angeles area hospitals 
presented with symptoms of pneumonia, only to discover later that this was only a 
secondary infection.  These patients were infected with a virus.  Their diagnosis and the 
subsequent identification of the human immunodeficiency virus (HIV) were key early 
events that presented the AIDS epidemic to the world (Barre-Sinoussi et al., 1983; Gallo 
et al., 1984).  Since that time, AIDS and AIDS-related illnesses have killed more than 25 
million people.  According to the World Health Organization (WHO) and the Joint 
United Nations Programme on HIV/AIDS (UNAIDS), Africa remains the epicenter of the 
AIDS pandemic, and more than a third of the recorded deaths in 2005 occurred in Sub-
Saharan Africa.  This large number of deaths in Africa has literally affected the fabric of 
society, as economic growth decreases and the number of orphaned children increases.  
Today it is estimated that 40 million people worldwide are living with HIV (UNAIDS, 
2006).  A detailed understanding of HIV molecular biology therefore remains a key 
objective as part of the effort to defeat this disease and epidemic.   
HIV is an enveloped ribonucleic acid (RNA) virus of the retroviridae family of 
viruses.  HIV-1 and HIV-2 are the two known HIV types and account for all current and 
  
new infections of today.  There are at least nine distinct HIV-1 subtypes (Geretti, 2006; 
Julg & Goebel, 2005).  Most subtypes can be effectively treated by the Antiretroviral 
treatments (ARTs) available today.  However, these drugs are not a cure and only prolong 
the lives of AIDS patients by inhibiting or slowing certain steps in the HIV life cycle.  
Moreover, ART-resistant strains are now prevalent, which necessitates the identification 
of new targets for antiviral therapies (Geretti, 2006; Wainberg, 2004). 
In recent years, there has been significant progress understanding the late stage of 
retroviral replication called budding.  The process of HIV-1 budding occurs when the 
virus becomes entrapped by the plasma membrane, and a membrane fission event 
releases the virion from the cell.  We now understand that HIV-1, the focus of this 
dissertation, does not encode the machinery required for viral egress, suggesting that 
these activities must be provided by host factors.  In 2001, the cellular host factor 
TSG101 was shown to be required for efficient virus budding (Demirov et al., 2002; 
Garrus et al., 2001; Martin-Serrano et al., 2001; VerPlank et al., 2001).  The work, 
described herein, contributed to the identification and characterization of the cellular 
protein network that functions together with TSG101 to aid in the HIV-1 budding 
process.   
 
The HIV-1 Life Cycle 
 
 The HIV-1 life cycle begins when the virus binds a host cell via a direct 
interaction between the viral Env glycoproteins on the virion exterior and CD4 receptors 
on the surface of target cells (Figure 1.1) (Gomez & Hope, 2005; Wang et al., 2000).  
This interaction facilitates a subsequent interaction with one of two co-receptors that are 
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conformational changes in the viral glycoproteins that juxtapose the cellular and viral 
membranes and facilitate membrane fusion.  Fusion of the viral and cellular membranes 
releases the viral “core” into the cytoplasm where it loses its outer capsid shell (a process 
termed “uncoating”) which releases the viral RNA genome (Gomez & Hope, 2005).  
Reverse transcriptase (RT), a viral enzyme that is packaged within the viral core, reverse 
transcribes the HIV genome to produce a DNA copy of the viral genome (Freed, 2001).  
This DNA genome and associated viral and cellular proteins are called the preintegration 
complex (PIC).  The PIC is imported into the nucleus, where the viral DNA genome is 
integrated at random sites in the host chromosomal DNA.  This integrated viral DNA 
copy (termed the “provirus”) is transcribed by RNA polymerase II under the control of 
the viral Tat transactivator to produce both full length viral RNA genomes as well as 
unspliced and singly spliced viral mRNAs (Gomez & Hope, 2005).  Incompletely spliced 
viral RNAs are exported from the nucleus by the viral Rev proteins.  In the cytoplasm 
these RNAs serve as templates for translation of the various viral proteins, including the 
viral Gag (structural proteins), Pol (viral enzymes), and Env (receptor binding/fusion) 
polyproteins.  Approximately 3000 copies of Gag assemble to form each virion.  Gag 
proteins recognize the plasma membrane through the N-terminal matrix (MA) domain, 
and package full length RNA genomes through direct interactions with the downstream 
nucleocapsid (NC) domains (Freed, 2001).  Once virion components have been recruited, 
a spherical particle begins to extrude from the surface of the cell (Figure 1.2).  The virion 
is then released through a fission mechanism that reseals the viral and plasma membranes 
(budding).  The newly released immature virus is not infectious until it advances through 












Figure 1.2. Spherical HIV particles arrested at a late stage of budding.  
EM images of thin-sectioned 293T cells transfected with an HIV expression vector and 
expression constructs for dominant negative (A) DsRed-CHMP4B and (B) DsRed-





























polyproteins by the viral protease followed by reorganization of the cleaved products 
(Freed, 2001).  Viral maturation initiates during budding and is completed soon 
thereafter.  Rearrangements during maturation create a central core particle that contains 
the viral RNA genome and associated enzymes, and is surrounded by a conical shell 
called the capsid (Freed, 2001).  Maturation creates an infectious particle, and completes 
the viral lifecycle. This dissertation focuses on the mechanism by which immature virions 
are released from the infected cell—the process of viral budding.    
 
The HIV-1 Genome and Virion Organization 
 
HIV-1 is a positive sense single stranded RNA (ssRNA) lentivirus.  Lentiviruses 
are defined by their virion structure and organization, genetic composition and manner of 
replication (Coffin et al., 1997).  Lentiviral cores are predominantly conical in shape and 
contain the material required for replication.  The viral RNA genome is approximately 9 
kilobases in size and encodes nine open reading frames (ORFs).  Translation of the ORFs 
ultimately leads to the production of 15 viral proteins because the major proteins are 
initially produced as polyproteins that are processed into a series of smaller mature 
proteins.  The three major polyproteins are Gag, Gag-Pol and Env (Figure 1.3A).  About 
5% of the time, ribosomal frameshifting during Gag translation produces the longer Gag-
Pol polyprotein (Freed, 2001; Jacks, 1990).  Gag-Pol co-assembles with Gag and Gag-Pol 
cleavage produces the essential viral enzymes (Freed, 2001). The six remaining ORFs 
encode for accessory proteins that aid HIV at multiple stages of viral replication. 
 
Gag Polyprotein 












Figure 1.3. HIV-1 genome and gag open reading frame.   
(A) Schematic of the HIV-1 genome with nine viral ORFs and two long terminal repeats 
or LTRs.  (B) gag open reading frame enlarged to show organization of MA, CA, NC, p6 
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assembly of the virion and viral egress.  These four domains are cleaved from each other 
by a viral protease during maturation into four structural proteins; MA (matrix), CA 
(capsid), NC (nucleocapsid), and p6 (Figure 1.3B) (Freed, 2001).  The MA protein is 
located at the N-terminus of Gag and is required for directing both Gag and Gag-Pol 
precursor polyproteins to the site of virus assembly (Freed, 2001).  MA associates with 
the plasma membrane via an N-terminal myristyl group and a binding site for the 
phosphatidyl inositol(4,5)diphosphate (PI(4,5)P2 (Freed, 2006; Saad et al., 2006).  The 
CA protein is internally positioned between MA and NC in the Gag polyprotein.  Once 
cleaved it forms the viral capsid, which encapsulates the viral genome along with NC and 
other viral enzymes.  The NC protein is also internally situated in Gag and binds and 
packages the viral RNA genome.  The C-terminal p6 region of the Gag polyprotein is 
responsible for incorporating Vpr (Checroune et al., 1995; Huang et al., 1995; Kondo et 
al., 1995; Lu et al., 1995), an accessory protein described later, and for recruiting the 
cellular factors required for efficient viral egress. 
In addition to the four proteins described above, Gag also encodes two spacer 
proteins, SP1 and SP2.  SP2 is located between NC and p6, while SP1 is farther upstream 
between CA and NC.  These additional spacer proteins are essential for viral infectivity 
and aid in the viral maturation process (Gottlinger et al., 1989; Krausslich et al., 1995; 
von Poblotzki et al., 1993).  One model holds that SP1 assists in the assembly process of 
the capsid core by providing an α -helix in the C-terminal domain that is transiently 
required for proper rearrangement during maturation (Accola et al., 1998).   
    
Pol Polyprotein 
The Pol polyprotein contains three enzymes essential for viral replication: PR 
11
  
(protease), RT (reverse transcriptase), and IN (integrase).  The viral PR enzyme is 
responsible for processing the Gag and Gag-Pol polyproteins.  This cleavage releases the 
final MA, CA, NC, p6, PR, RT, and IN proteins from their respective polyproteins, 
allowing necessary rearrangements during viral maturation (Freed, 2001).  The RT 
enzyme is required for reverse transcription of the RNA genome.  RT is a heterodimer 
containing two subunits, p66 and p51 (Hill et al., 2005).  The longer p66 subunit contains 
an additional ribonuclease H (RNase H) domain, which is responsible for cleaving the 
RNA strands of the RNA-DNA hybrids generated during reverse transcription (Frankel & 
Young, 1998; Hill et al., 2005).  IN is required for integration of the viral genome into the 
host genome (Hill et al., 2005).  The integration process takes place after reverse 




The Env polyprotein is composed of two glycoproteins required for viral entry:  
SU (surface/or gp120) and TM (transmembrane/or gp41) (Freed, 2001).  The SU 
glycoprotein recognizes and binds to CD4 and chemokine co-receptors on the surface of 
human cells while the TM glycoprotein spans the viral membrane.  The SU/TM 
heterodimer trimerizes to create spikes on the exterior of the assembled virus (Figure 1.4) 
(Freed, 2001).  HIV entry begins via binding of SU to specific receptors found on the 
surface of T cells, primary macrophages and some dendritic cells.  CD4 is the initial 
receptor for HIV-1; and this interaction induces a conformational change that allows SU 
to interact with chemokine co-receptors (Gomez & Hope, 2005).  The two most common 
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receptors are normally involved in cellular activities such as leukocyte chemotaxis 
(Dunfee et al., 2006; Lusso, 2006).  
HIV-1 strains exhibit one of two distinct patterns of infectivity, (M)-tropism or 
(T)-tropism.  Macrophage (M)-tropic viruses replicate in macrophages and commonly 
use the CCR5 co-receptor to infect CD4+ cells. (T)-tropic or T cell tropic isolates enter 
cells using the CXCR4 co-receptor and replicate in T cells.  These isolates are more 
likely to induce cell fusion in culture, whereas (M)-tropic isolates are non-syncytium 
inducing (Coffin et al., 1997; Dunfee et al., 2006; Frankel & Young, 1998).  Once SU 
engages the co-receptors, TM undergoes a conformation change that facilitates fusion of 
the viral membrane with the cell membrane (Dunfee et al., 2006; Frankel & Young, 
1998).   
 
Accessory Viral Proteins 
 
Six additional open reading frames encode for accessory proteins that aid in the 
viral life cycle.  Tat enhances the processivity of the transcribing polymerases, resulting 
in production of full length transcripts.  Rev is responsible for transporting unspliced and 
singly spliced mRNAs to the cytoplasm after transcription of the integrated viral genome 
(Hope & Pomerantz, 1995).  Vpu is involved in the degradation of CD4 receptors (to 
reduce the number of receptors that bind to Env in the endoplasmic reticulum), down 
regulation of MHC class I protein (which normally attracts T lymphocytes to destroy the 
cell), and virus release (through antagonism of the cellular innate immune restriction 
factor, tetherin) (Neil et al., 2008; Nomaguchi et al., 2008; Waheed et al., 2008).  Vif is 
an accessory protein that allows HIV to persist in cells that would normally be resistant to 
infection.  Vif functions by inducing the degradation of the innate immune restriction 
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factor, APOBEC3 (Stopak & Greene, 2005).  Nef acts similarly to Vpu and assists in 
CD4 receptor downregulation by rerouting them to the lysosome (Arien & Verhasselt, 
2008; Malim & Emerman, 2008).  Finally, Vpr assists early stages of viral replication in 
some cell types, probably by antagonizing another host immune restriction system 
(Malim & Emerman, 2008; Pandey et al., 2009).   
The HIV-1 virion is spherical and is approximately 110-150nm in diameter 
(Gentile et al., 1994).  The organization of the viral proteins is shown in Figure 1.4.  The 
outermost surface of the virion is a lipid bilayer that anchors and displays the 
glycoproteins making them available to recognize CD4+ host cells.  The MA protein 
lines the inside of the lipid layer and is believed to aid in anchoring the transmembrane 
Env proteins (Buchschacher et al., 1995; Cosson, 1996; Freed & Martin, 1996; Murakami 
& Freed, 2000).  The conical viral core is composed of a layer of CA protein (the 
“capsid”), which surrounds two copies of the RNA genome complexed with the viral NC 
protein (Freed, 2001).  The capsid core also encloses a number of other viral proteins 
such as the essential IN and RT enzymes as well as Vif, Nef and Vpr (Freed, 2001; 
Gomez & Hope, 2005).  The following sections provide detailed descriptions of the HIV-
1 assembly and budding processes.               
 
HIV-1 Assembly and Budding 
 
 As described previously, Gag is the structural polyprotein that coordinates viral 
assembly and budding (Freed, 1998; Freed, 2001; Gomez & Hope, 2005).  The four 
regions of the full length Gag polyprotein (MA, CA, NC, and p6) provide the functions 
necessary to carry out these important steps of the life cycle (Freed, 2001; Gomez & 
Hope, 2005).  The MA region directs the Gag and Gag-Pol polyproteins to the plama 
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membrane sites of viral assembly (Freed, 2001).  The CA region aids in Gag assembly 
through a carboxy-terminal dimerization site (Accola et al., 2000; Liang et al., 2003; 
Worthylake et al., 1999).  The NC region packages the viral RNA genome virion by 
binding a packaging signal (ψ) located just 5’ of the Gag gene (Tang et al., 1999).  NC is 
also thought to assist in Gag interactions during assembly via an RNA tether (Gomez & 
Hope, 2005).  The Gag protein is the only viral protein required for assembly (Gottlinger, 
2001) yet cannot sever the membrane, suggesting that cellular factors are recruited to 
facilitate this process.  The p6 domain of Gag recruits such cellular budding proteins 




 Cellular factors required for budding are recruited to the HIV-1 assembly site via 
a tetrapeptide motif, Pro-(Thr/Ser)-Ala-Pro (P(S/T)AP), or late domain located within p6 
(Figure 1.5).  Deletion of p6 or point mutations in the P(T/S)AP motif arrests virus 
budding at a late stage (Figure 1.2), in which the virus has fully assembled but remains 
connected to the cell via a membranous stalk (Gottlinger et al., 1991; Huang et al., 1995).  
Consequently, this motif is referred to as a “late domain” (Parent et al., 1995; Wills & 
Craven, 1991).  P(T/S)AP late domains are also required for efficient release of other 
enveloped viruses, including Ebola virus (Martin-Serrano et al., 2001) and the matrix 
protein of human T cell leukemia virus type 1 (HTLV-1) (Bouamr et al., 2003).  Since 
the initial discovery of the P(T/S)AP late domain in HIV-1, three other types of late 
domains have been discovered in the structural proteins of other enveloped RNA viruses.  
The YPDL late domain was discovered in the p9 domain of equine infectious anemia 




















Figure 1.5. Late domain motifs in structural proteins of enveloped RNA viruses.  
Abbreviations: EIAV, equine infectious anemia virus; HIV-1, human immunodeficiency 
virus type 1; HTLV-1, human T cell leukemia virus type 1; MMuLV, Moloney murine 
leukemia virus; MPMV, Mason-Pfizer monkey virus; RSV, Rous sarcoma virus; VSV, 
vesicular stomatitis virus; LCMV, lymphocytic choriomeningitis virus; SV5, Simian 



















































































































































































































contains a functional YPXL late domain, although in most cell types its activity is less 
important than the p6 P(T/S)AP late domain (Chen et al., 2005; Morita & Sundquist, 
2004; Puffer et al., 1997; Strack et al., 2003).  The PPXY late domain (where X is 
typically Pro) was originally identified in the Gag protein of the Rous sarcoma virus 
(RSV) (Parent et al., 1995; Wills et al., 1994).  Since its discovery, PPXY late domains 
have been identified in many other viruses, including rhabdo-, filo-, arena- and 
retroviruses (Bouamr et al., 2003; Craven et al., 1999; Harty et al., 2000; Perez et al., 
2003; Strecker et al., 2003; Yasuda & Hunter, 1998; Yuan et al., 1999).  Subsequently, 
FPIV late domains have been discovered in paramyxoviruses (Schmitt et al., 2005).  This 
motif has not been fully characterized, but can functionally exchange with P(T/S)AP and 
YPDL late domains (Schmitt et al., 2005).  Figure 1.5 depicts the different late domain 
motifs and the structural viral proteins in which they are located.  The identification of 
late domain motifs in many enveloped viruses together with the fact that these motifs can 
often function interchangeably, suggests that most (but not all) enveloped viruses bud 
from their host cells using similar pathways (Morita & Sundquist, 2004). 
 
Late Domain Binding Partners 
 
Binding partners have now been identified for all of the known late domains 
except the FPIV late domain.  The late domain activity of the PTAP motif in HIV-1 and 
Ebola virus were initially shown too bind and recruit the cellular protein TSG101 (tumor 
susceptibility gene 101)  (Demirov et al., 2002; Garrus et al., 2001; Gottlinger et al., 
1991; Huang et al., 1995; Martin-Serrano et al., 2001; VerPlank et al., 2001).  TSG101 is 
orthologous to the yeast protein Vps23p, which normally functions in the sorting of 
proteins in the ESCRT (endosomal sorting complexes required for transport) pathway 
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(Babst et al., 2000; Bishop & Woodman, 2001; Katzmann et al., 2001).  This pathway 
controls vacuolar (lysosomal in mammals) degradation of membrane proteins.  The 
ESCRT pathway functions to sort cargoes, destined for lysosomal degradation into 
vesicles that bud into the lumen of the late endosome or multivesicular body (MVB).  
The topology of vesicles budding into the MVB is similar to that of virus formation.  In 
both cases the vesicle or virus particle buds away from the cytoplasm into the lumen of 
the endosome or into the extracellular space, respectively (Figure 1.6).  This appears to 
be the reason that the cellular ESCRT pathway is usurped by HIV-1 and other viruses to 
facilitate viral egress. 
 The YPDL late domain motif of EIAV and other retroviruses facilitates budding 
by binding to the cellular factor, ALIX (also known as AIP-1) (Martin-Serrano et al., 
2003a; Strack et al., 2003; Vincent et al., 2003; von Schwedler et al., 2003), which also 
functions in the ESCRT pathway.  The PPXY motif has been shown to bind WW 
domains found in members of the NEDD4 family of ubiquitin E3 ligases (Macias et al., 
2002), and will be discussed in more detail later.  NEDD4 proteins also appear to 
function in the ESCRT pathway, although their precise function is less well understood 
than TSG101 and ALIX.   
 
The ESCRT Pathway and MVB Formation 
 
 Genetic screens performed in yeast have identified 18 ESCRT proteins that 
function in MVB vesicle formation (Babst, 2005; Katzmann et al., 2002).  These proteins 
were originally identified as vps (vacuolar protein sorting) mutants that induced aberrant 





















Figure 1.6. HIV-1 virus budding and vacuolar protein sorting.  Schematic illustrations of 
HIV assembly and budding, vacuolar protein sorting (VPS) and exosome formation.  HIV 
Gag proteins are shown in dark blue, and protein cargos that are sorted through the VPS 
pathway are shown in magenta, green and light blue.  For clarity, not all of the possible 











































enlarged compartments are essentially endosomes that fail to mature into multivesicular 
bodies, which forces the limiting membrane of the organelle to accumulate.   
 The ESCRT proteins form five distinct oligomeric complexes that are sequentially 
recruited to endosomal sites of vesicle formation (Babst et al., 2002a; Babst et al., 2002b; 
Bache et al., 2003; Bilodeau et al., 2003; Katzmann et al., 2001; Katzmann et al., 2003).  
The yeast and human ESCRT pathways are similar in outline and there is at least one 
human ortholog for each of the yeast Class E VPS proteins (Table 1.1) (Bache et al., 
2004; Eastman et al., 2005; Martin-Serrano et al., 2003a; Stuchell et al., 2004; von 
Schwedler et al., 2003; Ward et al., 2005).  The mammalian ESCRT pathway is 
considerably more complex than the yeast system and yeast MVB formation will 
therefore be described first, followed by a description of the mammalian ESCRT system 
and its involvement in HIV-1 budding. 
 
The Yeast ESCRT Pathway 
 
 MVB formation is the key step in the committed lysosomal degradation pathway 
(Figure 1.6).  This pathway is responsible for the degradation of essentially all membrane 
proteins, for example it mediates ligand-induced down regulation of receptors from the 
cell surface.  Such receptors are typically marked for degradation by ubiquitylation, 
endocytosed, and delivered to endosomal compartments (Babst, 2005).  Once there, 
ubiquitylated receptors on the limiting membrane are bound by the first oligomeric 
complex in the ESCRT pathway, the Vps27p-Hse complex (ESCRT-0 or HRS-STAM 
complex in mammals) (Bilodeau et al., 2002).  This complex recognizes ubiquitylated 
cargoes and concentrates them into specific domains on the endosomal membrane (Babst, 






















































































































































































































   
   





















































































































































































































































































































































































































































































































































































































































































































































































   
   


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The Vps27-Hse complex then recruits the endosomal sorting complex required for 
transport I (ESCRT-I) (Katzmann et al., 2003).  The ~350 kDa ESCRT-I complex is 
comprised of four proteins, Vps23p, Vps28p, Vps37p, and Mvb12p.  Like the Vps27-Hse 
complex, ESCRT-I can also bind directly to ubiquitylated cargoes (Katzmann et al., 
2001).  ESCRT-I, in turn, recruits a heterotetrameric complex (~155kDa) called ESCRT-
II, which contains single copies of Vps36p and Vps22p, and two copies of Vps25p.  
ESCRT-II has ubiquitin binding activity and again binds directly to ubiquitylated protein 
cargoes (Babst, 2005; Babst et al., 2002b; Bowers et al., 2004).  ESCRT-II recruits 
ESCRT-III, which forms large endosome-associated lattices, that contain multiple copies 
of the highly charged ESCRT-III proteins: Vps2p, Vps24p, Vps20p, and Snf7p (Babst et 
al., 2002a).  These lattices are thought to mediate membrane fission albeit through an 
unknown mechanism.     
Unlike ESCRT-I and ESCRT-II components, ESCRT-III subunits are monomeric 
in the cytoplasm and only oligomerize when recruited to the membrane (Babst et al., 
2002a).  One ESCRT-III subcomplex, comprised of Vps20p-Snf7p, is required for 
ESCRT-III association with the membrane via a myristyl group found at the N-terminus 
of Vps20p (Babst et al., 2002a).  The second ESCRT-III subcomplex, composed of 
Vps2p and Vps24p recruits the final ESCRT complex, Vps4p (Babst et al., 2002a; Babst 
et al., 1998).  Vps4p, is a AAA-type ATPase that utilizes ATP hydrolysis to release 
ESCRT machinery from the membrane, which allows for multiple rounds of vesicle 
formation (Babst et al., 2002a; Babst et al., 2002b; Katzmann et al., 2001).   
In addition to the ESCRT complexes described above, there are several additional 
ESCRT proteins that aid in the formation of vesicles at the yeast MVB.  Bro1p (the yeast 
27
  
ALIX homolog) associates with endosomal membranes through a recruitment that is 
specifically dependent on an interaction with the ESCRT-III protein, Snf7p (Odorizzi et 
al., 2003).  Did2p and Vps60p are ESCRT-III like proteins that display a weak Class E 
phenotype when deleted (Babst et al., 2002a; Raymond et al., 1992; Shiflett et al., 2004).  
These proteins facilitate recruitment of the Vps4p complex (Azmi et al., 2006; Bajorek et 
al., 2009; Kieffer et al., 2008; Lottridge et al., 2006; McCullough et al., 2008; Nickerson 
et al., 2006).  Vta1p is another Vps4p cofactor that interacts directly with both Vps4p and 
Vps60p (Azmi et al., 2006; Shiflett et al., 2004).  Doa4p, is a deubiquitinating enzyme 
that removes ubiquitin from cargoes as they are sorted into MVB vesicles (Dupre & 
Haguenauer-Tsapis, 2001; Reggiori & Pelham, 2001).  Localization of Doa4p to 
endosomal membranes is dependent on an interaction with the ESCRT-III protein, 
Vps24p (Amerik et al., 2000), and Bro1p (Luhtala & Odorizzi, 2004).  Because the yeast 
ESCRT proteins were identified from a genetic screen that examined only essential 
genes, the identification of additional essential ESCRT proteins seems likely (Raymond 
et al., 1992).  Indeed, the ubiquitin ligase Rsp5p (the yeast homolog of the mammalian 
NEDD4 proteins) is an essential yeast protein that is required for ESCRT-mediated 
sorting (Nikko & Andre, 2007).  Collectively, these aforementioned factors comprise the 
essential yeast ESCRT machinery.       
 
The Human ESCRT Proteins 
 
Human ESCRT proteins are believed to function is a manner similar to that 
described for the yeast system.  To date 30 human ESCRT proteins have been identified 
(Agromayor et al., 2009; Bache et al., 2004; Bajorek et al., 2009; Eastman et al., 2005; 
Martin-Serrano et al., 2003a; Morita et al., 2007; Stuchell et al., 2004; von Schwedler et 
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al., 2003; Ward et al., 2005).  Once the human ESCRT proteins were tentatively 
identified, it was important to test whether they exhibited similar interactions to those of 
their yeast counterparts.  The work described in Chapter 2 of this dissertation, together 
with similar work performed in the Bieniasz lab, characterized the protein-protein 
interactions that take place in this network of proteins (Figure 1.7) (Martin-Serrano et al., 
2003a; von Schwedler et al., 2003).  These studies were the first to show that the human 
ESCRT proteins also form five oligomeric complexes that are analogous to those of the 
yeast ESCRT pathway system: HRS-STAM, ESCRT(I-III), and VPS4 (Martin-Serrano et 
al., 2003a; von Schwedler et al., 2003). 
Like its yeast counterpart, the mammalian HRS-STAM complex recognizes 
ubiquitylated membrane proteins on endosomal membranes and targets then for 
incorporation into MVB vesicles (Asao et al., 1997; Bean et al., 2000; Raiborg et al., 
2002; Raiborg et al., 2001b; Shih et al., 2002).  This HRS recognition step appears to be 
bypassed when HIV usurps the ESCRT pathway to facilitate virus budding (Pornillos et 
al., 2003), as will be discussed later in this chapter.  This HRS-STAM complex then 
recruits the ESCRT-I complex through an interaction between HRS and TSG101 that 
involves a PSAP sequence motif on HRS (the equivalent of the P(T/S)AP late domain in 
HIV-1 Gag).   
Mammalian tumor susceptibility gene 101 (TSG101), the human ortholog of yeast 
Vps23p (Babst et al., 2000), functions as a member of the cytoplasmic human ESCRT-I 
complex along with the human VPS28 protein (the ortholog of yeast Vps28p) (Babst et 
al., 2000; Bishop & Woodman, 2001; Katzmann et al., 2001).  When I began my work, it 




















Figure 1.7.  Human ESCRT Protein Network. 
Schematic showing 28 human proteins, their subcomplexes, and their known protein-
protein interactions.  Interactions between proteins are denoted by arrows and are color 
coded based on the studies that identified the interaction (Bache et al., 2004: blue green, 
Eastman et al., 2004: green, Garrus et al., 2001: black, Martin-Serrano et al., 2003: gray, 
Howard et al., 2001: pink, Scott et al., 2005b: dark purple, Strack et al., 2003: dark blue, 
Stuchell et al., 2004: slate, von Schwedler et al., 2003: orange, Horii et al., 2006: brown) 























































human VPS37 orthologs were not known owing to their significant divergence in the 
primary sequence.  Several labs, including ours, therefore used both biochemical and 
bioinformatic approaches to identify four human VPS37 proteins (Bache et al., 2004; 
Eastman et al., 2005; Stuchell et al., 2004).  The identification and characterization of the 
human VPS37 proteins is described in Chapter 3.  The human ESCRT-I complex is also 
involved in the recognition of ubiquitylated cargoes, specifically through direct TSG101-
Ub interactions, and this topic will be discussed in detail later.      
By analogy to yeast, the human ESCRT-II and ESCRT-III complexes are 
presumed to be sequentially recruited to sites of MVB vesicle formation.  The human 
ESCRT-II complex is composed of three proteins, EAP20, EAP30 and EAP45, which are 
orthologous to yeast Vps25p, Vps22p, and Vps36p, respectively (Kamura et al., 2001; 
Martin-Serrano et al., 2003a; von Schwedler et al., 2003).  This complex was originally 
discovered as a putative RNA polymerase II elongation factor, and the subunits were 
therefore named ELL-associating proteins or EAPs (Kamura et al., 2001).  The TSG101 
subunit of ESCRT-I interacts with both EAP30 and EAP45 to recruit the ESCRT-II 
complex to the endosomal membrane (Langelier et al., 2006; Slagsvold et al., 2005).  
EAP45 has ubiquitin binding ability, and the importance of ubiquitin recognition by 
EAP45 will be discussed later.  ESCRT-II can in turn recruit the ESCRT-III complex 
through an interaction between EAP20 and the charge multivesicular body protein 6 
(CHMP6) (Langelier et al., 2006). 
  Human ESCRT-III proteins are composed of a family of highly charged 
proteins, most of which are called CHMP proteins (for charged multivesicular body 
proteins) (Table 1.1 and Figure 1.7).  There are more human than yeast ESCRT-III 
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proteins.  To date, 12 human ESCRT-III proteins have been identified.  They generally 
share a similar domain structure, and most are ~200 amino acids in length.  The human 
CHMP proteins can be organized into eight subclasses (CHMP1-7, and IST1) according 
to their homology to one another (Agromayor et al., 2009; Bajorek et al., 2009; Horii et 
al., 2006; von Schwedler et al., 2003).  The CHMP1-6 and IST1 families correspond to 
the seven yeast ESCRT-III-like proteins (Agromayor et al., 2009; Bajorek et al., 2009; 
von Schwedler et al., 2003).  An additional CHMP-like protein, CHMP7, is most similar 
to the CHMP6 subclass but is a much larger protein consisting of 453 amino acids (Horii 
et al., 2006).  CHMP7 interacts with CHMP4B and also functions in the mammalian 
endosomal pathway (Horii et al., 2006).  The human ESCRT-III complex appears to form 
lattices that are presumably similar to yeast ESCRT-III lattices.  The structure of the 
CHMP3 protein core was recently determined and shown to be a four helix bundle that 
forms a flat overall structure (Muziol et al., 2006).  Similarities in sequence, charge and 
domain structure suggest that all CHMP proteins will adopt similar structures (Muziol et 
al., 2006).   
The CHMP4 subset of human ESCRT-III proteins (CHMP4A, CHMP4B, and 
CHMP4C) interact directly with ALIX (ALG-2-interacting protein X) (Martin-Serrano et 
al., 2003a; von Schwedler et al., 2003).  ALIX also binds ESCRT-I, but is not a 
constitutive member of either ESCRT complex (Katoh et al., 2003; Katoh et al., 2005; 
Martin-Serrano et al., 2003a; Strack et al., 2003; von Schwedler et al., 2003).  ALIX can, 
in priciple, bridge ESCRT-I and ESCRT-III, thus providing an additional way to recruit 
ESCRT-III to site of vesicle formation.         
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ESCRT-III proteins also bind and recruit the VPS4 AAA ATPases, which then 
remove them from the membrane and thereby allow them to recycle and repeat the 
sorting process on other substrates (Martin-Serrano et al., 2003a; Scott et al., 2005b; 
Tsang et al., 2006; von Schwedler et al., 2003).  VPS4 proteins are ATPases associated 
with diverse cellular activities (AAA).  Humans have two VPS4 proteins, VPS4A and 
VPS4B, that share ~80% sequence similarity.  VPS4 proteins are composed of three 
different regions: an N-terminal microtubule interacting and trafficking (MIT) domain, a 
C-terminal AAA ATPase cassette, and a three-stranded, anti-parallel β -domain that is 
inserted into the small domain of the ATPase cassette (Scott et al., 2005a; Scott et al., 
2005b; Takasu et al., 2005).  The VPS4 proteins can form two stacked hexameric rings, 
which is similar to structures formed by the p97 AAA ATPase (Scott et al., 2005a).  The 
β-domain of VPS4 has been shown to associate with LIP5 (Vta1p in yeast) (Scott et al., 
2005a).  Vta1p and LIP5 stimulate VPS4 assembly and ATPase activites.  LIP5 also 
binds specifically to the ESCRT-III protein CHMP5 (Scott et al., 2005a). 
The interactions of VPS4 AAA ATPases with several different ESCRT-III 
proteins are described in Chapter 2, Chapter 4, Appendix A and Appendix B (Fujita et al., 
2004; Lin et al., 2005; Martin-Serrano et al., 2003a; Scott et al., 2005a; von Schwedler et 
al., 2003).  Specifically, I characterized how the N-terminal MIT domain of VPS4 binds a 
short peptide sequence tag located at the C-terminus of many CHMP proteins; CHMP1A-
1B, CHMP2A-2B, and CHMP3 (Chapter 4 of this dissertation).  These C-terminal tags 
also bind other MIT-domain containing proteins, including AMSH and UBPY 
(Agromayor & Martin-Serrano, 2006).   
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AMSH (associated molecule with the SH3 domain of STAM) and UBPY are 
deubiquitylating enzymes that are associated with the ESCRT pathway.(McCullough et 
al., 2004; Mizuno et al., 2006; Row et al., 2007; Row et al., 2006; Urbe et al., 2006).  
Both can also interact with the STAM (signal transducing adaptor molecule) subunit of 
the HRS complex (Kim et al., 2006; McCullough et al., 2004; McCullough et al., 2006; 
Urbe et al., 2006).  AMSH and UBPY can deubiquitylate MVB vesicle cargoes, although 
the exact sequence of deubiquitylation remains somewhat controversial (Agromayor & 
Martin-Serrano, 2006; McCullough et al., 2006; Mizuno et al., 2006; Row et al., 2006). 
 
ESCRT - Lipid Interactions 
 Several ESCRT proteins bind lipids, and these interactions help recruit them to 
endosomal sites of membrane fission.  Endosomes are enriched in phosphotidyl inositol 
3-phophate (PI(3)P).  HRS contains a FYVE domain, which specifically binds to PI(3)P 
(Katzmann et al., 2003; Komada & Soriano, 1999; Raiborg et al., 2001a).  Similarly, 
EAP45, a component of the ESCRT-II complex, also binds PI(3)P and other phosphatidyl 
(3) phosphates (Gill et al., 2007; Slagsvold et al., 2005).  Late endosomes are also 
enriched in PI(3,5)P2 and one member of the ESCRT-III complex, CHMP3, has been 
reported bind PI(3,5)P2 (Gillooly et al., 2000; Gillooly et al., 2003; Whitley et al., 2003).  
Another ESCRT-III protein, CHMP6, binds membranes via an N-terminal myristoyl 
group, albeit without any known lipid specificity (Yorikawa et al., 2005).  Both Bro1p 
and ALIX are thought to interact with membranes through their boomerang-shaped Bro1 
domain (Kim et al., 2005) and ALIX has been reported to bind lysobisphosphatidic acid 
(LBPA), which is a cone shaped lipid that plays a role MVB vesicle formation (Matsuo et 
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al., 2004).  The apparent importance of lipids, in MVB vesicle formation is emphasized 
by the fact that three out of the five oligomeric ESCRT complexes bind endosomal lipids.     
 
Ubiquitin in the ESCRT Pathway 
The ubiquitin post translational modification plays an important role in targeting 
cargoes for lysosomal degradation, and several ESCRT proteins have ubiquitin binding 
activities (Hicke & Dunn, 2003; Katzmann et al., 2001).  HRS contains two UIM motifs 
(ubiquitin interacting motifs) that are required for sorting ubiquitylated cargoes (Bilodeau 
et al., 2002; Polo et al., 2002; Raiborg et al., 2002; Shih et al., 2002; Swanson et al., 
2003).  TSG101 contains a UEV (ubiquitin E2 variant) domain, that is structurally similar 
to ubiquitin E2 ligases but lacks the active site cysteine residue that is required for 
ubiquitin transfer.  TSG101 can therefore bind, but not transfer ubiquitin (Pornillos et al., 
2002a; Sundquist et al., 2004; Teo et al., 2004).  The human ESCRT-II subunit, EAP45, 
contains a GLUE (Gram-like Ub binding to EAP45) domain, which allows this complex 
to recognize ubiquitin (Alam et al., 2006; Hirano et al., 2006; Langelier et al., 2006; 
Slagsvold et al., 2005).  In yeast, this activity is provided instead by the ubiquitin binding 
zinc finger motif.  Thus, the HRS, ESCRT-I, and ESCRT-II complexes all have ubiquitin 
binding activities that are required for cargo sorting.  Apparently, these different 
complexes cooperate to concentrate ubiquitylated proteins on endosomal membranes.  As 
those cargoes are sorted and sequestered inside vesicles, the covalently attached 
ubiquitins are removed and recycled by the UBPY and/or AMSH deubiquitylating 
enzymes (Agromayor & Martin-Serrano, 2006; McCullough et al., 2004; McCullough et 




Ubiquitin in HIV-1 Budding 
 Ubiquitylation also plays a role in the budding of viruses that contain the late 
domain motifs, P(T/S)AP and PPXY (Patnaik et al., 2000; Vogt, 2000).  Interestingly, the 
YP(X)nL late domain appears to function independently of a ubiquitin requirement 
(Patnaik et al., 2002).  As noted earlier, the P(T/S)AP motif recruits TSG101/ESCRT-I, 
while the PPXY motif interacts with NEDD4 family of ubiquitin ligases, and both of 
these host factors are involved in ubiquitin transfer or recognition.  Thus, it seems 
possible that Gag proteins may, in part, have evolved to mimic the ubiquitylated cargoes 
that are sorted into budding viruses.  Other observations that tie ubiquitin to virus 
budding include: (1) ubiquitin is enriched inside the virions of many retroviruses (Ott et 
al., 1998; Putterman et al., 1990), (2) Gag proteins of HIV-1 and MuLV are 
monoubiquitylated at multiple sites (Ott et al., 2000), (3)  the concentration of ubiquitin 
found on Gag proteins can be altered depending on the presence or absence of late 
domains (Martin-Serrano et al., 2004; Strack et al., 2000), and (4) depleting cellular 
ubiquitin levels can arrest virus budding at a late stage (Patnaik et al., 2000; Schubert et 
al., 2000; Strack et al., 2000).  
          
ESCRT Proteins and HIV-1 Budding 
 As noted above, retroviruses interact with several human ESCRTs, which 
apparently serve as entry points into the ESCRT pathway.  As illustrated in Figure 1.8, 
late domains within viral structural proteins can interact with TSG101, ALIX, and/or the 
NEDD4 proteins to “hijack” them to sites of virus assembly.  In principle, gaining an 
understanding of how the proteins in this pathway are involved in retroviral budding 

















































































































































































































































































To date, a number of downstream ESCRT proteins have been shown to be 
required for viral egress.  Specifically, subunits of the ESCRT-I complex, have been 
shown to be important for budding of HIV-1 (Demirov et al., 2002; Garrus et al., 2001; 
Goff et al., 2003; Goila-Gaur et al., 2003; Martin-Serrano et al., 2001; Martin-Serrano et 
al., 2003b; VerPlank et al., 2001), Ebola (Licata et al., 2003; Martin-Serrano et al., 2001; 
Shehu-Xhilaga et al., 2004; Timmins et al., 2003), HTLV-1 (Bouamr et al., 2003), 
MPMV (Gottwein et al., 2003), and possibly RSV (Johnson et al., 2005; Medina et al., 
2005). Thus, TSG101/ESCRT-I appears to be important for all viruses that bud using 
P(T/S)AP late domains.  Similarly, the VPS28 binding site on TSG101 is required for 
HIV budding, suggesting that VPS28 also plays a role in PTAP-dependent budding 
(Martin-Serrano et al., 2003b; Stuchell et al., 2004).  Similarly, VPS37B, VPS37C, and 
MVB12 have also been shown to inhibit late domain dependent virus release (Eastman et 
al., 2005; Morita et al., 2007).  Thus, the entire ESCRT-I complex is required for efficient 
HIV-1 budding.  
Several ESCRT-II and ESCRT-III components have also been tested for their 
requirement in viral egress.  Surprisingly, ESCRT-II does not appear to be required 
because the essential EAP20 subunit can be depleted without affecting virus release 
(Langelier et al., 2006).  Several ESCRT-III proteins, including CHMP2A, CHMP3, 
CHMP4B and CHMP4C, can potently inhibit the HIV-1 budding pathway when they are 
over expressed as dominant negative constructs, indicating that they are involved in (or 
can dominantly inhibit) HIV budding (von Schwedler et al., 2003).  However, siRNA 
knockdown of CHMP6 does not affect the ability of HIV-1 to release from cells.  




VPS4 is the only known enzyme in the MVB pathway, and it uses the energy of 
ATP hydrolysis to release the ESCRT machinery for use in multiple rounds of vesicle 
formation.  The VSP4 proteins play an important role in the budding of many enveloped 
viruses, including HIV-1 (Garrus et al., 2001; Scott et al., 2005b) , MPMV (Gottwein et 
al., 2003) , Ebola virus (Licata et al., 2003) and MLV (Garrus et al., 2001) budding.      
ALIX is another ESCRT protein that binds directly to YPXL late domains.  Not 
surprisingly, ALIX is required for the release EIAV (Strack et al., 2003).  In contrast, 
ALIX is not essential for HIV-1 budding in most cell types, though it can contribute to 
the efficiency of HIV, Ebola and MLV budding (Martin-Serrano et al., 2004; Strack et 
al., 2003).  Moreover, ALIX is present in HIV-1 particles and HIV budding can be 
supported by ALIX when the Gag P(T/S)AP late domain is mutated (Strack et al., 2003; 
von Schwedler et al., 2003).  It is therefore likely that HIV-1 has evolved to “hedge its 
bets” by entering the ESCRT pathway at different sites. 
The NEDD4 family of ubiquitin E3 ligases can also facilitate retroviral release 
and are recruited through an interaction between their WW domains and PPXY late 
domain motif.  The requirement for NEDD4 family members has been tested for a 
number of different viruses including RSV (Kikonyogo et al., 2001; Martin-Serrano et 
al., 2004; Strack et al., 2000), HTLV-1 (Blot et al., 2004; Bouamr et al., 2003), Ebola 
(Timmins et al., 2003; Yasuda et al., 2003) MPMV (Yasuda et al., 2002) and HIV-1 
(Chung et al., 2008; Usami et al., 2008).  However, there is some disagreement as to 
which ligase can function for the different viruses, and the mechanistic roles of these 
ligases in budding is not yet clear.     
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In summary, it is now clear that the human ESCRT protein network is usurped by 
many enveloped viruses to escape from cells.  However, not all of the relevant factors are 
known, and the exact mechanism of fission has yet to be elucidated.  Research in these 
areas therefore remains active with the ultimate goal of moving the field closer to 




 The goal of my thesis research was to characterize the pathway required for HIV-
1 budding—the human ESCRT pathway.  Chapter 2 describes the identification and 
characterization of most of the components of the human ESCRT protein network.  My 
specific contribution to Chapter 2 was to identify candidate human ESCRT proteins 
based upon bioinformatic homolog searches and to test their protein-protein interactions 
using directed yeast two hybrid experiments and other biochemical methods.  Chapter 3 
describes the bioinformatic and biochemical approaches I used to identify the third class 
of proteins that form subunits of human ESCRT-I (VPS37A-D), and to characterize the 
requirement of ESCRT-I proteins involved in HIV-1 budding.  My contribution to 
Chapter 3 was to identify VPS37B and characterize its interactions within the human 
ESCRT-I complex.  Chapter 4 describes the identification and characterization of VPS4 
binding sites on human ESCRT-III proteins and the determination of three dimensional 
structures of VPS4 MIT-ESCRT-III complexes.  Chapter 5 summarizes my research and 
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The Protein Network of HIV Budding
of other pathogenic human viruses including Ebola andUta K. von Schwedler,1 Melissa Stuchell,1
Barbara Mu¨ller,3 Diane M. Ward,2 HTLV-I (Freed, 2002; Pornillos et al., 2002c). PTAP late
domains recruit the cellular protein TSG101 to facilitateHyo-Young Chung,1 Eiji Morita,1
Hubert E. Wang,4 Thaylon Davis,4 virus budding (Demirov et al., 2002a; Garrus et al., 2001;
Martin-Serrano et al., 2001; VerPlank et al., 2001). InGong-Ping He,4 Daniel M. Cimbora,4
Anna Scott,1 Hans-Georg Kra¨usslich,3 uninfected cells, TSG101 functions in the biogenesis of
the multivesicular body (MVB) (Katzmann et al., 2002),Jerry Kaplan,2 Scott G. Morham,4
and Wesley I. Sundquist1,* which suggests that HIV may bind TSG101 in order to
gain access to the downstream machinery that cata-1Department of Biochemistry
2Department of Pathology lyzes MVB vesicle budding. Consistent with this model,
a dominant-negative Vps4A protein that inhibits MVBUniversity of Utah
Salt Lake City, Utah 84132 biogenesis also blocks release of HIV-1 and other enve-
loped viruses (Garrus et al., 2001; Licata et al., 2003;3Abteilung Virologie
Universita¨tsklinikum Heidelberg Martin-Serrano et al., 2003). The mammalian MVB path-
way is not yet fully defined, however. Hence, it is unclearD-69120 Heidelberg
Germany whether other proteins in the MVB pathway participate
in HIV-1 budding.4Myriad Pharmaceuticals, Inc.
Salt Lake City, Utah 84108 Genetic screens in yeast have defined 17 different
proteins that appear to play direct roles inMVBbiogene-
sis (reviewed in Katzmann et al., 2002). All are required
for vacuolar protein sorting (VPS), and are termed “classSummary
E” proteins because their deletion or inactivation in-
duces formation of abnormally enlarged, highly tubu-HIV release requires TSG101, a cellular factor that
sorts proteins into vesicles that bud intomultivesicular lated endosomal membrane compartments that fail to
mature normally into MVBs (termed “class E compart-bodies (MVB). To test whether other proteins involved
in MVB biogenesis (the class E proteins) also partici- ments”). Recent studies by Emr and coworkers have
revealed that most class E proteins exist predominantlypate in HIV release, we identified 22 candidate human
class E proteins. These proteins were connected into as soluble proteins or subcomplexes that are sequen-
tially recruited from the cytoplasm to function at sites ofa coherent network by 43 different protein-protein
interactions, with AIP1 playing a key role in linking MVB vesicle formation (termed ESCRTs, for Endosomal
Sorting Complexes Required for Transport) (Babst etcomplexes that act early (TSG101/ESCRT-I) and late
(CHMP4/ESCRT-III) in the pathway. AIP1 also binds al., 2002a, 2002b; Katzmann et al., 2003; Odorizzi et al.,
2003). After proteins are sorted into MVB vesicles, thethe HIV-1 p6Gag and EIAV p9Gag proteins, indicating that
it can function directly in virus budding. Human class E assembled class E proteins are then released upon ATP
binding/hydrolysis by the AAA ATPase, Vps4p. Thus,proteins were found in HIV-1 particles, and dominant-
negative mutants of late-acting human class E pro- the different factors and stages of yeastMVBbiogenesis
are now understood in outline. The present studies wereteins arrested HIV-1 budding through plasmal and en-
dosomal membranes. These studies define a protein undertaken with the goals of defining the network of
proteins required for humanMVBbiogenesis and testingnetwork required for human MVB biogenesis and indi-
cate that the entire network participates in the release whether HIV-1 budding requires the function of proteins
that act later in this pathway.of HIV and probably many other viruses.
Introduction Results
HIV spreads via extracellular particles that can enter Modeling the Human Protein Interaction Network
and exit cells. The characterization of viral and cellular Required for MVB Biogenesis
proteins involved in HIV entry has provided a greater A systematic search for human homologs of yeast class
understanding of early stages in the viral life cycle, and E proteins yielded at least one acceptable match for all
led to new therapeutics (Biscone et al., 2002). In con- 17 yeast proteins, with the exception of Vps37p (Figure 1
trast, the equally important process of HIV release is and Supplemental Table S1 available at http://www.cell.
less well understood, and many of the cellular factors com/cgi/content/full/114/6/701/DC1). The resulting 22
involved in this fundamental stage of the viral life cycle human proteins can be grouped in analogy to the yeast
remain to be identified and characterized (for recent ESCRT subcomplexes, and the groupings shown in Fig-
reviews see Freed, 2002; Pornillos et al., 2002c). ure 1A are consistent with studies in mammalian sys-
Efficient HIV release requires the cis-acting, tetrapep- tems indicating that: (1) HRS, STAM1/2, TSG101, and
tide P(S/T)AP “late domain” found in the p6 domain of VPS28 all act early in MVB formation (Asao et al., 1997;
all HIV Gag proteins, and also in the structural proteins Babst et al., 2000; Bache et al., 2003a, 2003b; Bishop
et al., 2002; Bishop andWoodman, 2001; Lu et al., 2003;




Figure 1. Model for the Human Class E Protein Interaction Network
(A) Schematic illustration showing 22 putative human class E proteins, their subcomplexes, and interactions. Interactions between proteins
are denoted by arrows and are color-coded as previously known (black) or novel (red). ESCRT-I, II, III complexes are modeled after analogous
yeast complexes (Katzmann et al., 2002). Detection methods, interactions (in brackets) and relevant protein fragments (in parentheses) were:
a) Yeast two-hybrid screens of cDNA libraries: [6] (TSG101317–390/VPS2810–221), [11] (TSG1011–266/AIP1584–868), [19] (EAP3043–258/CHMP61–130), [20]
(EAP45317–386/CHMP61–130); b) Directed yeast two-hybrid screens [4, 6, 8–9, 11–12, 15–18, 21–30, 32–35, and 38–41] (all full-length proteins); c)
Interactions between purified proteins detected using GST pull-down assays: [13] (AIP11–716/EIAV p9), [14] (AIP1–716/HIV-1 p6), [16] (AIP11–716/
CHMP4B), and [9, 30–32, 36–37, 42–43] (all full-length proteins); d) Interactions between purified proteins detected using Biacore biosensor:
[11] (Tsg1011–145/AIP1714–723). References for previously reported interactions are: [1] and [2] (Asao et al., 1997), [3] (Bache et al., 2003a; Lu et
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form a stable complex in mammalian cells (Kamura et and CHMP2B did not show any positive interactions.
Our experiments reconfirmed several yeast two-hybridal., 2001).
In several cases, a single yeast protein apparently has interactions described previously in mammalian sys-
tems: TGS101/TSG101 (Martin-Serrano et al., 2003),two or more human orthologs, implying greater com-
plexity in the mammalian MVB pathway. This is most TSG101/VPS28 (Bishop and Woodman, 2001), AIP1/
AIP1 (Chatellard-Causse et al., 2002), CHMP1A/VPS4B,evident late in the pathway; e.g., the single yeast Vps4p
protein has two apparent human orthologs: VPS4A and and CHMP2A/VPS4B (Howard et al., 2001). We also
found a series of interactions that were previously un-VPS4B, and the six related proteins of the yeast ESCRT-
III class have 10 apparent human orthologs, the charged documented in mammalian systems, but were analo-
gous to interactions previously described in yeast (e.g.,MVB proteins or CHMP proteins. The six yeast proteins
perform distinct functions: two (Vps32p/Snf7p and CHMP4B/CHMP6, AIP1/CHMP4A-C) (Babst et al., 2002a;
Odorizzi et al., 2003), or were consistent with biochemi-Vps20p) form a proximal lattice that binds directly to the
MVB membrane, two (Vps2p/Did4p and Vps24p) form a cal or genetic experiments in yeast (e.g., ESCRT-I re-
cruits ESCRT-II to the endosomal membrane (Babst etdistal layer on the first, and the remaining two (Did2p
and Vps60p/Mos10p) apparently have partially redun- al., 2002b), Snf7p (CHMP4A-C) recruits Bro1p (AIP1)
(Odorizzi et al., 2003), and ESCRT-II recruits Vps20pdant and/or regulatory roles (Babst et al., 2002a). A phy-
logenetic analysis showed that the 10 related human (CHMP6) (Babst et al., 2002b). It is therefore apparent
that the MVB pathway is conserved in outline from yeastCHMP proteins can also be subdivided into six analo-
gous groups (Figure 1A and Supplemental Figure S1 to man.
Importantly, our two screens revealed 25 new classavailable on Cell website).
E protein-protein interactions that had not previously
been described in any system. These included the firstProtein Interactions within the Human Vps Class
E Protein Network links between ESCRT-I and ESCRT-II (TSG101/EAP45,
TSG101/EAP30), and between ESCRT-I and AIP1Extensive yeast two-hybrid analyses were performed to
test our model for the humanMVB pathway and to iden- (TSG101/AIP1). Collectively, our data imply a hierarchy
of protein interactions required for MVB formation, withtify new protein-protein interactions that could link the
entire protein network together, which has not been HRS complex recruiting ESCRT-I; ESCRT-I recruitingAIP1
and ESCRT-II; AIP1 and ESCRT-II recruiting ESCRT-III;possible in any system including yeast. Potential inter-
actions between human class E proteins were tested and ESCRT-III recruiting VPS4A/B (see Figure 1A).
using both random library screening and directed yeast
two-hybrid assays, which provided overlapping and TSG101/AIP1 Interactions
The novel interaction between TSG101 and AIP1 de-complementary information (Figure 1, Supplemental
Figure S1 and Table S1 available on Cell website). In tected in the yeast two-hybrid experiments was charac-
terized in greater detail because it provided, to ourthe random screen, early (TSG101) and late (CHMP6)
acting class E proteins were used as baits in automated knowledge, the first direct link between the human
ESCRT-I and ESCRT-III complexes. Deletion analysesscreens of human cDNA libraries, with multiple con-
structs employed to identify interacting domains. These revealed that the N-terminal UEV domain of TSG101
(residues 1–145) bound the proline-rich C-terminal re-screens confirmed one previously known TSG101 inter-
action, TSG101/VPS28 (Bishop and Woodman, 2001), gion of AIP1 (residues 586–868) (Figures 1B and 2A).
The TSG101 UEV domain binds specifically to P(S/T)APand revealed three novel interactions: TSG101/AIP1,
CHMP6/EAP30, and CHMP6/EAP45. All four interactions sequences, but a mutation in the UEV domain (M95A)
abolishes P(S/T)AP binding (Pornillos et al., 2002a,were confirmed in semiquantitative liquid -galactosi-
dase two-hybrid assays (Figure 1B). 2002b). TheM95Amutation also eliminated AIP1 binding
to both the full-length and TSG1011–145 proteins (FigureThe directed screen tested for all possible intra- and
intermolecular interactions between the 18 human class 2A, far right, red bar), indicating that the TSG101 UEV
domain bound a P(S/T)AP-like sequence in the proline-E proteins predicted to act downstream of TSG101 (in-
cluding TSG101 itself). A total of 28 interactions were rich region of AIP1.
There is a conserved PSAP motif within the proline-identified and 16 of the 18 proteins tested interacted
with at least one other class E protein (Figures 1A and rich region of AIP1 (residues 717–720), and we therefore
tested whether the TSG101 UEV domain could bind this1C). CHMP5 constructs were toxic or self-activating,
VerPlank et al., 2001), [6] (Bishop and Woodman, 2001), [7] (Kamura et al., 2001), [8] and [9] (Howard et al., 2001), [10] (Scheuring et al., 2001),
[12] (Chatellard-Causse et al., 2002) and [14] (Strack et al., 2003).
(B) Protein-protein interactions detected in yeast two-hybrid library screens and confirmed using semiquantitative -galactosidase assays.
Positive signals from yeast expressing prey-AD/bait-BD pairs (black bars) are shown together with signals from control cells expressing AD/
bait-BD (yellow) and prey-AD/BD pairs (blue). Interaction numbers (below) correspond to those in Figure 1A, and the HRS/TSG101 interaction
served as a positive control (Pornillos et al., 2003). Signals were normalized relative to the appropriate positive signal (given in fluorescence
units adjacent to black bars).
(C) Directed yeast two-hybrid interactions between human class E proteins detected in X--gal assays. From left to right, each image shows
X--gal signals from yeast patches containing AD/bait-BD (negative control), prey-AD/BD (negative control), and prey-AD/bait-BD (positive
interaction). All interactions shown were positive in multiple repetitions of these experiments and are denoted as strong (s, signal in 1–2 days),
medium (m, signal in 3 days), and weak (w, signal in 4 or more days). Very weak interactions not scored as positive were: CHMP3/CHMP4B,




Figure 2. TSG101/AIP1 Interactions
(A) -galactosidase assays showing two-
hybrid interactions between AD/TSG1011–145-
BD (yellow, negative control), AIP1-AD/BD
(blue, negative control), AIP1-AD/TSG1011–145-
BD (black), AD/M95A-TSG1011–145-BD (green,
negative control), and AIP1-AD/M95A-
TSG1011–145-BD (red).
(B) Biosensor binding isotherms for GST-
AIP1714–723 binding to wt (squares, KD  142 
0.5 M) or M95A mutant (ovals) TSG101 UEV.
Raw binding data for this figure are given in
Supplemental Figure S2A (available on Cell
website).
motif directly using Biacore biosensor experiments. and -CHMP5 were poorly soluble and therefore not
tested). As shown in Figure 3A,AIP11–716 boundCHMP4B,Pure recombinant TSG101 UEV domain bound specifi-
cally to a peptide spanning AIP1 residues 714–723 (de- but not the other CHMPproteins. A single pointmutation
(L217A) near the C terminus of CHMP4B blocked AIP1noted AIP1714–723; KD  142  0.5 M), and binding was
again eliminated by the TSG101 M95A mutation (Figure binding (Figure 3A, compare lanes 7 and 8). Although
the functional interactions between AIP1 and CHMP42B and Supplemental Figure S2A available on Cell web-
site). Hence, the TSG101 UEV domain binds directly to proteins presumably occur primarily within membrane
bound complexes, it was possible to coimmunoprecipi-the 717PSAP720 element of AIP1.
tate AIP1-Myc and CHMP4B-FLAG proteins that were
overexpressed in 293T cells (Figure 3B). Overall, weAIP1/CHMP4 Interactions
The yeast two-hybrid data also indicated that AIP1 inter- conclude that AIP1 binds directly and specifically to
the CHMP4 proteins, but not to CHMP proteins fromacts with all three members of the CHMP4 family of
ESCRT-III proteins, but not with other CHMP proteins. other families.
GST pull-down assays were performed to test for direct,
specific protein-protein interactions between AIP11–716 Interactions of AIP1 and Viral Proteins
Recent evidence suggests that AIP1 may play a directand representatives from 5 of the 6 different CHMP sub-
classes (1B, 2A, 3, 4B, and 6; GST-CHMP4A, -CHMP4C, role in the release of several enveloped viruses, includ-
Figure 3. CHMP Protein Interactions
(A) CHMP/AIP1 interactions analyzed in GST
pull-down assays. Excess pure AIP11–716 (lane
1, 10% of input) was incubated with glutathi-
one beads prebound with different GST fusion
proteins (lanes 2–10, lower bands). Bound
AIP1–716 was separated by SDS-PAGE and vis-
ualized by Coomassie blue staining (upper
bands in lanes with asterisks).
(B) Coimmunoprecipitation of CHMP4B and
AIP1. 293T cells were cotransfected with
AIP1-Myc expression vector and with either
pcDNA3.1 control vector (lane 1) or CHMP4B-
FLAG expression vector (lane 2). Proteins
were immunoprecipitated (IP) from the ly-
sates using anti-FLAG antibodies and de-
tected by Western blotting with anti-Myc (top
image) or anti-FLAG (middle image). A West-
ern blot (anti-Myc) of the soluble lysate is
shown in the bottom image (1% input).
(C) CHMP/VPS4 interactions analyzed by
GST pull-downassays. Pure VPS4A or VPS4B
(lanes 1 and 2; 0.7 g, 5% of input, 10-fold
molar excess) were incubated with glutathi-
one beads prebound with GST alone (lanes
3 and4),GST-CHMP1B (lanes 6 and7), orGST-
CHMP2A (lanes 9 and 10). GST-CHMP1B and
GST-CHMP2A alone are shown in lanes 5 and
8, respectively. Note that GST-CHMP1B/
VPS4A and GST-CHMP2A/VPS4B comigrate
in lanes 6 and 10, respectively.
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Figure 4. Virion Incorporation and HIV-1 Gag Redistribution to Class E Compartments
(A) Cellular and HIV-1-associated proteins detected by Ponceau S staining (upper left blot) and Western blotting with the indicated antibodies.
Lanes labeled “cells” correspond to extracts from 105 uninfected MT4 cells (positive control), lanes labeled “CA” correspond to 1 g pure CA
(negative and loading control). Lanes labeled virions 1–3 correspond to independent preparations of purified HIV-1 particles (1gCA equivalent),
sample 2* was treated with subtilisin. Recombinant AIP1–716 and VPS4B protein standards are also shown. Full-length AIP1 protein (arrowhead)
is 868 amino acids long, and the presence of multiple bands in the cell and virion lanes presumably reflects multiple protein isoforms,
posttranslational modification, degradation products, and/or crossreacting proteins.
(B) Confocal fluorescence microscopic images showing the distribution of CHMP4B (first column, red) and Gag-GFP or GagPTAP-GFP
(second column, green) in cells expressing CHMP4B-FLAG (top row, negative control) or dominant-negative DsRed-CHMP4B (middle and
lower rows). Overlaid red and green images at right show colocalization at the class E compartment of DsRed-CHMP4B with Gag-GFP (yellow
arrow). White cross bars mark the directions of the reslicing done in the XZ (bottom inset) and YZ planes (right inset). Single Z-sections are
shown in the first three columns, and merged Z-stacks (“merged overlay”) are shown in the fourth. Scale bar is 10 m.
ing HIV-1. As shown above, AIP1 binds directly to et al., 2003). We have confirmed their observation and
shown that both conserved leucines are required for fullTSG101, which in turn binds the 7PTAP10 late domain
of HIV-1 p6Gag and facilitates virus budding. Moreover, affinity AIP1 binding (Supplemental Figure S2B available
on Cell website). It is therefore likely that Gag forms aGo¨ttlinger and coworkers now report that AIP1 can bind




Figure 5. HIV-1 Release and Infectivity Are
Inhibited by Dominant-Negative CHMP and
VPS4B Proteins
Analyses of HIV-1 Gag protein expression
(Western blot, middle image), virion release
(top image), and viral infectivity (lower image)
in the presence of the dominant-negative
CHMP and VPS4B proteins: (A) CFP-CHMP4C,
DsRed-CHMP4B, DsRed-CHMP2A or CHMP-
YFP and (B) mutant VPS4B proteins. Levels
of cytoplasmic Gag proteins relative to the
relevant controls were determined by inte-
grating the CA and MA band intensities in
lighter exposures (numbers given at bottom
of the blot). Note the characteristic late defect
in intracellular processing of the CA-p2 pro-
tein seen in all cases where virus release is
inhibited. Viral titers were determined in sin-
gle-cycle MAGI infectivity assays of superna-
tants from transfected cells (blue cells/0.1
ml supernatant).
budding. However, mutations that disrupt the TSG101/ CHMP Proteins Bind VPS4 Proteins
Yeast two-hybrid interactions linked many of theGag interaction typically inhibit HIV-1 release to a much
greater extent than do mutations that disrupt the AIP1/ ESCRT-III/CHMP proteins to the two human VPS4 pro-
teins, and we therefore tested whether recombinantGag interaction, indicating that the class E proteins are
probably recruited primarily through the TSG101/Gag VPS4 and CHMP proteins could interact directly. As
shown in Figure 3C, pure recombinant mammalianinteraction (Demirov et al., 2002b; Go¨ttlinger et al., 1991).
It has also been suggested that AIP1 may bind to the VPS4A and VPS4B proteins bound to GST-CHMP1B
(lanes 6 and 7) and GST-CHMP2A (lanes 9 and 10) butYPDL late domain found in the p9 domain of the equine
infectious anemia virus (EIAV) Gag (Vincent et al., 2003). not to GST alone (lanes 3 and 4). Analogous VPS4 bind-
ing interactions were also seen for the two other CHMPAlthough AP-2 was initially described as a cellular bind-
ing partner for the YPDL late domain (Puffer et al., 1998), proteins tested (CHMP4B and CHMP6, data not shown).
These observations imply that, as in yeast (Babst et al.,this has been puzzling because AP-2 functions primarily
in endocytosis rather than MVB formation. More re- 2002a), the mammalian VPS4 enzymes likely act directly
on the subunits of the CHMP protein lattice.cently, however, AIP1 has been proposed as an alterna-
tive binding partner for the EIAV late domain because
AIP1 orthologs from several organisms can bind YPXL HIV-1 Packaging and Gag Colocalization
of Human Class E Proteinssequences (Vincent et al., 2003). We therefore tested
whether AIP1 and EIAV-p9 could form a complex in vitro. Cellular factors that participate in viral budding may be
packaged into virions, and we have previously shownAs shown in Figure 3A (lane 9), AIP11–716 bound GST-p9
and this interaction was specific for the p9 23YPDL26 late that theESCRT-I proteins TSG101andVPS28are specif-
ically packaged into HIV-1 virions (J.E. Garrus, K.M.domain motif, because binding was abolished (lane 10)
by a mutation of the central proline residue (P24A) that Stray, B.M., H.-G.K., andW.I.S., unpublished data). Pro-
teins that act later in theMVBpathway have not yet beenalso inhibits EIAV release (Puffer et al., 1997). Thus, AIP1
can bind both HIV-1 p6 and EIAV p9, indicating that both tested for virion incorporation, however. We therefore
analyzed purified HIV-1 particles from acutely infectedviruses enter the mammalian class E protein network,
at least in part, through direct interactions with AIP1. human MT4 cells for the presence of AIP1, CHMP1A,
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CHMP2A, VPS4A, and VPS4B. The purity of the virion ized to the class E compartments inducedby expression
of the DN VPS4-E235Q protein (Supplemental Figure S4preparations was evaluated on silver stained SDS-gels
(not shown) and by Western blotting, which revealed available on Cell website).
Gag-GFP redistributed significantly from the plasmano detectable contamination with a series of cellular
proteins such as the abundant 14-3-3 protein (Figure membrane/cell periphery into class E compartments
upon expression of either DsRed-CHMP4B (Figure 4B)4A, bottom right and data not shown; see also Muller
et al., 2002). or VPS4B-E235Q (data not shown). Similar results were
obtained for dominant-negative versions of the CHMP2AAll of the proteins tested were readily detected in cell
extracts (Figure 4A and data not shown). However, only and VPS4A proteins (data not shown). Moreover, the
degree to which Gag-GFP redistributed apparently de-AIP1 and VPS4B were present in multiple independent
preparations of HIV-1 particles, with a significantly pended upon TSG101 binding to Gag, as colocalization
of wt Gag-GFP/DsRed-CHMP4B was observed in 68%stronger signal for AIP1 (Figure 4A, lanes labeled virions
1, 2*, and 3). Subtilisin treatment, which degrades pro- of the cells examined (n  19), whereas colocalization
of mutant GagPTAP-GFP/DsRed-CHMP4B was un-teins on the virion exterior (Ott et al., 2000), did not
significantly reduce the AIP1 or VPS4B signals (lanes common (18%, n  48; Figure 4B, bottom image). Our
data therefore support a model in which nonfunctionallabeled virions 2*), indicating that these proteins were
located inside the viral particles. Absolute levels of vi- CHMP and VPS4 proteins cause Gag proteins to accu-
mulate together with TSG101 and other trapped classrion-associated proteins were estimated by comparing
virus-associated CA, AIP1, and VPS4B proteins against E proteins on the surface of aberrant late endosomal
compartments.known quantities of recombinant proteins. 5–10 ng of
AIP1 and 0.1–0.5 ng of VPS4B per g of CA were de-
tected. Assuming that there are 5000 Gag molecules Dominant-Negative CHMP and VPS4B Proteins
per virion (V. Vogt, personal communication), this implies Block HIV-1 Release and Infectivity
that, on average, 3–12.5 molecules of AIP1 and 0.5–2.5 The functional involvement of the CHMP and VPS4B
molecules VPS4B were incorporated into each viral proteins in HIV-1 release was also tested using domi-
particle. nant-negative proteins. A DN CHMP1A protein can be
created by fusing large polypeptides to the protein’s C
terminus (Howard et al., 2001). We found, however, thatThe PTAP Late Domain Helps Target HIV-1 Gag
to Mammalian Class E Compartments many such CHMP fusion constructs were cytotoxic and
reducedGag protein expression.We therefore surveyedIn most cell lines, HIV-1 Gag is released primarily from
the plasma membrane, whereas in macrophages the a series of 25 N- and C-terminal CHMP fusion proteins
for the ability to inhibit virus release without stronglyvirus buds directly into MVB/late endosomal compart-
ments (Pelchen-Matthews et al., 2003; Raposo et al., reducing Gag expression (see Supplemental Table S2
available on Cell website).2002). These two observations can be unified by amodel
in which: (1) Gag is targeted to the late endosome As shown in Figure 5A, HIV-1 release was dramatically
inhibited by coexpression with CFP-CHMP4C, DsRed-through interactions with the class E proteins; (2) Gag
then traffics to the plasma membrane via an endosomal CHMP2A, DsRed-CHMP4B, and CHMP3-YFP. Virus re-
lease was analyzed by: (1) Western blot detection ofpathway; and (3) viral budding can occur at different
stages along this pathway depending on the cell type. virion-associated MA and CA proteins released by cells
expressing HIV-1 (upper images), and (2) reductions ofThis model suggests that HIV-1 Gag may accumulate
on endosomal membranes upon arrest of MVB forma- viral titers in single cycle MAGI assays (lower images).
Intracellular Gag protein expression was analyzed bytion, as is the case for the class E proteins themselves
(see Supplemental Figure S3 available on Cell website). Western blot detection of cytoplasmic MA and CA pro-
teins (middle images). Controls for these experimentsTo test this idea, we examined whether dominant-
negative CHMP4B and VPS4B proteins altered HIV-1 included the appropriate empty vectors (negative con-
trols) and HIVPTAP mutants (positive controls for ar-Gag-GFP localization. A dominant-negative (DN) VPS4B
protein was created by mutating residues required for rested HIV-1 budding).
Themost dramatic effects were observed for the CFP-ATP binding (K180Q) or hydrolysis (E235Q) (see also
Fujita et al., 2003), and a dominant-negative CHMP4B CHMP4C construct, which did not alter cellular Gag
expression levels, but reduced virus release to nearlyprotein was created by fusing DsRed to the protein’s N
terminus (Howard et al., 2001). The expected class E undetectable levels in the Western blot assay and re-
duced the release of infectious virus more than 30-fold.phenotypes induced by expression of VPS4B-K180Q,
VPS4B-E235Q, and DsRed-CHMP4B were confirmed in DsRed-CHMP2A, DsRed-CHMP4B, and CHMP3-YFP
also reduced viral infectivity significantly (10-, 17-, anda series of control experiments showing that: (1) the
DN VPS4B proteins inhibited ligand-induced lysosomal 73-fold, respectively), albeit with modest reductions in
Gag protein expression (2- to 3-fold).degradation of surface MHC-I and EGFR proteins (Sup-
plemental Figure S3A–S3F available on Cell website); Coexpression of the dominant-negative VPS4B pro-
teins inhibited virus release 100-fold for both mutants(2) the DN VPS4B and CHMP4B proteins induced forma-
tion of aberrantly enlarged, vacuolated “mammalian (Figure 5B), although Gag expression levels were again
reducedmodestly (2- to 3-fold in theWestern blot assay,class E” compartments that stained positive for both
lysosomal and endosomal markers (Supplemental Fig- middle image). In contrast, the wt VPS4B (negative con-
trol) produced a comparable 2-fold reduction in cellularure S4 available on Cell website); and (3) the soluble,




Figure 6. HIV-1 Budding Arrest Induced by Dominant-Negative CHMP and VPS4B Proteins
EM images of thin-sectioned 293T cells transfected with HIV alone (A), HIVPTAP (B), or HIV and dominant-negative DsRed-CHMP4B (C and
D), DsRed-CHMP2A (E), or DsRed-VPS4B-E235Q (F–P). Thick scale bars are 1 m; thin scale bars are 100 nm. Open arrows indicate virions
arrested in budding at the plasma membrane; arrowheads indicate thickened protein coats on plasma or endosomal membranes; and black
arrows indicate striations in the stalks of arrested virions. n: nucleus; e: highly vacuolated class E compartment.
in viral titer (3.5-fold). These data demonstrate that the negative CHMP2A,CHMP4B, andVPS4Bproteins. Thin-
sectioned 293T cells transfected with wt HIV-1 DNAdominant-negative CHMP and VPS4 proteins diminish
particle release and infectivity very significantly, indicat- alone displayed very few cell-associated virions, and
these typically exhibited the conical viral cores that areing that they likely play a functional role in HIV-1 release.
the hallmark of the mature infectious virus (Figure 6A). In
contrast, coexpression of HIV-1 with dominant-negativeDominant-Negative VPS4B and CHMP Proteins
Arrest HIV-1 Budding at a Late Stage DsRed-CHMP2A, DsRed-CHMP4B, or VPS4B proteins
caused viruses to arrest at a very late stage in assembly,Electron microscopy was used to determine the stage
at which virus release was arrested by the dominant- in which extensive clusters of immature particles accu-
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mulated at the plasma membrane but remained con-
nected via membrane stalks (Figure 6, open arrows).
This arrest resembled a late domain phenotype, except
that GagPTAP mutants frequently arrested at a some-
what earlier stage (often following membrane distortion,
but prior to stalk formation; Figure 6B and see Garrus
et al., 2001), suggesting that virus release may proceed
through multiple stages and that the dominant-negative
VPS4B,CHMP4B, andCHMP2Aproteins inhibited a very
late step(s) in release.
Cells coexpressing HIV-1 and VPS4B-E235Q proteins
Figure 7. Schematic Model for the HIV-1 Budding Arrest Inducedexhibited aberrant clusters of tubules and vacuoles that
by Expression of Dominant-Negative VPS4 Proteinswere not observed in control cells. These presumably
The illustration emphasizes how nascent viral particles arrest to-corresponded to the class E compartments seen by
gether with class E protein complexes at both endosomal andfluorescence microscopy (Figures 6F–6H, labeled “e”
plasma membranes when VPS4 proteins are unable to hydrolyze
and see Supplemental Figure S4 available on Cell web- ATP (denoted by the black X). Proteins and complexes are color-
site). Strikingly, we frequently observed HIV particles coded as in Figure 1A. The figure is simplified in that oligomeric
arrested in the process of budding into the vacuoles proteins are represented only once (e.g., Gag, TSG101, AIP1, and
CHMP proteins), only the plasma membrane arrest is shown, andassociated with these compartments (Figures 6G and
many temporal and spatial details of the illustrated interactions re-6H) as well as into other, smaller clusters of intracellular
main to be elucidated.vacuoles (Figures 6I, 6J, and 6P). Viruses arrested while
budding through intracellular and plasma membranes
were morphologically indistinguishable, and we there- indicating that VPS4B acts near sites of viral assembly
fore conclude that VPS4B-E235Q imposes similar and release. Although additional studies will be required
blocks at internal and external membranes. to understand HIV-1 release in molecular detail, the ap-
The size and appearance of the internal compart- parent requirement for more than 20 cellular proteins in
ments varied considerably, as did the morphologies of this essential viral process provides many potential new
the arrested virions (e.g., in content and in stalk length targets for therapeutic intervention.
and width). Nevertheless, there were two indications Our studies also begin to define the different roles of
that cellular protein complexes might be functioning at human class E proteins in MVB biogenesis. As in yeast,
the sites of viral budding. Firstly, we and others often human CHMP6 appears to be recruited by the ESCRT-
observed a thickening of the cytoplasmic faces of mem- II complex, whereas the CHMP4 proteins are recruited
branes near sites of virus budding, which may corre- by AIP1 (see Figures 1 and 7) (Babst et al., 2002b; Odo-
spond to the ESCRT-III protein coat (see Figures 6H, 6I, rizzi et al., 2003). Importantly, we also found that TSG101
6L and 6P, arrowheads) (Pelchen-Matthews et al., 2003). and AIP1 make a series of key interactions along the
Secondly, ring-like striations were sometimes observed MVBpathway:HRS/TSG101→TSG101/EAP30,45;TSG101/
within the membrane stalks of viruses arrested by the AIP1→AIP1/CHMP4A-C that collectively link the human
dominant-negative VPS4B-E235Q protein (Figures 6K– HRS, ESCRT I, II, and III complexes (Bache et al., 2003a;
6P, highlighted by black arrows). These striations were Pornillos et al., 2003, and this work).
not observed for PTAP viruses (which are presumably It is striking that the UEV domain of TSG101 can bind
defective in recruitingTSG101 andother classEproteins to PTAP motifs found in three different proteins in the
and rarely showed narrow membrane stalks). We there- pathway (HRS, TSG101 itself, and AIP1) (Bache et al.,
fore speculate that the membrane coats and/or stria- 2003a; Katzmann et al., 2003; Lu et al., 2003; Pornillos
tions may represent trapped cellular machinery that et al., 2003) as well as in the HIV-1 p6Gag protein (Demirov
might normally help to catalyze protein sorting, mem- et al., 2002a; Garrus et al., 2001; Martin-Serrano et al.,
brane fission, and/or virus release from wild-type cells. 2001; VerPlank et al., 2001). TSG101 could, in principle,
bind multiple partners simultaneously as it self-oligo-
merizes in two-hybrid assays (Figures 1A and 1C). Alter-Discussion
natively, TSG101 may bind sequentially to the different
PTAP elements, producing conformational changes thatOur experiments define the human class E protein net-
work and strongly support the idea that HIV-1 utilizes could give directionality to the pathway. In either case,
we speculate that viral protein binding to the recognitionthis entire network during viral egress (see Figure 7).
Most importantly, HIV-1 release can be arrested at a domains of TSG101 and AIP1 may serve not only to
recruit the machinery of vesicle formation, but also tolate stage by deletion or mutation of at least 8 different
human class E proteins, which function both early alter normal protein-protein interactions required during
protein sorting and MVB vesicle formation. This could(TSG101, VPS28) (Garrus et al., 2001; Martin-Serrano et
al., 2001, 2003), and late (CHMP2A, CHMP3, CHMP4B, activate the vesicle fission machinery and/or allow viral
proteins to substitute for cellular protein cargos.CHMP4C, VPS4A, VPS4B) in the MVB pathway. In addi-
tion, HIV-1 particles packagemultiple copies of proteins Although it is not yet clear where HIV-1Gag firstmeets
(or recruits) the human class E proteins, the retroviralthat act both early (TSG101, VPS28), and later (AIP1) in
the MVB pathway. They are also enriched in at least one Moloney Murine Leukemia Gag protein traffics along




membrane (Basyuk et al., 2003). Moreover, several known late domains (PTAP, PPXY, YPDL, and/or LXXL)
groups have demonstrated that in macrophages, HIV-1 (Garrus et al., 2001; Martin-Serrano et al., 2003).
buds primarily into intracellular compartments that cor- In conclusion, multiple classes of enveloped viruses
respond to multivesicular bodies (Pelchen-Matthews et utilize the unique budding topology of MVB vesicles as
al., 2003; Raposo et al., 2002). Our studies also support a nonlytic mechanism for escaping cells. Here, we have
a role for endosomal compartments in both Gag traffick- identified an extensive network of human proteins in-
ing and virus budding. Specifically, we find that even volved in both cellular protein trafficking and virus re-
in nonmacrophage lineages (293T cells), where viruses lease, setting the stage for understanding how these
seem to bud predominantly from the plasmamembrane, proteins help catalyze protein sorting, membrane defor-
induction of a class E phenotype causes HIV-1 Gag to mation, and fission from the cytoplasmic face of a bud-
concentrate and arrest while budding into class E com- ding vesicle or virus.
partments.
Intracellular budding is particularly noticeable under
Experimental Proceduresclass E conditions because arrested viral particles accu-
mulate on membranes, and possibly also because the
Yeast Two-Hybrid Experiments
trappedclassEproteinsmay recruitGagmore efficiently Directed two-hybrid assays with full-length human class E genes
than in wild-type cells (where the class E proteins are (Supplemental Table S1 available at Cell website) were performed
using the Matchmaker GAL4 Yeast Two-Hybrid 3 system (Clontech).predominantly cytosolic). Nevertheless, we and others
Library screening was performed as described (Garrus et al., 2001),(Sherer et al., 2003; M. Thali, personal communication)
with eleven different TSG101 and four different CHMP6 baitshave observed intracellular HIV-1 budding even in wild-
screened against 3-11 106 activation domain (AD) fusions derivedtype 293T cells, particularly with the HIVPTAP mutant
from human spleen, brain, and macrophage cDNA libraries.
(which again facilitates visualization because the viruses Two-hybrid interactions were tested in -Leu, -Trp, -Ade, -His,
arrest while budding). Conversely, we (andmany others) X--gal (50 g/mL) plate assays (Figure 1C) or in semiquantitative
have observed wt virus in the process of budding di- liquid culture -galactosidase activity assays (Figure 1B). In liquid
assays, yeast transformants were picked and grown in 100 l (-Leu,rectly from the plasma membranes of 293T and HeLa
-Trp) SD media in 96 well flat-bottomed plates to an average A610cells (e.g., see Supplemental Figure S5 available on Cell
of 0.4. Resorufin -D-galactopyranoside (RDG) assay solutionswebsite). It therefore appears that HIV-1 can bud into
were 1:1 mixtures of: (1) 25 mM PIPES, [pH 7.2]; 10 mM RDG, andboth internal endosomal and plasma membranes, and
(2) 250 mM PIPES, [pH 7.2]; 10% NP-40; 0.24 Units/ml lyticase. 20
the degree to which the alternate sites are utilized in l of the RDG mix was added to each well, and fluorescence was
different cell types may simply reflect differences in the measured after 0 and 1–2 hr of incubation at 37C (SpectraMAX
GeminiXS, Molecular Devices, Inc. Sunnyvale, CA; excitation at 566relative rates of virus budding versus Gag trafficking to
nm, emission at 628 nm, with a 610 nm cutoff filter).the plasmamembrane. Importantly, virions that bud into
intracellular compartments can still emerge from the cell
via the exosome pathway, i.e., when the limiting MVB
Protein Expression and Purification
membranes fusewith theplasmamembrane and release Expression Constructs
their vesicles (or viruses) as exosomes (Denzer et al., The EIAV p9 gene was PCR-amplified as an NdeI–BamHI-fragment
2000; Pornillos et al., 2002c; Raposo et al., 2002). The from a proviral EIAVUK plasmid (a gift from Frank Cook, University
of Kentucky) (Cook et al., 1998). Other genes were amplified byparallels between exosomes and viruses are further em-
PCR (with the first 5 codons optimized for E. coli expression) fromphasized by the fact that AIP1 and TSG101, as well as
templates listed in Supplemental Table S1 (available on Cell web-MLV Gag proteins, are found in preparations of murine
site). Genes were subcloned into the NdeI/BamHI sites of a modified
exosomes (Thery et al., 2001). A full discussion of the pGEX2T vector (WISP01-69, for GST fusion proteins) or pET11a
potential relationships between exosomes and viruses (Novagene, for AIP11–716) and verified by sequencing. AIP11–716 lacked
is given in Gould et al. (2003). the proline-rich region, which hindered expression of full-length
AIP1. Mutations were introduced by PCRmegaprimer mutagenesis.It will be of interest to understand what factors influ-
Protein Expressionence where the virus buds, how Gag traffics via the
BL21(DE3) E. coli cells were grown to mid log, induced with 0.5 mMendosomal network to the plasma membrane, and
IPTG, and recombinant proteins were allowed to accumulate forwhether viruses can control these events. These issues
2–4 hr (23C). Cells were harvested, lysed using lysozyme (10 g/l
could impact viral pathogenesis because endosomal culture) and sonication, and insoluble material was removed by
pathways could be used to promote directional release centrifugation (30 min at 25,000  g).
(e.g., see Igakura et al., 2003; McDonald et al., 2003) GST fusion proteins were purified by glutathione affinity chroma-
tography, cleaved to remove glutathione, and repurified by conven-and because the primary sites of virus release likely
tional chromatography (Pornillos et al., 2002a). Untagged AIP11–716change during AIDS disease progression as the tropism
was precipitated with 55% saturated ammonium sulfate after a 27%of the virus evolves from macrophages (internal bud-
precut, redissolved in 25 mM MOPS [pH 7.0], 5 mM -ME, and
ding) to T cells (plasma membrane budding). purified by Q-Sepharose chromatography (Amersham Pharmacia;
A final important finding implied by this and related elution at 250 mM NaCl from a linear gradient of 0–1 M over 400
work is that multiple different classes of enveloped vi- mL). Fractions containing AIP11–716 were pooled, adjusted to 1 M
ammonium sulfate, and purified by phenyl-Sepharose chromatogra-ruses exit cells via the sameMVB pathway. In support of
phy (Amersham Pharmacia; pure AIP11–716 eluted at80 mM ammo-this idea, two human class E proteins (AIP1 and TSG101)
nium sulfate from a linear gradient of 1–0 M over 200 ml). Massbind directly to structural proteins from two different
spectrometry confirmed the identity of AIP1–716 (minus the N-terminalviruses (HIV-1 p6/TSG101/AIP1 and EIAV p9/AIP1) and
methionine). Yields were typically 20 mg AIP1–716 per liter culture.
link them directly into the MVB pathway. Moreover, a The expression and purification of human VPS4 proteins will be
dominant-negative VPS4A protein that induces a class described elsewhere (A.S., F.G. Whitby, W.I.S., and C.P. Hill, unpub-
lished data).E phenotype blocks the release of viruses that bud via all
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Protein Interactions PTAP-GFP have been described (Garrus et al., 2001; Hermida-Mat-
sumoto and Resh, 2000)Biosensor Measurements
Binding affinities of pure Tsg101 UEV domains to immobilized GST-
AIP1714–723 (AREPSAPSIP) were quantified using a Biacore biosensor Immunofluorescence
COS-7 cells growing on glass cover slips in 60mmdishes (in DMEM/(20C in 20 mM sodium phosphate, 150 mM NaCl, 0.01% P20, 50
g/mL BSA, [pH 7.2]) (Garrus et al., 2001). 10% FBS) were transfected with 2 g plasmid DNA and 12 l Gene-
Jammer (Stratagene) as per manufacturer’s instructions. Twenty-GST Affinity Cochromatography
GST-CHMP fusion proteins used in affinity cochromatography (pull- four hr posttransfection, cells were fixed in 3.7% formaldehyde/PBS
and permeabilized in 0.1% Triton X-100/PBS/1%BSA. Cells weredown) assays (Figure 3) were expressed from pGEX vectors in
BL21(DE3) E. coli, prebound to glutathione agarose (Amersham- incubated with either rabbit anti-M6PR (1:200, from Peter Lobel) or
mouse anti-Lamp-2 (1:200, Developmental Hybridoma) at 23C forPharmacia), and tested for binding to AIP11–716, VPS4A, or VPS4B
following manufacturer’s instructions. 60 min. Samples were washed and incubated with goat antirabbit
or antimouse Alexa 488-conjugated antibodies (1:750, MolecularImmunoprecipitations
293T cells (10 cm plate) were cotransfected (Lipofectamine 2000, Probes). FLAG-tagged CHMP4 proteins were detected using Alexa
488-or Alexa 594-congugated anti-FLAG (1:750, Sigma M2). ImagesInvitrogen) with 6 g pcAIP1-Myc expression vector (see below)
and 6 g CHMP4B-FLAG or control vector (modified from were collected as single wavelengths on an Olympus FVX confocal
fluorescent microscope with a 60 Pianapo objective (1.4 NA oil),pcDNA3.1). Cells were harvested (24 hr), lysed for 30 min on ice in
20 mM Tris·HCl [pH 7.4], 150 mM NaCl, 0.5% NP-40, with 2 M using Fluoview 2.0.39 software. 0.5 m thick Z sections or merged
Z stacks are shown. Reslicing and three-dimensional representationpepstatin, 1 mM PMSF, 10 g/mL leupeptin, 5 g/mL aprotinin, and
clarified by centrifugation (16,000 g for 30 min). Lysate (1 mg total of Z sections were created with Volocity imaging software (Impro-
vision).protein) was incubated (3 hr, 4C) with 1 g of anti-FLAG antibody
(M2, Sigma) and antimouse IgG rabbit antibody (Zymed) conjugated
to Protein A Sepharose (Amersham Bioscience). Unbound proteins HIV Protein Expression in 293T Cells
For Western blots of Gag expression, infectivity assays and EM,were removed by washing with lysis buffer, and bound proteins
analyzed by Western blotting with anti-FLAG (1:5000; Sigma M2) or 293T cells in 6-well plates were transfected with 9 l Lipofectamine
2000 (Invitrogen) per 2 g HIV-R9  1 g other expression vectorsanti-Myc antibodies (clone 9E10, 1:1000, Covance Inc.).
per well as described (Garrus et al., 2001).
Antibody Production
Gag Western Blots and Viral Replication AssaysAntibodies to recombinant AIP11–716 (sera UT324UT325), CHMP2A
Cytoplasmic proteins and sucrose-pelleted virions (Figure 5) were(UT318), VPS4A (UT289), and VPS4B (UT292) were raised in New
harvested 36 hr after transfection, resolved by 12% SDS-PAGE,Zealand White Rabbits (Covance Inc.). Affinity columns were pre-
blotted, and detected by ECL as described (von Schwedler et al.,pared with 1 mg of purified GST fusion proteins coupled to NHS-
1998). Primary antibodies were rabbit anti-CA #40 at 1:2000 andactivated crosslinked agarose (1 ml HiTrapTM NHS-activated HP
rabbit anti-MA at 1:20,000. HIV infectious titers were assayed bycolumn, Amersham Biosciences) following manufacturer’s instruc-
MAGI assays in P4 cells (von Schwedler et al., 1998).tions. Antiserum (1 mL) was applied to PBS-equilibrated columns,
incubated (1 hr, 23C), and washed with 10 ml PBS. Bound antibody
Electron Microscopywas eluted in 50 mM glycine, 150 mM NaCl, [pH 2.5], neutralized
For EM studies, transfected 293T cells were fixed, stained, andimmediately by addition of 0.2 M Tris·HCl, [pH 8.0], concentrated
embedded in Spurr’s plastic 48 hr after transfection (Garrus et al.,using Vivaspin 0.5 ml concentrators (Vivascience) and dialyzed
2001), and EM images were obtained at magnifications of 5000–against PBS. Anti-CHMP1A was a gift from Dan Stauffer.
150,000.
Detection of Proteins Incorporated into HIV-1 Particles
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Efficient human immunodeficiency virus type 1
(HIV-1) budding requires an interaction between the
PTAP late domain in the viral p6Gag protein and the
cellular protein TSG101. In yeast, Vps23p/TSG101 binds
both Vps28p and Vps37p to form the soluble ESCRT-I
complex, which functions in sorting ubiquitylated pro-
tein cargoes into multivesicular bodies. Human cells
also contain ESCRT-I, but the VPS37 component(s) have
not been identified. Bioinformatics and yeast two-hy-
brid screening methods were therefore used to identify
four novel human proteins (VPS37A–D) that share weak
but significant sequence similarity with yeast Vps37p
and to demonstrate that VPS37A and VPS37B bind
TSG101. Detailed studies produced four lines of evi-
dence that human VPS37B is a Vps37p ortholog. 1)
TSG101 bound to several different sites on VPS37B, in-
cluding a putative coiled-coil region and a PTAP motif.
2) TSG101 and VPS28 co-immunoprecipitated with
VPS37B-FLAG, and the three proteins comigrated to-
gether in soluble complexes of the correct size for hu-
man ESCRT-I (350 kDa). 3) Like TGS101, VPS37B be-
came trapped on aberrant endosomal compartments in
the presence of VPS4A proteins lacking ATPase activity.
4) Finally, VPS37B could recruit TSG101/ESCRT-I activ-
ity and thereby rescue the budding of both mutant Gag
particles and HIV-1 viruses lacking native late domains.
Further studies of ESCRT-I revealed that TSG101 muta-
tions that inhibited PTAP or VPS28 binding blocked
HIV-1 budding. Taken together, these experiments de-
fine new components of the human ESCRT-I complex
and characterize several TSG101 protein/protein inter-
actions required for HIV-1 budding and infectivity.
Like other enveloped viruses, HIV-11 must bud from pro-
ducer cells to spread infection. HIV budding requires both
cis-acting viral elements and trans-acting cellular proteins (re-
viewed in Ref. 1). Efficient release and replication of HIV-1 in
most cell types, including primary cells, require a conserved
cis-acting P(S/T)AP motif (the “late domain”), located in the
C-terminal p6 region of the structural Gag protein (2–5). The
P(S/T)AP late domain binds and recruits the cellular protein
TSG101 (tumor susceptibility gene 101), which facilitates effi-
cient separation of the viral and cellular membranes during the
final stages of virus release (6–9). In addition to HIV-1, several
other pathogenic human viruses, including human T-cell leu-
kemia virus type I (Retroviridae), Ebola virus (Filoviridae) and
Lassa virus (Arenaviridae), also use P(S/T)AP late domains to
recruit TSG101 during virus budding (7, 10–13). In turn,
TSG101 helps to recruit a complex set of cellular machinery
that is normally used for protein sorting, membrane distortion,
and fission at the multivesicular body (MVB) (1).
Much of our understanding of MVB biogenesis comes from
studies in yeast (reviewed in Refs. 14 and 15). Vps23p, the
yeast ortholog of TSG101, binds two other proteins, Vps28p
and Vps37p, to form a stable soluble 350-kDa complex called
ESCRT-I (endosomal sorting complex required for transport)
(16). ESCRT-I is recruited to the endosomal membrane
through an interaction with the upstream Vps27p-HRS com-
plex (17–21). Once on the membrane, ESCRT-I helps recruit a
series of downstream proteins and complexes (the “Class E”
proteins), which collectively sort ubiquitylated proteins into
vesicles that bud into the maturing endosome to create MVBs.
In most cases, these protein sorting and vesiculation events
ultimately target proteins for degradation in the interior of the
lysosome (vacuole in yeast).
Although the humanMVB pathway is more complex and less
well characterized than the yeast pathway, there is now good
evidence for conservation of ESCRT-I composition and function
from yeast to humans. First, TSG101 and VPS28 are required
for the ubiquitin-dependent delivery of cathepsin D and endo-
cytosed receptors to the lysosome (e.g. Refs. 17 and 22–24).
Second, mammalian TSG101 and VPS28 also function together
as part of a soluble 350-kDa ESCRT-I complex (22, 25). How-
ever, a significant limitation in our understanding of the hu-
man ESCRT-I complex is that orthologs of VPS37 have not yet
been identified in animals.
As illustrated in Fig. 1A, TSG101 is a multifunctional, mul-
tidomain protein composed of an N-terminal ubiquitin E2 var-
iant (UEV) domain (residues 1–145), a proline-rich region (res-
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idues 146–215), a predicted central coiled-coil region
(residues 240–311), and a conserved helical C-terminal do-
main (residues 330–390). TSG101 appears to function pri-
marily as an adaptor protein, and the different regions of
TSG101 engage in a series of protein/protein interactions
within the ESCRT-I complex, including the following. 1) The
TSG101 N-terminal UEV domain binds P(S/T)AP peptide mo-
tifs. Potential cellular binding sites include a downstream
PTAP motif within TSG101 itself and P(S/T)AP motifs within
at least two other Class E proteins, HRS and AIP1 (17–20,
26–28). 2) The C-terminal region of TSG101/Vps23p binds
VPS28/Vps28p (14, 25, 29). This interaction is important for
MVB formation and may also control the steady-state levels of
TSG101 (30). 3) Finally, deletion of a predicted central coiled-
coil region within Vps23p blocks incorporation of Vps37p into
the ESCRT-I complex, suggesting that this region of Vps23p
may form (or contain) the Vps37p-binding site (16).
Given the parallels between MVB vesicle formation and
HIV-1 budding, it has become important to characterize the
different TSG101 protein/protein interactions that function in
ESCRT-I assembly and test their involvement in virus bud-
ding. The goals of this study were therefore to identify human
VPS37 orthologs and to test the importance of known TSG101/
ESCRT-I interactions in HIV-1 budding.
MATERIALS AND METHODS
VPS37 Homology Searches—In one procedure, the yeast Srn2p/
Vps37p protein sequence (NCBI accession number NP_013220) was
submitted to the NCBI PSI-BLAST search engine and compared with
all known proteins. The first iteration identified apparent VPS37 or-
thologs in fungi and Japanese rice (NCBI accession number AAS01952).
A composite profile built from these sequences was then compared with
all known proteins to identify VPS37 orthologs in animals. All se-
quences above the default threshold (18 total) were incorporated into
the search profile, and a final iteration identified four human proteins:
VPS37A/HCRP1 (hepatocellular carcinoma-related protein 1; NCBI Lo-
cusLink 137492), VPS37B (NCBI LocusLink 79720), VPS37C (NCBI
LocusLink 55048), and VPS37D/WBSCR24 (Williams-Beuren syn-
drome chromosome region 24; NCBI LocusLink 155382).
In a second procedure, the five proteins shown to bind TSG101 in a
global analysis of protein/protein interactions in Drosophila (31) were
compared against the human protein data base. One of the Drosophila
proteins (CG1115-PA; NCBI accession number NP_649518) showed
clear sequence similarities to VPS37B and VPS37C (E  1  106) and
weaker similarities to VPS37A (E  1.4) and VPS37D (E  0.034).
Plasmid Construction—Mammalian expression vectors for wild-type
(WT) and PTAP mutant HIV-1NL4-3, WT and mutant VPS4A, and small
interfering RNA (siRNA)-resistant TSG101 (TSG*-FLAG) have been
described (6). Additional point mutations were introduced into pIRES-
TSG*-FLAG using Kunkel or QuikChange (Stratagene) mutagenesis.
Deletion mutants were created by PCR amplifying the desired region of
pIRES-TSG*-FLAG and subcloning the product into pIRES2-EGFP.
VPS37B constructs were PCR-amplified from an expressed sequence
tag (DDBJ/GenBankTM/EBI accession number BE909752; American
Type Culture Collection, Manassas, VA) with the sequence encoding the
C-terminal FLAG epitope within the 3-primer. VPS28 (GenBankTM
accession number BC019321) constructs were PCR-amplified from a
QUICK-Clone human HeLa cDNA pool (Clontech) using gene-specific
primers. For expression in Escherichia coli, the VPS28 coding region
was subcloned into WISP01-69, a modified pGEX2T vector (Amersham
Biosciences), to create WISP01-136, which expresses VPS28 as a GST
fusion protein.
Yeast Two-hybrid Binding Assays—Global and directed yeast two-
hybrid screens were performed as described previously (19, 26). Briefly,
directed two-hybrid assays with full-length TSG101 and VPS37B and
deletion constructs were performed using the Matchmaker Gal4 yeast
two-hybrid 3 system (Clontech). In each experiment, five test clones and
five controls were selected at random and tested for -galactosidase
activity in Leu/Trp/Ade/His X--gal (50 g/ml) plate assays.
Directed two-hybrid assays with full-length TSG101 and VPS28 and
deletion constructs were performed using the MP30 vector system (32).
To identify yeast colonies producing -galactosidase, cells were lifted
onto filter paper disks, lysed by freeze-thawing in liquid nitrogen, and
assayed with X--gal. For quantitation of -galactosidase activity, 20
colonies/plate were randomly selected, pooled, grown on synthetic liquid
medium, and assayed with chlorophenol red -D-galactopyranoside or
o-nitrophenyl--D-galactopyranoside (6).
VPS37B-FLAG Immunoprecipitation Experiments—293T cells
(10-cm plate) were transfected using LipofectAMINE 2000 (Invitrogen)
with 13 g of pCIneo-VPS37B-FLAG or the control pCIneo-FLAG vec-
tor. Cells were harvested after 24 h; lysed for 30 min on ice in 1 ml of 50
mM Tris-HCl (pH 7.4), 150 mM NaCl, and 0.1% Nonidet P-40 containing
2 M pepstatin, 1 mM phenylmethylsulfonyl fluoride, 10 g/ml leupep-
tin, and 5 g/ml aprotinin; and then clarified by centrifugation at
16,000  g for 20 min. Lysate (1 mg of total protein) was incubated
overnight at 4 °C with anti-FLAG antibody M2-agarose affinity beads
(Sigma, A 2220). Unbound proteins were removed by lysis buffer
washes, and bound proteins were stripped by boiling in SDS-PAGE
buffer and analyzed by Western blotting.
Western Blotting—Virus from the supernatants of transfected cells
was pelleted through a 20% sucrose cushion in a microcentrifuge at
13,000 rpm for 90 min at 4 °C and resuspended in 25 l of 1 SDS gel
loading buffer. Samples (5–7.5 l) were separated by 12% SDS-PAGE,
transferred, blocked (typically with 5% nonfat dry milk, but as low as
0.1% when detecting endogenous TSG101), blotted with antisera, and
protein bands were detected by enhanced chemiluminescence (ECL,
Pierce). Transfected human embryonic kidney 293T cells (1 well from a
6-well plate) were harvested directly into 40–45 l of radioimmune
precipitation assay buffer (10 mM Tris-Cl (pH 7.0), 150 mM NaCl, 1%
Nonidet P-40, and 0.1% SDS) and incubated on ice for 4 min. Samples
were clarified by microcentrifugation at 13,000 rpm for 4 min at 4 °C,
and lysates were resuspended in an equal volume of 2 SDS gel loading
buffer. Aliquots (5–10 l) were resolved by 12–17.5% SDS-PAGE.
Bound antibody was detected by ECL using SuperSignal West Pico
(Pierce) according to the manufacturer’s instructions. The following
primary antibodies were used: rabbit anti-HIV CA protein antibody
(1:2000), rabbit anti-HIV MA protein antibody (1:25,000; Didier Trono,
Geneva, Switzerland), murine monoclonal anti-TSG101 antibody 4A10
(1:100–1000; GeneTex, Inc.), murine monoclonal anti-FLAG antibody
M2 (1:5000; Sigma), and rabbit anti-NEDD4 antibody (1:5000; Pharm-
ingen). Anti-VPS28 antibodies (1:500–1500) were raised against recom-
binant VPS28 (see below) in New ZealandWhite rabbits (Covance, Inc.).
Gel Filtration—293T cells transfected with pCIneo-VPS37B-FLAG
(as described for the immunoprecipitation experiments) were harvested
after 24 h; lysed for 30 min on ice in 1 ml of phosphate-buffered saline
(pH 7.4) and 0.1% Tween 20 containing 2 M pepstatin, 1 mM phenyl-
methylsulfonyl fluoride, 10 g/ml leupeptin, and 5 g/ml aprotinin; and
clarified by centrifugation at 16,000  g for 30 min. The lysate was
fractionated by gel filtration chromatography on a Sephacryl S300
column (Amersham Biosciences). Proteins in the 1.4-ml fractions were
trichloroacetic acid-precipitated, washed with acetone (22), and ana-
lyzed by Western blotting. Apparent molecular masses were obtained
by comparison with a standard curve derived from chromatography of
proteins of known mass.
Immunofluorescence—COS-7 cells grown on glass coverslips on
60-mm dishes were cotransfected with 100 ng of vector expressing
VPS37B-FLAG and 900 ng of vector expressing WT or K173Q VPS4A-
GFP using 2.5 l of LipofectAMINE 2000 following the manufacturer’s
instructions. Cells were fixed and permeabilized 24 h post-transfection
in 4% paraformaldehyde and phosphate-buffered saline, incubated with
rabbit anti-FLAG antibody (1:500) at 4 °C for 16 h, washed with phos-
phate-buffered saline, and incubated with Alexa 594-conjugated goat
anti-rabbit antibodies (1:500) to detect FLAG-tagged VPS37 proteins.
Images were collected as single wavelengths on an Olympus FVX con-
focal fluorescent microscope using Fluoview Version 2.0.39 software.
0.3–0.7-m-thick Z sections are shown.
Gag-VPS37B Rescue Experiments—All Gag and Gag-VPS37B ex-
pression constructs were based on pGag-GFP (a gift from Dr. Marilyn
Resh) (33). Expression vectors for GagPTAP-GFP and Gagp6 were
created as described (19), and GagPTAP-VPS37B and Gag-VPS37B
expression constructs were created by replacing the GFP coding region
with the VPS37B coding sequence. Plasmid DNA encoding either Gag-
GFP or Gag-VPS37B constructs was cotransfected together with
Gagp6 plasmid DNA into 293T cells (2 ml, 6-well plates). Protein
expression and release of viruses and virus-like particles (VLPs) were
analyzed by Western blotting 24 h post-transfection.
Viral Replication Assays—Infectivity of HIV-1 particles released into
the supernatants from cells transfected with R9 constructs was deter-
mined in single-cycle MAGIC replication assays as described (34), ex-
cept that infections were performed at three different dilutions in
triplicate in 48- or 96-well plates. Blue cells and syncytia were counted
2 days post-infection.
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TSG101 Depletion/Replacement Experiments—Synthetic 21-nucleo-
tide siRNA duplexes with 2-nucleotide 2-deoxythymidine 3- or uridine
3-overhangs were targeted to TSG101 coding nucleotides 413–433 (35).
293T cells in 6-well plates (2-ml culture volume) were transfected twice
at 24-h intervals using LipofectAMINE 2000 (6). The first transfection
was with 50 nM siRNA duplexes and either 2 g of pSL1180 carrier
plasmid (Amersham Biosciences) or 2 g of WT or mutant siRNA-
resistant pIRES-TSG*-FLAG expression vector. The second transfec-
tion was performed with the same siRNA duplex (50 nM) and 500 ng of
vector R9. Viral supernatants and cytoplasmic lysates were harvested
after an additional 24–28 h and analyzed for protein expression and
virus infectivity. All transfections and subsequent analyses were re-
peated at least three independent times.
Recombinant VPS28 Purification—E. coli BL21(DE3) cells trans-
formed with WISP01-136 were induced with 1 mM isopropyl--D-thio-
galactopyranoside to express recombinant GST-VPS28 and grown for
4 h at room temperature. Following cell lysis, soluble GST-VPS28 was
purified by glutathione-Sepharose affinity chromatography (GSTPrep
FF, Amersham Biosciences) and eluted with 20 mM glutathione. Fol-
lowing dialysis in 50 mM Tris-HCl (pH 8.0), 100 mM NaCl, and 1 mM
dithiothreitol, the fusion protein was cleaved with 1 mg of tobacco etch
virus protease/100 mg of protein for 24 h at 23 °C; free GST was
removed by two rounds of glutathione-Sepharose affinity chromatogra-
phy; and VPS28 protein was purified to homogeneity by anion exchange
chromatography on immobilized Q-Sepharose (Amersham Biosciences).
VPS28 eluted at 300 mM NaCl from a linear gradient of 50 mM to 1 M
NaCl in 25 mM Tris-HCl (pH 8.0) and 5 mM 2-mercaptoethanol.
Detection of Proteins Incorporated into Virus Particles—Human
MT-4 T-cells were infected with HIV-1NL4-3 by co-culture as described
previously (36). 60 h post-infection, a supernatant was harvested, and
virus was purified by pelleting through a 20% (w/w) sucrose cushion,
followed by velocity centrifugation through an iodixanol gradient as
described (37). Particles were concentrated by ultracentrifugation, and
the purity of the samples was verified by SDS-PAGE, followed by silver
staining. For Western blotting, virus particles corresponding to 1 g of
CA protein (adjusted by comparison with purified recombinant CA
protein) (38) and 1 g of recombinant CA protein (control) and extracts
from 105 uninfected MT-4 cells were separated by 17.5% SDS-PAGE
(200:1 acrylamide/bisacrylamide).
RESULTS
Identification of Candidate Human VPS37 Proteins—As dis-
cussed above, the human ESCRT-I complex presumably con-
tains TSG101, VPS28, and VPS37. However, VPS37 orthologs
have not yet been identified in humans or any other higher
eukaryote, apparently because the primary sequence has di-
verged considerably from yeast Vps37p (which shares 20%
sequence identity with any known human protein). We there-
fore pursued three different approaches to identify VPS37 can-
didates, and these approaches independently identified the
same family of human proteins.
In the first approach, the yeast Vps37p protein sequence was
used to search for human VPS37 candidates by creating PSI-
BLAST composite profiles of putative VPS37 orthologs from
higher eukaryotes (see “Materials and Methods” for details).
Four human proteins were identified using this approach:
VPS37A/HCRP1 (39), VPS37B, VPS37C, and VPS37D/WB-
SCR24. In the second approach, we searched for human ho-
mologs of the five proteins previously shown to bind TSG101 in
a global map of Drosophila protein/protein interactions (31).
This approach again yielded the same four proteins as the best
human protein matches to one of the five Drosophila TSG101-
binding partners (Fig. 1B). Finally, we performed extensive
yeast two-hybrid screens of human spleen cDNA libraries with
the goal of identifying human TSG101-binding proteins de
novo. These screens employed 12 different TSG101 fragments
as baits and identified two different “minimal” fragments of
VPS37A as binding partners for TSG101-(12–326) (identified
nine times in total) (Table I) and one fragment of VPS37B
(VPS37B-(1–126), identified once) as a binding partner for
TSG101-(12–326).
VPS37A–D are most similar within an 150-amino acid
region that has been designated the mod_r domain (Fig. 1B)
(40). This is also the region of highest homology to yeast
Vps37p and to the putative Drosophila VPS37 ortholog. Each
mod_r domain contains at least one segment that is strongly
predicted to form a coiled coil, as does the yeast Vps37p protein.
Interestingly, our yeast two-hybrid screening studies indicated
that the TSG101-binding sites on VPS37A and VPS37B span at
least part of the mod_r domain. Thus, the screening and align-
ment analyses suggested that all four human VPS37 proteins
might be Vps37p orthologs that bind TSG101 via their con-
served mod_r domains. To test this hypothesis, we selected
VPS37B for detailed studies because 1) its domain structure
most closely resembles that of yeast Vps37p; 2) its mod_r do-
main has the highest identity to the Drosophila VPS37 protein
(Fig. 1B) (data not shown); and 3) VPS37B mRNA is expressed
in a wide variety of tissues (see NCBI UniGene Cluster
Hs.77870 Homo sapiens), including macrophages and lympho-
cytes, which are the natural hosts for HIV-1 replication.
Yeast Two-hybrid Binding Studies—“Reverse” library
screens were performed using six different VPS37B bait frag-
ments, and these screens identified four different TSG101 frag-
ments as binding partners for one of the baits (VPS37B-(50–
170)) (Table I). Thus, unbiased library screens that employed
either VPS37B or TSG101 baits successfully identified the re-
ciprocal protein as a binding partner. A series of directed yeast
two-hybrid experiments were then performed to confirm the
interaction and to map the TSG101/VPS37B interaction sites.
As shown in Fig. 2A, full-length TSG101-DBD and VPS37B-AD
proteins interacted strongly, whereas empty vector controls
showed no detectable background binding. Deletion mapping
experiments revealed that the TSG101 interaction site is lo-
cated within a central fragment of VPS37B that spans residues
65–112. This minimal binding site is also contained in all of the
VPS37B fragments identified in the library screens (Table I).
Deletion of an additional 11 residues from the C terminus (to
residue 101), which removed even more of the second predicted
coiled-coil sequence in VPS37B, blocked TSG101 binding, sup-
porting the idea that the coiled coil is important for the TSG101
interaction.
Deletion analyses were also performed to map the binding
site for VPS37B on TSG101 (Fig. 2, A and B). These analyses
were complicated, however, because all three TSG101 frag-
ments initially tested bound VPS37B to some extent. Binding
was weakest for TSG101-(1–145), which showed a weak inter-
action with the full-length VPS37B protein (Fig. 2A, lower
panel) and a moderate interaction with VPS37B-(65–198) (Fig.
2B). TSG101-(1–145) corresponds to the PTAP motif-binding
UEV domain, and VPS37B contains a PTAP motif (residues
185–188). We therefore tested whether the PTAP site on
TSG101 mediates the TSG101-(1–145)/VPS37B-(65–198) inter-
action using a point mutation (M95A) within the TSG101 UEV
domain that blocks PTAP binding (41). This mutation elimi-
nated the TSG101-(1–145)/VPS37B-(65–198) interaction (Fig.
2B, lower panel), indicating that the TSG101 UEV domain did
indeed contact VPS37B-(65–198) through the PTAP motif-
binding groove. Similarly, we found that the pure recombinant
TSG101 UEV domain (residues 1–145) bound specifically to a
nine-amino acid peptide spanning the VPS37B PTAP site as
analyzed in biosensor binding experiments (ELAPTAPLPY;
KD  155 M) (data not shown). Thus, the N-terminal TSG101
UEV domain binds directly, but weakly, to the VPS37B PTAP
motif. Importantly, however, the TSG101 M95A mutation did
not appreciably inhibit the interaction between the full-length
TSG101 and VPS37B proteins (Fig. 2A, lower panel). Hence,
the VPS37B PTAP motif is not the primary binding site for
TSG101. This situation is analogous to the TSG101/HRS inter-
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action, where the TSG101 UEV domain can bind an HRS PSAP
sequence, but the primary interaction(s) between the two pro-
teins occurs elsewhere (17–20).
TSG101 fragments spanning residues 158–309 and 310–390
also interacted with full-length VPS37B in the yeast two-hy-
brid experiments (Fig. 2B). Indeed, positive VPS37B interac-
tions were detected for a series of non-overlapping fragments
spanning the C-terminal end of TSG101 (Fig. 2B) (data not
shown). It is therefore possible that VPS37B makes multiple
contacts both upstream and downstream of TSG101 residue
310. However, we cannot rule out the alternative possibility
that the observed TSG101/VPS37B interactions may, in some
cases, be bridged via the endogenous yeast ESCRT-I complex,
particularly as determinants of TSG101 homo-oligomerization
are also found in this region (29). In any event, these compli-
cations precluded a more precise mapping of the VPS37B-
binding site on TSG101.
Finally, directed yeast two-hybrid experiments were also
used to test for VPS37B interactions with other known human
Class E proteins, and two human Class E proteins tested pos-
itive in these assays: VPS37B itself and HRS (data not shown).
The former interaction indicates that VPS37B likely forms
homo-oligomeric interactions. The latter interaction suggests
that VPS37B may play an important role in helping the up-
stream HRS complex to recruit ESCRT-I to the endosomal
membrane. We note that Bieniasz2 has similarly found that the
VPS37C protein interacts with HRS in two-hybrid assays.
Yeast Vps37p exhibits two-hybrid interactions with three ad-
ditional yeast Class E proteins (Vps20p, Vps28p, and Vps36p)
(43), but we did not observe analogous interactions between the
human orthologs in our experiments.
Human VPS37B Forms a Complex with TSG101 and VPS28
in Vivo—We next tested whether VPS37B forms stable com-
2 P. D. Bieniasz, personal communication.
TABLE I










FIG. 1. Schematic illustrations showing the putative domain structures and binding partners of TSG101 (A) and VPS37-like
proteins (B). A, schematic illustration of TSG101 showing the amino acid numbering scheme and approximate interaction sites of known binding
partners. The dashed line highlights the observation that the C-terminal two-thirds of TSG101 can bind itself, although the precise sequence
requirements for homo-oligomerization have not yet been determined (29). PRO, proline-rich region; CC, predicted coiled-coil region; S-Box,
steadiness box region (30). Regions designated as coiled coils had a predicated coiled-coil propensity of 0.1 as analyzed by the program Multicoils
(67) or 0.2 as analyzed by the program Coils (68). B, VPS37-like proteins from Drosophila (CG1115-PA) and humans (as indicated) are shown
schematically, together with their NCBI LocusLink identifiers. Percent identities between the mod_r domains of CG1115-PA and the human
proteins are shown in blue. Note that the N-terminal ends of the VPS37C and VPS37D/WBSCR24 proteins have not been determined experimen-
tally, and the dashed line shows an alternative possible N terminus for VPS37D/WBSCR24. Putative domain identities were obtained from the
Swiss Protein Knowledgebase (69), except that the E2 domain designation for VPS37A/HCRP1 was changed to “UEV” because the domain lacks
an active-site cysteine residue.
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plexes with TSG101 and VPS28 in human cells. As shown in
Fig. 2C (right panels, right lanes), immunoprecipitation of ex-
ogenously expressed VPS37B-FLAG from soluble 293T cell ex-
tracts efficiently co-immunoprecipitated both TSG101 and
VPS28. This was a specific interaction, as neither TSG101 nor
VPS28 was detected in control co-immunoprecipitation reac-
tions with mock-transfected cells (left lanes). Interestingly,
VPS37B overexpression also increased the steady-state levels
FIG. 2. TSG101/VPS37B binding studies. A, yeast two-hybrid binding signals arising from coexpression of the indicated pairs of test (right)
or control (left) proteins. In the upper panel, a full-length TSG101-DBD fusion protein was coexpressed with the VPS37B-AD fusions shown to the
right. In the lower panel, full-length VPS37B was coexpressed with the TSG101 fragments shown to the right. Note that VPS37B bound both
TSG101-(1–145) and TSG101-(1–157) to a similar extent (not shown). Controls and test interactions were examined for five independent clones
expressing the appropriate pairs of proteins. Blue indicates positive interactions, and the relative strength of each relevant interaction is
summarized to the left. PRO, proline-rich region; CC, predicted coiled-coil region; S-Box, steadiness box region (30). B, yeast two-hybrid binding
signals arising from coexpression of the designated pairs of proteins or controls. C, co-immunoprecipitation of endogenous TSG101 and VPS28 with
VPS37B-FLAG. Left panels, Western blot signals observed for the input lysate (50 g of total protein input); right panels, Western blot signals
following immunoprecipitation (IP) of VPS37B-FLAG (500 g of total protein input). Right lanes, lysates from cells expressing VPS37B-FLAG;
left lanes, control cell extracts. IB, immunoblot.
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of VPS28 (lower left panel, compare the two lanes). This effect
was observed in multiple experiments, but the relative in-
creases in VPS28 levels varied between the different experi-
ments. Thus, our data demonstrate that the TSG101, VPS28,
and VPS37B-FLAG proteins associate within cells and indicate
that elevated VPS37B levels can stabilize VPS28, presumably
via ESCRT-I complex formation.
The Human ESCRT-I Complex—Gel filtration chromatogra-
phy was used to test whether VPS37B, TSG101, and VPS28
form higher order complexes of the size expected for human
ESCRT-I. Previous studies have demonstrated that soluble
human ESCRT-I complexes elute from gel filtration columns
with an apparent molecular mass of 350 kDa (22, 25). As
shown in Fig. 3, exogenously expressed and tagged VPS37B
also precisely eluted together with TSG101 and VPS28 in com-
plexes of 350 kDa. Moreover, all three proteins were present
in the same complexes, as immunoprecipitation of VPS37B-
FLAG from these fractions again co-immunoprecipitated
TSG101 and VPS28 (data not shown). We therefore conclude
that VPS37B-FLAG associates stably with the human
ESCRT-I complex.
VPS37B-FLAG and endogenous TSG101 were also present
in smaller complexes of overlapping but slightly different sizes
(116 and 106 kDa, respectively). In contrast, VPS28 was
found only in the350-kDa complex. In the absence of VPS37B
overexpression, all of the endogenous TSG101 protein is nor-
mally present within the ESCRT-I complex (22), and it is there-
fore likely that the smaller TSG101 and VPS37B subcomplexes
accumulate because VPS28 levels, although increased in the
presence of elevated VPS37B, are still limiting when VPS37B
is overexpressed.
VPS37B Is Trapped on Endosomal Membranes in the Ab-
sence of VPS4A ATPase Activity—Under steady-state condi-
tions, ESCRT-I and other Class E proteins are present primar-
ily in dispersed soluble complexes. To function in MVB cargo
sorting and vesicle formation, however, these complexes must
transiently associate with endosomal membranes. Following
vesicle formation, these complexes then disassemble and are
released from the membrane through the action of the VPS4
ATPases associated with a variety of cellular activities (25, 26,
44–50). Thus, in the absence of VPS4 ATPase activity, Class E
proteins are recruited to the endosomal membrane, but become
trapped on aberrant endosomal compartments (Class E com-
partments). This behavior can be seen for the VPS4A-GFP
protein itself, where the wild-type protein was present in dis-
persed soluble complexes (Fig. 4A, second panel), whereas a
dominant-negative VPS4A mutant lacking the ability to bind
and hydrolyze ATPase activity (K173Q) was trapped on endo-
somal membranes (Fig. 4B, second panel).
Analogous experiments were used to test whether VPS37B is
recruited to endosomal membranes in a VPS4A-dependent
fashion, as has been seen previously for the other mammalian
ESCRT-I components (25). As expected, VPS37B-FLAG was
distributed throughout the cell as a soluble protein when coex-
pressed with WT VPSP4A-GFP. This “dispersed” phenotype
was observed in nearly all (90%) of the VPS4A-GFP/VPS37B-
FLAG cells examined. In contrast, when VPS37B-FLAG was
coexpressed together with the dominant-negative K173Q
VPS4A-GFP mutant, most of the VPS37B-FLAG protein be-
came concentrated at punctate cytoplasmic sites (88% of the
cells examined). These sites corresponded to Class E compart-
ments, as confirmed by the co-localization of VPS37B-FLAG
and K173Q VPS4A-GFP (Fig. 4B, fourth panel). We therefore
conclude that VPS37B behaves like the other two ESCRT-I
proteins, i.e. the protein exists predominantly in dispersed
soluble complexes under steady-state conditions, but can also
associate transiently with the endosomal membrane and be
released by the action of VPS4A.
FIG. 4. Immunofluorescent images showing the localization of
VPS37B in the presence of the WT VPS4A-GFP protein (A) and
the dominant-negative K173Q VPS4A-GFP mutant protein (B).
VPS4A-GFP proteins appear green, and VPS37B-FLAG proteins appear
red. The first panels in A and B show the phase-contrast image (with
cell boundaries outlined for clarity), and the fourth panels show an
overlay of the second and third panels. Note that the dominant-negative
K173Q VPS4A mutation caused both VPS4A and VPS37B-FLAG pro-
teins to re-localize to the same sites on the Class E endosomal compart-
ment. The “disperse” localization shown for VPS37B-FLAG in the pres-
ence of the WT VPS4A-GFP protein was seen in 90% of the images
examined (47/52), whereas the “punctuate/Class E” localization shown
for VPS37B-FLAG in the presence of the dominant-negative K173Q
VPS4A-GFP protein was seen in 88% of the images examined (29/33).
FIG. 3. Gel filtration analyses of hu-
man ESCRT-I components. Cells over-
expressing VPS37B-FLAG protein were
lysed, and the soluble lysate was fraction-
ated by gel filtration chromatography.
Fractions were analyzed by Western blot-
ting to determine the elution profiles of
TSG101, VPS28, and VPS37B. Western
blots were digitized, and the intensities
were plotted to show relative protein con-
centration. The elution positions of molec-
ular mass standards are shown above the
chromatograph and were used to estimate
the apparent molecular masses of the dif-
ferent protein complexes (labeled above
the peaks). Inset, Western blots from al-
ternating fractions collected through the
ESCRT-I elution profile. IB, immunoblot.
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Human VPS37B Recruits ESCRT-I Activity—We next tested
whether VPS37B can direct functional ESCRT-I activity to
HIV-1 budding sites in vivo. Previous studies have demon-
strated that ESCRT-I can support HIV-1 Gag particle release,
even when recruited to sites of viral particle assembly via
non-native interactions. For example, mutant retroviral Gag
proteins that would otherwise be retained can bud from cells
when fused directly to various proteins or domains that can
recruit ESCRT-I, including ubiquitin (51), TSG101 (7), VPS28
(52), and HRS (19). In some cases, these Gag fusion proteins
can even co-assemble and rescue in trans the release of infec-
tious HIV-1 virions that lack endogenous late domains, al-
though Gag processing and virus infectivity are typically at-
tenuated when larger proteins are fused to the C-terminal end
of Gag. Thus, the heterologous rescue of virus release and
infectivity provides a sensitive assay for ESCRT-I activity in
vivo, and this approach was therefore used to test whether
VPS37B can recruit functional ESCRT-I activity to sites of
virus budding.
As expected, an HIV-1 construct lacking the p6Gag PTAP late
domain (HIV-1PTAP) was not released efficiently from 293T
cells and was very poorly infectious (Fig. 5A, compare lanes 1
FIG. 5. VPS37B polypeptides can rescue the release of HIV-1 constructs that lack PTAP late domains (A) and Gagp6 VLPs (B). A,
VPS37B can rescue the release and infectivity of mutant HIV-1 virions that lack endogenous PTAP late domains. Upper panel, Western blot of
HIV-1 particle-associated MA and CA proteins released from cells following transfection with 2 g of WT HIV-1 proviral R9 plasmid (positive
control; lane 1) or mutant proviral R9 plasmid in which the PTAP late domain of p6Gag was mutated to AAAA (HIV-1PTAP; lanes 2–6). Cells were
cotransfected with plasmid expressing GFP alone (negative control; lane 2), Gag-GFP (1 g, positive control; lane 3), GagPTAP-GFP (1 g,
negative control; lane 4), Gag-VPS37B (3 g, control for the infectivity effects of the VPS37B fusion; lane 5), or GagPTAP-VPS37B (3 g, test for
the ability of VPS37B to rescue virus budding; lane 6). Total vector levels were normalized to 5 g by addition of a vector expressing GFP alone.
Middle panel, Western blot of the same samples showing cytoplasmic Gag protein expression. Note that the bands labeled p41 and p25 are Gag
processing intermediates. Lower panel, viral titers in the supernatants of the same samples. Titers were determined in single-cycle MAGIC assays
and are plotted on a log scale. B, VPS37B can rescue the release of VLPs formed by Gag proteins that lack p6 (Gagp6). Upper panel, Western blot
of VLPs released from cells following transfection with 2 g of plasmid expressing the HIV-1 Gagp6 protein (all lanes). Cells were cotransfected
with plasmid expressing GFP alone (negative control; first lane), Gag-GFP (positive control; second lane), GagPTAP-GFP (negative control; third
lane), Gag-VPS37B (control for any effects of fusing VPS37B to Gag; fourth lane), or GagPTAP-VPS37B (test for the ability of VPS37B to rescue
VLP release; fifth lane). Plasmid quantities were the same as described for A. Lower panel, Western blot of the same samples showing cytoplasmic
expression of the various Gag proteins.
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and 2). However, HIV-1PTAP release was rescued by coex-
pression with a wild-type Gag-GFP protein that could co-as-
semble with the viral Gag proteins and thereby recruit
ESCRT-I activity to the sites of particle assembly (compare
lanes 2 and 3). Virus infectivity was also substantially (al-
though not fully) rescued by coexpression of the Gag-GFP pro-
tein (lower panel). The incomplete rescue of virus infectivity
presumably reflected the detrimental effects of fusing GFP to
the C-terminal end of the Gag protein. As expected, mutation of
the PTAP late domain in the Gag-GFP construct abrogated its
ability to rescue virus release and infectivity (compare lanes 3
and 4), confirming that rescue was late domain-dependent.
Gag-VPS37B fusion constructs could also rescue the release
of HIV-1PTAP, and in this case, the rescue did not depend
upon the presence of the Gag PTAP late domain in the fusion
construct (Fig. 5A, compare lanes 5 and 6). Virus infectivity
was substantially rescued as well, albeit to a 3-fold lower level
than in the Gag-GFP control (possibly because VPS37B (31
kDa) is even larger than GFP (27 kDa)). Gag-VPS37B fusion
proteins also rescued the release of mutant Gag VLPs in trans
(Fig. 5B). Indeed, GagPTAP-VPS37B was significantly more
effective in mediating VLP release than was the Gag-GFP
control construct (compare second and fifth lanes). We there-
fore conclude that the VPS37B polypeptide has the ability to
recruit functional ESCRT-I activity in vivo, as assayed by its
ability to rescue the release and infectivity of mutant HIV-1
and the release of mutant Gag VLPs.
Interestingly, additional higher molecular mass species were
consistently seen to be associated with the different Gag spe-
cies in all of the Gag-VPS37B rescue experiments. These addi-
tional species likely correspond to mono- and multiubiquity-
lated Gag proteins based upon the observed mobility shifts (7
kDa larger). Thus, the VPS37B polypeptide can apparently
recruit ubiquitin ligase activity (or, alternatively, reduce ubiq-
uitin hydrolase activity (53)) to sites of virus budding.
TSG101 PTAP Binding Activity Is Essential for HIV-1 Re-
lease—We further tested whether other known TSG101/ES-
CRT-I interactions play important roles in HIV-1 release. To
assay the functions of mutant TSG101 proteins, endogenous
TSG101 was first depleted from 293T cells using siRNA. This
treatment typically inhibited the release of infectious HIV-1
particles up to 50-fold. siRNA-resistant TSG101 expression
constructs were then reintroduced into the cells lacking endog-
enous TSG101, and the ability of the ectopic TSG101 proteins
(denoted TSG*) to rescue HIV-1 release and infectivity was
tested. Expression of the WT TSG* protein typically rescued
virus release to within 2-fold of the undepleted control. Com-
plete rescue was not always achieved, presumably because
TSG* expression levels were sometimes lower than endogenous
protein levels (see “Supplemental Results” and Supplemental
Fig. 1 for full details).
TSG101 depletion/rescue experiments were first used to test
whether the PTAP binding activity of TSG101 is required for
HIV-1 release. As noted above, the HIV-1 p6Gag 7PTAP10 motif
binds in a groove in the TSG101 UEV domain, and TSG101
residues that make important contacts include Tyr63, which
forms one side of the Pro10 binding pocket, and Met95, which
makes extensive intermolecular hydrophobic interactions with
the p6 Pro7 and Ala9 residues (54). Alanine substitutions of
these two TSG101 residues reduce the affinity of the TSG101
UEV domain/p6 interaction partially (Y63A, 14-fold reduced)
or nearly completely (M95A, 52-fold reduced) (54). These mu-
tants were therefore used to test for a correlation between
TSG101/p6 binding affinity and the ability of TSG101 to sup-
port the release of infectious HIV-1.
Infectious HIV-1 release was reduced 35-fold upon depletion
of TSG101 and rescued to within 2-fold of control levels upon
reintroduction of WT TSG* (Fig. 6, compare lanes 2–4). In
contrast, efficient HIV-1 release was not rescued by equivalent
levels of either of the two TSG* PTAP motif-binding proteins,
as reflected by reduced particle release, accumulation of un-
processed intracellular Gag proteins, and low infectious titers
(lanes 5 and 6). Nevertheless, the weak binding Y63A mutant
did support modest levels of virus release and infectivity
(20% of the WT TSG* control), whereas the non-binding
M95A mutant failed to rescue any detectable virus release or
infectivity above background levels (6). Thus, TSG101 must
bind PTAP sequences with full affinity to support efficient
HIV-1 release from 293T cells.
VPS28 Binds the C-terminal Domain of TSG101—Previous
work in other laboratories has shown that VPS28 binds
TSG101 and that the VPS28-binding site is located in the
C-terminal third of TSG101 (16, 25, 29). In good agreement
with these observations, VPS28 was identified 28 different
times in our yeast two-hybrid library screens that employed
TSG101 baits. TSG101-(317–390) was the smallest fragment
that bound VPS28 in these screens, which confirmed that
VPS28 binds the C-terminal region of TSG101. Similarly, pure
recombinant VPS28 bound specifically to GST-TSG101-(330–
FIG. 6. TSG101 PTAP binding is essential for HIV-1 release.
Cells were mock-transfected (lane 1) or transfected with the proviral R9
plasmid (lanes 2–6). Cells were cotransfected with siRNA duplexes to
deplete TSG101 (lanes 3–6); with an siRNA duplex of inverted sequence
(specificity control; lane 2); and with vectors expressing siRNA-resist-
ant constructs (TSG*) encoding WT TSG* (lane 4), mutant TSG* (lanes
5 and 6), or no protein (control; lane 3). First panel, anti-TSG101
Western blot showing levels of endogenous TSG101 and ectopic TSG*-
FLAG; second panel, anti-CA and anti-MA Western blot showing par-
ticle-associated CA and MA proteins released into the supernatant;
third panel, anti-CA and anti-MA Western blot showing cytoplasmic
lysates from the same samples; fourth panel, titers of virus released into
the supernatants.
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390) in “pull-down” experiments, demonstrating that the
TSG101/VPS28 interaction is direct (data not shown).
Directed two-hybrid experiments and deletion analyses were
used to confirm the initial binding data and to map the VPS28-
binding site more precisely. As summarized in Fig. 7, VPS28
bound well to full-length TSG101 and TSG101-(330–377). De-
letion of an additional 17 residues from the N-terminal end of
this construct (through residue 346) reduced VPS28 binding
FIG. 7. TSG101/VPS28 interactions and HIV-1 release. A, the VPS28-binding site is located within the C-terminal domain of TSG101.
Schematic illustrations of TSG101 and the TSG101-DBD fusion constructs are shown above. TSG101-DBD binding to VPS28-AD constructs was
tested in semiquantitative liquid yeast two-hybrid assays (summarized to the right). Relative -galactosidase activity was determined and is
expressed as  (25–40-fold above background levels),  (10–25-fold above background levels), or  (undetectable binding). For reference, a
filter lift assay showing the relative -galactosidase activity resulting from the interaction between VPS28 and TSG101-(359–390) (negative) or
TSG101-(330–377) (positive) is shown to the left. Note that the TSG-(330–358)-DBD fusion protein activated -galactosidase expression in the
absence of VPS28-AD. Therefore, TSG-(330–358)-AD was tested for binding to a VPS28-DBD fusion protein. PRO, proline-rich region; CC,
predicted coiled-coil region; S-Box, steadiness box region (30). B, the C-terminal residues of TSG101 are essential for HIV-1 budding. Cells were
transfected with the proviral R9 expression construct (lanes 1–7), depleted of endogenous TSG101 using a specific siRNA (denoted TSG; lanes
2–7) or a control siRNA duplex of inverted sequence (lane 1), and cotransfected with plasmids expressing the indicated TSG* protein (lanes 3–7).
First panel, anti-FLAG Western blot showing exogenous TSG*-FLAG levels; second panel, anti-CA and anti-MA Western blot of sucrose-pelleted
virions showing virus release; third panel, anti-CA and anti-MA Western blot of cytoplasmic lysates showing Gag protein expression levels; fourth
panel, anti-VPS28 Western blot showing endogenous VPS28 levels; fifth panel, viral titers in MAGIC infectivity assays of culture supernatants.
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significantly, and deletion of 12 more residues (through residue
359) eliminated VPS28 binding entirely. Similarly, C-terminal
deletions of TSG101 through residue 359 reduced VPS28 bind-
ing, and deletions through residue 347 eliminated detectable
VPS28 binding. In all cases, expression of the relevant
TSG101-DBD constructs was confirmed by Western blotting
with an anti-DBD antibody (data not shown). We therefore
conclude that the entire VPS28-binding site spans TSG101
residues 330–377, although 20-residue deletions from ei-
ther end of this region can be tolerated without complete loss of
VPS28 binding.
TSG101 Proteins Lacking the VPS28-binding Site Fail to
Rescue HIV-1 Release—We next investigated whether the
TSG101/VPS28 interaction is required for HIV-1 release by
testing whether a series of C-terminally truncated TSG* pro-
teins can support virus release. As shown in Fig. 7B, the
TSG*330–390, TSG*347–390, and TSG*359–390 proteins
all failed to rescue HIV-1 release and infectivity in cells de-
pleted of endogenous TSG101 (compare lanes 3 and 4–6). In
contrast, a TSG* protein lacking only the final six residues
(TSG*385–390) supported efficient HIV-1 release and infec-
tivity (lane 7). The failure of the shorter TSG* proteins to
rescue release was not due to their impaired expression or
stability (first panel) or to altered HIV-1 Gag expression (third
panel). We therefore conclude that TSG101 proteins missing all
or part of the VPS28-binding site are unable to support HIV-1
release and hence that this region of TSG101 performs essen-
tial function(s) in virus budding.
Analyses of the TSG101 and VPS28 protein levels in our
experiments revealed two notable trends. Endogenous VPS28
protein levels were dramatically reduced in the absence of
TSG101 proteins with intact VPS28 interaction sites (Fig. 7B,
fourth panel). This was true both in the complete absence of
TSG101 (lane 2) and in the presence of truncated TSG* pro-
teins lacking the entire VPS28-binding site (lanes 4–6). In
contrast, VPS28 protein levels were higher in the presence of
longer TSG* proteins that were competent to bind VPS28 (lane
7), and the absolute levels of VPS28 correlated well with the
expression levels of the longer TSG* proteins (lanes 3 and 7).
These observations suggest that VPS28 may be unstable when
it is not bound to TSG101. The presence of cellular VPS28 also
correlated well with successful HIV-1 release, as virus release
was observed whenever VPS28 levels were high, but not when
VPS28 levels were low.
Conversely, deletion of the VPS28-binding region increased
the steady-state levels of exogenous TSG* (Fig. 7B, compare
lanes 3 and 7 with lanes 4–6). This observation is consistent
with a previous report that the post-translational stability of
TSG101 is negatively regulated by an element in the C-termi-
nal region termed the “steadiness box” (residues 346–390) (30).
Our data suggest the possibility that the steadiness box corre-
sponds to the VPS28-binding site and, more generally, indicate
that formation of a stable TSG101-VPS28 complex (22, 25)
helps regulate the steady-state levels of both proteins.
ESCRT-I Incorporation into HIV-1 Particles—Previous stud-
ies have shown that overexpressed TSG101 can be recruited to
sites of virus budding at the plasma membrane (7), that a
fragment of TSG101 spanning the UEV domain can be incor-
porated into virus particles (8), and that EIAV Gag-VPS28
fusion proteins can recruit TSG101 into VLPs. However, these
experiments did not address whether endogenous ESCRT-1
components are normally incorporated into HIV-1 particles,
and this information is important for understanding precisely
how the complex functions in particle release. We therefore
quantitated the levels of VPS28 in highly purified HIV-1
particles.
As anti-VPS28 antibodies were not commercially available,
human VPS28 was expressed in E. coli, purified to homogene-
ity, and used to elicit anti-VPS28 antibodies in rabbits (Fig.
8A). High titer HIV-1 preparations (109 infectious units/ml)
containing minimal cellular contaminants were obtained from
acutely infected MT-4 cells and purified by velocity gradient
centrifugation (36). The purity of the sample was evaluated on
silver-stained SDS gels, which showed that the Gag proteins
were the main constituents and demonstrated minimal con-
tamination with cellular proteins (data not shown) (55).
VPS28 could be detected on Western blots of pure recombi-
nant proteins (Fig. 8B, lane 1), cell extracts (lane 2), and puri-
fied HIV-1 virions (lane 4). VPS28 incorporation into HIV-1
particles was confirmed in independent virus preparations and
by analysis of subtilisin-treated virions, which eliminated con-
taminating cellular vesicles and degraded proteins on the
virion exterior (56), but did not significantly reduce the amount
of VPS28 in the preparations (data not shown). The absolute
quantities of VPS28 present within the virion were estimated
by comparing the levels of virion-associated VPS28 and CA
proteins with known quantities of pure recombinant CA and
VPS28 (Fig. 8A) (data not shown). In different virus prepara-
tions, between 1 and 5 ng of VPS28/g of CA was detected,
corresponding to a molar ratio of 1:200–1000. Assuming
5000 Gag molecules/virion (57), this implies that 5–25 mole-
cules of VPS28 were incorporated per virion.
FIG. 8. Endogenous VPS28 and TSG101 are incorporated into
HIV-1 virions, whereas NEDD4 is not. A, Coomassie Blue-stained
gel showing the stepwise purification of recombinant VPS28 protein.
Lane U, uninduced E. coli cell extract; lane I, induced cell extract; lane
1, glutathione-Sepharose-bound proteins; lane 2, proteins following to-
bacco etch virus protease cleavage; lane 3, purified VPS28. B, anti-
VPS28 Western blot of 5 ng of purified recombinant VPS28 (lane 1),
lysate from 105 MT-4 cells (lane 2), and purified HIV-1 particles corre-
sponding to 1 g of CA protein (lane 4). 1 g of CA protein was used as
a control (lane 3) to rule out antibody cross-reactivity in the virion
preparation because VPS28 and CA have similar mobilities. Note that
two cross-reacting species of higher molecular mass were observed in
the crude lysate (lane 2). C, anti-TSG101Western blot of lysate from 105
MT-4 cells (lane 1), 1 g of recombinant CA protein (control for antibody
cross-reactivity; lane 2), and purified HIV-1 particles corresponding to 1
g of CA protein (lane 3). D, anti-NEDD4 Western blot of the samples
described for A. Molecular mass markers (in kilodaltons) are shown to
the left of each panel.
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We also screened for HIV-1 incorporation of endogenous
TSG101 and NEDD4 as well as overexpressed VPS37B-FLAG.
These experiments were not quantitative, however, because we
lacked the appropriate recombinant protein standards. Never-
theless, endogenous TSG101 was readily detected in both cell
extracts and purified virus particles (Fig. 8C), indicating that
the protein was specifically incorporated by HIV-1. Interest-
ingly, both TSG101 and endogenous murine leukemia viral
Gag proteins were also detected in exosomes (MVB vesicles
released from cells) (58–60), which further emphasizes the
similarities between viral particle release and MVB vesicle
biogenesis. In contrast, NEDD4 was not detected in virions
(Fig. 8D), despite the fact that this protein was readily detected
in cell extracts and has been reported to bind TSG101 (61).
Several other control proteins that partially localized to the
plasma membrane were also undetectable in the purified virus
preparations, confirming that these preparations were not con-
taminated with cellular proteins (data not shown). We there-
fore conclude that TSG101, like VPS28, is also specifically
incorporated into HIV-1 particles, whereas NEDD4 is not.
NEDD4 was detected in purified particles of Mason-Pfizer
monkey virus, a virus that buds via a different late domain
(PPPY) (62), reinforcing the idea that these two different late
domains perform distinct functions in virus budding. Finally,
we were unable to confirm that VPS37B was specifically incor-
porated into HIV-1 particles. Although VPS37B-FLAG was
detected in purified virions, the levels appeared very low rela-
tive to the levels of overexpressed protein in the producer cells
(data not shown). These observations raise the possibility that
VPS37B may be lost during the process of viral assembly.
DISCUSSION
The p6Gag PTAP late domain is required for efficient HIV-1
replication in most cell types, including primary cells (5). The
PTAP late domain recruits TSG101, which in turn functions
within a multiprotein complex (ESCRT-I) that links the virus
to cellular machinery that normally functions in protein sort-
ing and vesicle formation in the MVB (reviewed in Ref. 1).
Previous studies have demonstrated that the N-terminal half
of TSG101 (residues 1–249) is not required for virus budding
when the C-terminal half of the protein (residues 250–390) is
fused directly to the viral Gag protein (7). Thus, the N-terminal
half of TSG101 appears to function primarily in recruiting the
protein to the sites of virus budding, whereas the C-terminal
half of the protein contains binding sites for other proteins that
function in virus budding, including the other members of the
ESCRT-I complex, VPS28 and VPS37. Our studies were per-
formed with the goals of identifying human orthologs of VPS37
and testing the importance of different TSG101 interactions in
HIV-1 release.
TSG101 Recruitment—TSG101 is recruited to sites of virus
release, at least in part, through direct interactions with P(S/
T)AP late domains found in the structural proteins from a
number of different enveloped viruses, including HIV-1 (6–9).
Using TSG101 depletion/replacement assays, we found an ex-
cellent correlation between the affinities of WT and mutant
TSG101 proteins for the HIV-1 PTAP late domain and their
ability to support HIV-1 release from 293T cells. The mutations
under study presumably also affected TSG101 interactions
with cellular binding partners because the TSG101 UEV do-
main can also bind to P(S/T)AP motifs located within a series of
cellular proteins, including HRS (17–20), AIP1 (26–28),
TSG101 itself (17), and VPS37B (this work). However, as
TSG101 fragments lacking the UEV domain can support virus
budding when fused directly to the HIV-1 Gag protein, these
TSG101 UEV domain/cellular protein interactions cannot be
absolutely essential for HIV budding, although they may help
to “activate” the autoinhibited full-length TSG101 protein (17–
20). Hence, our experiments further confirm the functional
importance of the TSG101 UEV domain/Gag P(S/T)AP interac-
tion for HIV-1 release and indicate that any reductions in
PTAP binding affinity (or levels of active TSG101 protein) can
be expected to reduce viral titers. This makes the TSG101 UEV
domain/PTAP motif-binding pocket an attractive target for in-
hibitor development.
Identification of Human VPS37 Proteins—As a necessary
step in understanding how the human ESCRT-I complex func-
tions in virus release and MVB biogenesis, we identified a
series of putative human VPS37 proteins and characterized
one of them, VPS37B, in detail. A number of criteria establish
human VPS37B as an ortholog of yeast Vps37p, including the
following. 1) The two proteins share modest but identifiable
sequence similarity. 2) Both proteins bind to central/C-termi-
nal regions of TSG101/Vps23p (16). 3) Both proteins can form
stable subunits of 350-kDa ESCRT-I complexes. 4) Both pro-
teins become trapped on the Class E endosomal compartment
in the absence of VPS4 ATPase activity. 5) VPS37B can recruit
functional human ESCRT-I activity in vivo, as judged by its
ability to support the release of infectious HIV-1 virions lacking
endogenous PTAP late domains.
VPS37B belongs to a family of four human proteins that
share clear sequence similarity (Fig. 1B), and our data demon-
strate that at least one of the other proteins (VPS37A) binds
TSG101. Thus, it appears that all of these proteins may be
VPS37 orthologs. Although this idea remains to be tested ex-
perimentally, there is already precedence for this type of diver-
sity in the mammalian MVB pathway, where other single yeast
proteins appear to have diverged into multiple human proteins
that perform overlapping or redundant functions (e.g. human
VPS4A and VPS4B are both orthologs of yeast Vps4p). It will
therefore be of interest to determine the relationship between
the different human VPS37-like proteins, all of which appear to
be widely expressed.
The sequence similarities between the different human
VPS37-like proteins (and the putative Drosophila VPS37 pro-
tein) are strongest within an 150-residue domain (the mod_r
domain). This domain was first identified in the Drosophila
modifier of rudimentary (Mod_r) protein, which modulates ex-
pression of the rudimentary protein (40). Although mod_r do-
mains are found within a number of eukaryotic proteins, their
functions are not well understood, and the presence of a mod_r
domain therefore cannot yet be used to infer biological activity.
Importantly, our mapping experiments indicate that the
VPS37B mod_r domain contains the binding site for TSG101,
which represents the first well characterized biochemical func-
tion for any mod_r domain.
Beyond their conserved mod_r domains, the different human
VPS37-like proteins each contain unique elements that suggest
interesting and unique biological functions. Specifically, VPS37B
uniquely contains a PTAP motif, which is the binding site for the
TSG101 UEV domain; VPS37C and VPS37D contain N- and
C-terminal extensions of unknown function; and VPS37A/
HCRP1 contains a putative UEV domain. This is of potential
significance because other UEV domains bind ubiquitin (6, 16,
63, 64) and because ubiquitin performs a number of important
roles in the MVB and HIV-1 budding pathways (1, 14, 15). How-
ever, the residues known to bind ubiquitin and PTAP sequences
are not conserved in alignments of the TSG101 and VPS37A/
HCRP1 UEV domains (39), and the function of this domain
therefore remains to be determined experimentally.
HCRP1 was previously identified by positional cloning and
shown to be down-regulated in hepatocellular carcinoma devel-
opment (39). Although the protein has not been shown defini-
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tively to act as a tumor suppressor in vivo, its expression is
reduced in human cellular carcinomas, and reduction of
VPS37A/HCRP1 levels in the human cellular carcinoma cell
line BEL-7404 stimulates cell growth and enhances cell inva-
siveness in vitro (39). Similarly, reductions of TSG101 levels
allowed NIH3T3 cells to grow on soft agar and to form meta-
static tumors in nude mice (65), although genetic deletions of
TSG101 do not induce tumor formation (66). It therefore ap-
pears that altered levels (or composition) of ESCRT-I can give
rise to improperly regulated cell growth in some contexts.
Human ESCRT-I and HIV-1 Release—In addition to TSG101
and VPS37B, the human ESCRT-I complex also contains
VPS28. VPS28 binds a C-terminal site on TSG101 that we have
mapped to residues 330–377 and is unstable in the absence of
this binding site. As in yeast, it appears that the TSG101,
VPS28, and VPS37B proteins must be present in multiple
copies to create a complex of 350 kDa. Consistent with this
idea, all three proteins bind to themselves in directed yeast
two-hybrid experiments, suggesting that they can form homo-
oligomers (Refs. 25, 26, and 29 and this work). At this stage, we
cannot rule out the possibility that human ESCRT-I complexes
may also contain additional proteins, and the other human
VPS37 paralogs are obvious candidates.
Importantly, HIV-1 release was not supported by truncated
TSG101 proteins that were missing their VPS28-binding sites
(and therefore exhibited reduced VPS28 levels). This observa-
tion supports the idea that VPS28 plays a functional role in
virus release and is in excellent agreement with previous work
of Bieniasz and co-workers (27), who also found that VPS28 is
required for HIV-1 release and identified several mutations in
TSG101 residues 360–370 that inhibit both VPS28 binding and
HIV-1 budding. Further evidence for a direct role for ESCRT-I
in virus budding was provided by our observation that endog-
enous TSG101 and VPS28 were both specifically incorporated
into highly purified HIV-1 particles prepared from infected
T-cells, although we were unable to demonstrate specific incor-
poration of VPS37B. We estimate that, on average, 5–25 VPS28
molecules are incorporated into each virus particle. It is likely
that virion levels of TSG101 are lower, however, as the stoichi-
ometry of Vps28p to Vps23p in the yeast ESCRT-I complex is
estimated to be 1:6 (16).
In summary, our studies have identified human VPS37B as
a new component of the human ESCRT-I complex and revealed
that VPS37B can rescue the release of HIV-1 Gag proteins that
lack endogenous PTAP late domains. Thus, all three known
members of the human ESCRT-I complex are able to support
virus release and infectivity (Refs. 7 and 52 and this work),
demonstrating remarkable flexibility in the requirements for
viral entry into the MVB biogenesis pathway.
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ESCRT-III recognition by VPS4 ATPases
Melissa D. Stuchell-Brereton1*, Jack J. Skalicky1*, Collin Kieffer1, Mary Anne Karren1, Sanaz Ghaffarian1
& Wesley I. Sundquist1
The ESCRT (endosomal sorting complex required for transport)
pathway is required for terminal membrane fission events in
several important biological processes, including endosomal
intraluminal vesicle formation1,2, HIV budding3 and cytokinesis4.
VPS4 ATPases perform a key function in this pathway by recog-
nizingmembrane-associated ESCRT-III assemblies and catalysing
their disassembly5–7, possibly in conjunction with membrane fis-
sion. Here we show that themicrotubule interacting and transport
(MIT) domains of human VPS4A and VPS4B bind conserved
sequence motifs located at the carboxy termini of the CHMP1–3
class of ESCRT-III proteins. Structures of VPS4A MIT–CHMP1A
and VPS4B MIT–CHMP2B complexes reveal that the C-terminal
CHMP motif forms an amphipathic helix that binds in a groove
between the last two helices of the tetratricopeptide-like repeat
(TPR) of the VPS4 MIT domain, but in the opposite orientation
to that of a canonical TPR interaction. Distinct pockets in theMIT
domain bind three conserved leucine residues of the CHMPmotif,
and mutations that inhibit these interactions block VPS4 recruit-
ment, impair endosomal protein sorting and relieve dominant-
negative VPS4 inhibition of HIV budding. Thus, our studies reveal
how the VPS4 ATPases recognize their CHMP substrates to facil-
itate the membrane fission events required for the release of
viruses, endosomal vesicles and daughter cells.
MIT domains are found in a number of proteins involved in cel-
lular trafficking, where they frequently function as protein inter-
action modules8,9. The ESCRT-III proteins, in particular, interact
with a series of different MIT-domain-containing proteins10 includ-
ing VPS4A and VPS4B6,11, spastin12, AMSH (associated molecule
with the SH3 domain of STAM)10,13–15, and others10. Biosensor bind-
ing experiments demonstrated that the human VPS4B MIT domain
bound both full-length CHMP1B and a shorter, more soluble con-
struct (CHMP1B65–196) with dissociation constants of about 30 mM
(Fig. 1a, dark blue and red curves)11. A series of amino-terminal
deletion constructs were used to map the minimal VPS4B MIT-
binding site on CHMP1B, and these experiments revealed that a
construct spanning just the C-terminal 17 residues of CHMP1B
bound the VPS4BMIT domain with nearly full affinity (Fig. 1a, green
curve; Kd 346 1 mM (mean6 s.d.). In contrast, a CHMP1B con-
struct lacking this region (CHMP1B65–180) did not bind (Fig. 1a,
black curve), in good agreement with reports that deletion of the C
terminus of CHMP3 blocks VPS4 and AMSH binding14,16. Similar
binding data were obtained for the VPS4AMIT domain (not shown),
indicating that the C-terminal end of CHMP1B is necessary and
sufficient for VPS4 MIT binding.
The ten canonical human ESCRT-III proteins fall into two general
classes (CHMP1–3 and CHMP4–6) based on sequence homology
and functional similarities. These two classes can be further subdi-
vided into the six different CHMP families, each of which corre-
sponds to one of the six ESCRT-III-like proteins in yeast7,17,18.
Sequence alignments revealed that three highly conserved leucine
residues are arrayed in a heptad repeat at the C termini of
CHMP1–3 proteins but not CHMP4–6 proteins (Fig. 2a, CHMP1A
positions 187, 191 and 194). Mutation of either of the two most
conserved leucine residues within CHMP1B decreased VPS4A and
VPS4B MIT binding more than tenfold, confirming the importance
of these residues for interactions between VPS4 MIT and CHMP1B
(Fig. 1a, orange and teal curves and data not shown).
*These authors contributed equally to this work.
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Figure 1 | VPS4 MIT–CHMP binding interactions. a, Biosensor binding
isotherms showing VPS4B MIT binding to the wild-type and mutant
CHMP1Bproteins depicted schematically in the inset. The data demonstrate
that the final 17 residues of CHMP1B are necessary and sufficient for full-
affinity VPS4B MIT binding and that binding is inhibited by mutations in
the two most conserved residues within this region (L189A and L192A).
Duplicate data points are shown for each condition, and estimated
dissociation constants derived from fits to single site binding models
(curves) were as follows: CHMP1B, 296 1mM; CHMP1B65–196, 336 1 mM;
CHMP1B180–196, 346 1 mM; CHMP1BL189A, 3536 8 mM; CHMP1BL192A,
8106 40mM (means6 s.d.). Note that in other cases, VPS4 MIT domains
bound even more tightly to isolated binding sites than to the corresponding
full-length CHMP proteins, which is consistent with an autoinhibitory
mechanism (refs 16, 29, 30; data not shown). b, Biosensor binding isotherms
showing C-terminal peptides from CHMP1A and CHMP2B binding
GST–VPS4A MIT and GST–VPS4B MIT under different solution
conditions. The data show that both VPS4MIT domains bind specifically to
the CHMP1A and CHMP2B C termini, and that the affinities vary with
different MIT domains, CHMP proteins and solution conditions.
Representative data are shown for low salt and pH conditions (‘L’, 20mM
phosphate pH5.5 (NMR conditions); squares) and medium salt and pH
conditions (‘M’, 20mM Tris-HCl pH8.0, 100mM NaCl; circles). Estimated
dissociation constants derived from fits to single-site bindingmodels were as
follows: VPS4A MIT–CHMP1A180–196 (black), 4.616 0.02 mM (L) and
33.46 0.2 mM (M); VPS4A MIT–CHMP2B195–213 (red), 71.86 0.3mM (L)
and 1786 1 mM (M); VPS4B MIT–CHMP1A180–196 (blue), 13.46 0.1 mM
(L) and 74.06 0.3 mM (M); VPS4B MIT–CHMP2B195–213 (green),
2736 0.2mM (L) and 4026 2 mM (M). Background binding of both CHMP
peptides to control GST surfaces was negligible under both conditions, as
shown for the medium-salt conditions (CHMP1A180–196, orange;
CHMP2B195–213, cyan).
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To assess the generality of VPS4 MIT binding to the C termini of
the CHMP1–3 proteins, peptides corresponding to these regions of
CHMP1A, CHMP1B, CHMP2A and CHMP2B were tested and
shown to bind the MIT domains of VPS4A and VPS4B in every case
(Fig. 1b, Supplementary Fig. 1, and data not shown). Thus, this
sequence motif constitutes a generalized VPS4 MIT-binding site. In
contrast, binding of VPS4MIT to proteins of the CHMP4–6 class was
much more variable and the binding site did not map to the C
terminus of CHMP6 (the one case studied in detail). VPS4 MIT
domains can therefore also bind a subset of the CHMP4–6 proteins,
but the recognitionmode is different and will be described elsewhere.
Our initial surveys revealed that dissociation constants for MIT
binding to CHMP1A, CHMP1B, CHMP2A and CHMP2B peptides
varied throughout the micromolar range, with tighter binding gen-
erally associated with VPS4A, with reduced temperatures, with
reduced ionic strengths and with slightly acidic conditions. Several
of these trends are evident in the isotherms for VPS4 MIT domains
binding to CHMP1A180–196 and CHMP2B195–213 (Fig. 1b). Repre-
sentative strong (VPS4A MIT–CHMP1A180–196; Kd 4.6 mM) and
weak (VPS4B MIT–CHMP2B195–213; Kd 273 mM) complexes were
selected for structural studies by NMR. Studies of VPS4A MIT–
CHMP1A180–196 and free VPS4B MIT were straightforward and
yielded high-quality structures (Fig. 2, Supplementary Figs 1–3 and
Supplementary Table 1), whereas assignment of intermolecular nuc-
lear Overhauser effects in the weaker VPS4B MIT–CHMP2B195–213
complex required reference to the VPS4A MIT–CHMP1A180–196
structure (Supplementary Fig. 4, Supplementary Table 1 and Sup-
plementary Methods). Thus, although the two VPS4 MIT–CHMP
structures were similar, only the VPS4AMIT–CHMP1A180–196 com-
plex is described here in detail.
N-terminal domains of AAA ATPases generally dictate substrate
specificity and therefore vary considerably in structure19. The VPS4A
MIT domain is a three-helix bundle11,20, and CHMP1A180–196 forms a
fourth helix that binds in the groove between helices 2 and 3 (Fig. 2b,
c). The three conserved CHMP1A180–196 leucine residues line one
side of the amphipathic helix, and each binds in a hydrophobic
pocket along the groove (Fig. 2c–f). These interactions seem to con-
stitute the primary recognition determinants, but complementary
salt bridges are also made by three of the adjacent conserved
CHMP1A residues (Glu 184, Arg 190 and Arg 195; see Fig. 2). The
structure nicely explains existing mutagenesis data showing the
importance of several MIT residues for CHMP binding11. In particu-
lar, the VPS4A MIT Leu 64 residue has a critical function in helping
to define all three MIT-binding pockets (highlighted in blue in
Fig. 2c–f), and an L64A mutation decreases CHMP1B bindingmore
than 30-fold11. The structures indicated that an Asp residue at this
position would weaken binding even further by interacting unfa-
vourably with all three conserved CHMP1–3 leucine residues, and,
indeed, VPS4A MITL64D did not detectably bind glutathione
S-transferase (GST)-tagged CHMP1B180–196 at protein concentra-
tions up to 250 mM (Supplementary Fig. 5). A VPS4A MIT E68A
mutation also decreased the CHMP1B binding affinity 2–3-fold11,
which is consistent with the conserved salt bridge observed between
VPS4A Glu 68 and CHMP1A Arg 190.
The structures further revealed that two previous proposals for
MIT–CHMP interactions were incorrect. Specifically, CHMP1–3
proteins do not bind between MIT helices 1 and 2 to complete a
canonical four-helix bundle20, nor does the binding of the CHMP
helix between MIT helices 2 and 3 complete a second paired tetra-
tricopeptide helical repeat11. Instead, the CHMP helix binds parallel
toMIT helix 3, whereas a TPR-like interaction would have the oppo-
site orientation. Hence, although the TPR-like disposition of the
three MIT helices helps to define the geometry of the CHMP binding































































2B 195 KATIS ER VD 213












4B 208 EEEDDDMKELENWAGSM 224




Figure 2 | Structural basis for VPS4 MIT recognition of CHMP1–3.
a, Alignments of ESCRT-III protein C termini. C-terminal sequences of
human proteins from the six CHMP classes are shown explicitly, together
with a graph showing the degree of sequence conservation within aligned
CHMP1–3 C termini (50 sequences; see Supplementary Table 2) and the
consensus sequence (below the graph). Note that ESCRT-III proteins of the
CHMP4–6 class do not conform to the consensus. b, Solution structure of
the VPS4A MIT–CHMP1A180–196 complex, with the three conserved
CHMP1A180–196 leucines shown explicitly. This helical colour scheme is also
used in c–f. c, Structure of the VPS4A MIT–CHMP1A180–196 complex. The
MIT domain is shown in a space-filling model with Leu 64 highlighted in
blue; important residues on both sides of the interface are shown explicitly.
Arrows denote the approximate orientations of the three leucine-binding
pockets shown in d–f. d–f, Close-up views of the three leucine-binding
pockets of theVPS4AMITdomain showing the hydrophobic pocket views in
detail, as well as complementary charge interactions between Glu 184 and
Arg 57 (d), between Arg 195 and Glu 37 (e), and between Arg 190 and Glu 68
(Asp 65) (f); CHMP1A residues are listed first.
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Yeast Vps4 is required for the formation of intraluminal vesicles
that transport membrane proteins into the late endosome and ulti-
mately into the lumen of the vacuole5,6. Loss of Vps4 activity there-
fore induces the formation of aberrant endosomes (termed class E
compartments) and inhibitsmembrane protein cargoes such as green
fluorescent protein-labelled carboxypeptidase S (GFP–CPS) from
accumulating within the vacuole (Fig. 3; compare rows 1 and 2). A
single L64D point mutation within the Vps4 MIT domain also
impaired the vacuolar accumulation of the GFP–CPS cargo signifi-
cantly at 30 uC and almost entirely at 37 uC, showing that the struc-
turally characterized VPS4 MIT–ESCRT-III interface is required for
efficient endosomal protein sorting.
Mutations that block ATP binding by Vps4 (for example
Vps4K179Q) also induce class E compartment formation; in this case
all of the ESCRT machinery, including Vps4 itself, remains trapped
on the class E compartments, leading to punctate Vps4 staining
in virtually every cell (Supplementary Fig. 6)5,6. However, the sec-
ondary L64D MIT-domain mutation substantially redistributed the
Vps4L64D/K179Q protein from class E compartments back into the
cytoplasm (Supplementary Fig. 6). Thus, this mutation inhibits pro-
tein sorting at least in part by preventing the recruitment of Vps4 to
endosomal membranes.
The importance of the MIT–CHMP interaction for VPS4 recruit-
ment to mammalian endosomes was also tested by comparing
the cellular distributions of different exogenously expressed GFP–
VPS4A fusion proteins (Fig. 4a). As in yeast, VPS4 ATP-binding
mutants (for example VPS4AK173Q) induce the formation of mam-
malian class E compartments that trap VPS4 and other ESCRT
Vps4
(WT)







































Figure 3 | The Vps4 MIT Leu64Asp mutation inhibits membrane protein
sorting into the vacuolar lumen. a, Confocal fluorescence slices of live yeast
cells showing localization of the model membrane protein cargo, GFP–CPS,
in the presence of wild-type (WT) Vps4 (top row), no Vps4 (middle row) or
Vps4L64D (bottom row), at 30 uC. FM4-64 staining (red) was used to define
the limiting vacuolar membrane (open circles) and to reveal class E
compartments (intense puncta in the middle and bottom rows). Overlaid
fluorescence and differential interference contrast (DIC) images are shown
in the right two columns for reference. Scale bar, 5mm. b, Graphic
quantification of the experiment shown in a, demonstrating that the
Vps4L64D mutant inhibits GFP–CPS trafficking into the lumen of the
vacuole. GFP–CPS localization was examined at 30 uC (open columns) and
37 uC (filled columns). Data are from three independent experiments (100

































































































































































Figure 4 | SecondaryMITLeu64mutationsdecreaseendosomal recruitment
and inhibition of HIV-1 budding by VPS4A proteins that lack ATP-binding
activity. a, Upper panels: confocal fluorescence slices showing representative
distributions of wild-type (WT) GFP–VPS4A, GFP–VPS4AK173Q,
GFP–VPS4AK173Q/L64A and GFP–VPS4AK173Q/L64D, in transfected COS7 cells.
Lowerpanel:quantificationshowing that theK173QmutationcausesVPS4Ato
become trapped on aberrant endosomal membranes (class E compartments)
and that secondarymutations at Leu 64 restore the cytoplasmic localization of
VPS4A partly (L64A) or almost fully (L64D). Black columns, diffuse staining;
grey columns, punctate staining. Data are from two independent experiments
(at least 100 cells per experiment); error bars indicate s.d. b, Secondary L64A
and L64Dmutationsdecrease dominant inhibitionofHIV-1 vector release and
infectivity by GFP–VPS4AK173Q. Lanes 3–8 show HIV-1 vector titres (lower
panel) and virion release (upper panels) on co-expression with GFP–VPS4A
(lanes 3, negative control), GFP–VPS4AL64A (lanes 4, negative control),
GFP–VPS4AL64D (lanes 5), GFP–VPS4K173Q (lanes 6, positive control) or the
doubly mutant GFP–VPS4K173Q/L64A (lanes 7) or GFP–VPS4K173Q/L64D (lanes
8) proteins. Virion release (top panel, virus) was assayed by western blot
detection of virion-associated CA proteins. The lower western blots show,
respectively, cell-associated Gag, exogenous GFP–VPS4A proteins and a
c-tubulin loading control. Controls lacking HIV-1 vector and exogenous
GFP–VPS4A are shown in lanes 1 and 2, respectively. Vector titres (infectious
unitsml21) are shown in the bottompanel (triplicatemeasurements; error bars
indicate s.d.). c, Schematicmodel showingVPS4 recruitment to themembrane-
associated ESCRT-III lattice. An idealized membrane-associated ESCRT-III
lattice, based on the CHMP3 crystal structure and lattice contacts2,29, is shown
with the C-terminal tails on the CHMP1–3 subunits exposed to interact with
the MIT domains of a dodecameric VPS4 protein (grey). The VPS4 ATPase
activity releases the assembled ESCRT-III lattice from the membrane andmay
also be coupled to vesicle formation (not shown).
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machinery on their extended surfaces (Fig. 4a; compare VPS4A with
VPS4AK173Q)
6,21,22. Quantitative analyses revealed that wild-type
GFP–VPS4A was distributed diffusely throughout cytoplasm in
85% of cells, whereas GFP–VPS4AK173Q was trapped on punctate
class E compartments in 79% of cells (Fig. 4a, lower panel). How-
ever, the secondary L64A mutation significantly decreased punctate/
class E localization of VPS4AK173Q/L64A (to 47%), and the more det-
rimental L64Dmutation decreased punctate/class E localization even
further (25%), to nearly the same level as that of the wild-type protein
(15%). The redistribution of doubly mutant VPS4A proteins is par-
ticularly significant for two reasons: first because these experiments
were performed in the presence of endogenous wild-type VPS4A and
VPS4B, which probably co-polymerize with the VPS4K173Q/L64A,D
mutants and augment endosomal recruitment, and second because
LIP5/Vta1, a VPS4 cofactor, seems to interact with both VPS4 and
ESCRT-III proteins and may therefore also contribute to VPS4
recruitment23–25.
We also tested whether the secondary L64A and L64D mutations
decreased the dominant inhibition ofHIV-1 release and infectivity by
the VPS4AK173Q mutant. As reported previously
26, overexpression of
the VPS4AK173Q mutant strongly inhibited HIV-1 release, decreasing
infectious titres more than 500-fold (Fig. 4b). However, incorpora-
tion of secondary L64A or L64Dmutations restored virus release and
infectivity 35-fold and 55-fold, respectively, albeit to levels that were
still about tenfold below those seen for wild-type VPS4A. Although
the incomplete rescue by the VPS4AK173Q/L64A,D double mutants
probably reflects a complex combination of competing effects, this
experiment indicates that secondary Leu 64 mutations decrease the
severity of class E compartment formation and thereby release endo-
genous ESCRT machinery to function in virus budding.
VPS4 enzymes are composed of three different functional ele-
ments: the N-terminal MIT domain, which binds the ESCRT-III
lattice, a central AAA ATPase cassette, which mediates oligomeriza-
tion and hydrolyses ATP, and a b-domain, which is inserted into the
small domain of the ATPase cassette and is required for LIP5/Vta1
cofactor binding27. VPS4 enzymes assemble into dodecamers com-
posed of two stacked hexameric rings, with MIT domains posi-
tioned above a large central chamber created within one of the two
asymmetric rings (Fig. 4c; Z. Yu, G. Gonciarz, W. I. Sundquist, C. P.
Hill and G. J. Jensen, personal communication). The ESCRT-III
lattice is not yet fully characterized, but biochemical and crystal-
lographic analyses16,28–30 have shown that ESCRT-III protein oligo-
merization and membrane binding are autoinhibited by terminal
elements that include the C-terminal helices described here.
Removal of these elements promotes CHMP3 dimerization in solu-
tion and permits CHMP3 to be crystallized in protein ‘strips’ that
contain two distinct dimer interfaces and create a continuous basic
membrane-binding surface28. ESCRT-IIImembrane associationmay
therefore serve to expose (and concentrate) the C-terminal CHMP1–
3 helices. This oligomeric array of exposed binding sites would then
promote the recruitment and assembly of dodecameric VPS4
enzymes bymeans of their MIT domains. TheMIT domains, in turn,
seem to reside at the ends of flexible tethers27,28 and could therefore
‘feed’ ESCRT-III subunits into the open central chamber of the
assembled enzyme.
METHODS SUMMARY
Biosensor binding experiments. Biosensor binding experiments were per-
formed as described11,26 with purified VPS4B MIT protein binding to immobi-
lizedGST–CHMP1Bproteins (Fig. 1a) or C-terminal CHMPpeptides binding to
immobilized GST–VPS4 MIT proteins (Fig. 1b). All binding isotherms were
fitted to simple 1:1 binding models.
Structural studies by NMR. Solution structures of VPS4A/VPS4BMIT–CHMP
complexes were determined with NMR spectroscopic analyses of two sets of
mixed isotope-labelled samples (all in fast exchange): 13C,15N-VPS4A/VPS4B
MIT plus excess 12C,14N-CHMP1A180–196/CHMP2B195–213 and excess
12C,14N-
VPS4A/VPS4B MIT plus 13C,15N-CHMP1A180–196/CHMP2B195–213. Bound
structures were determined for the 13C,15N-labelled component in each sample,
and then docked to create binary complexes by using data from half-filtered
nuclear Overhauser enhancement spectroscopy.
GFP–CPS sorting in yeast cells. vps4D yeast cells (SEY6210 genetic background)
harbouring pRS415MET251GFP–CPS (GFP–CPS expression) and either
pRS4161VPS4 or pRS4161vps4L64D (Vps4 expression) or an empty control
plasmid were imaged by confocal microscopy and scored for GFP fluorescence
that was primarily at the limiting vacuolar membrane or primarily within the
vacuolar lumen. Yeast class E compartments and vacuolar membranes were
revealed by staining with FM4-64.
GFP–VPS4 localization in mammalian cells. COS7 cells grown on coverslips
were transfected with wild-type and mutant enhanced green fluorescent protein
(EGFP)–VPS4A expression vectors26. Cells were fixed 18 h after transfection,
imaged by confocal fluorescence microscopy, and scored as having either cyto-
plasmic or punctate GFP–VPS4 distributions.
HIV-1 vector release and infectivity. 293T cells were transfected with EGFP–
VPS4 expression constructs together with anHIV-1 vector system (pCMVDR8.2
plus pWPTS-nlsLacZ plus phCMV-VSVG). Cells and supernatants containing
virions were harvested separately 48 h after transfection. Cellular protein
expression levels and virion release were analysed by western blotting, and vector
titres were determined by transducing HeLa-M cells.
Full protocols. Detailed methods describing sequence alignments, protein
expression and purification, binding studies, NMR structure determinations,
cell biology and virology experiments are provided in Supplementary Methods.
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
Summary and Conclusions 
 
   The research described within this dissertation made a significant contribution to 
the general understanding of the protein network required for both vesicle formation at 
the multivesicular body (MVB) and the release of HIV-1 from host cells during virus 
budding.  Prior to the research described in Chapters 1-4, the cellular factors TSG101 
(tumor susceptibility gene 101) and VPS28 (vacuolar protein sorting 28) were known to 
be required for efficient HIV-1 budding (Garrus et al., 2001; Martin-Serrano et al., 2001; 
Martin-Serrano et al., 2003).  This discovery led to further investigation of their native 
functions in protein sorting at the late endosome or MVB, where our studies were guided 
by the genetically defined yeast ESCRT (endosomal sorting complex required for 
transport) pathway (Babst et al., 2000; Bishop & Woodman, 2001; Hurley & Emr, 2006; 
Saksena et al., 2007).  The similar topologies of vesicle formation at the MVB and HIV-1 
budding suggested that characterizing the human ESCRT pathway would help to 
understand virus budding. 
 To define the human ESCRT pathway, we used bioinformatic approaches to 
identify 22 putative human homologs of yeast ESCRT proteins.  Chapter 2 described not 
only the identification of these human ESCRT proteins but also their protein-protein 
interaction network, which proved to be similar to that of the yeast system.  The 
 identification of human ESCRT complexes and their interactions has advanced our 
understanding of ESCRT pathway functions not only in retroviral budding, but also the 
ESCRT-mediated processes of cellular protein sorting, MVB vesicle formation and 
cytokinesis (Azmi et al., 2008; Carlton et al., 2008; Fujita et al., 2004; Im et al., 2009; 
Katoh et al., 2005; Kieffer et al., 2008; Langelier et al., 2006; Lin et al., 2005; 
McCullough et al., 2008; Muziol et al., 2006; Pires et al., 2009; Scott et al., 2005b; Shim 
et al., 2007; Shim et al., 2008; Stuchell-Brereton et al., 2007; Tsang et al., 2006; Usami et 
al., 2007; Xiao et al., 2008; Yorikawa et al., 2005; Zamborlini et al., 2006; Zhou et al., 
2009). 
The well characterized yeast ESCRT system facilitated the identification of a 
large number of human counterparts.  However, not all components of the human ESCRT 
pathway could be identified based on sequence homology alone.  ESCRT-I, as described 
in Chapter 3, is the first committed complex of the ESCRT pathway (Garrus et al., 2001; 
Martin-Serrano et al., 2001; Martin-Serrano et al., 2003).  Prior to publication of the work 
described in Chapter 3, three yeast ESCRT-I components had been identified: Vps23p, 
Vps28p, and Vps37p.  Sequence similarities made it straightforward to identify the 
human homologs of Vps23p and Vps28p, as TSG101 and VPS28, respectively.  
However, the human homolog of Vps37p was not obvious, apparently owing to 
significant primary sequence divergence.  We therefore pursued more sophisticated 
bioinformatics approaches to identify human VPS37 candidates.  Chapter 3 describes the 
identification of four putative human VPS37 proteins and the characterization of the 
interaction between one of these proteins, termed VPS37B, and another ESCRT-I 
subunit, TSG101.  Identification of the human VPS37 proteins led to a more complete 
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 description of the human ESCRT-I complex (Bache et al., 2004; Eastman et al., 2005; 
Stuchell et al., 2004).  Several labs have since published important papers identifying 
MVB12 as the final ESCRT-I subunit and demonstrating its functional importance in 
yeast and human ESCRT-I (Chu et al., 2006; Curtiss et al., 2006; Morita et al., 2007; 
Oestreich et al., 2006; Oestreich et al., 2007).  Moreover, the discovery of VPS37 and 
MVB12 laid the groundwork necessary for structural studies of the ESCRT-I quaternary 
complex (Kostelansky et al., 2007; Kostelansky et al., 2006).     
Having obtained a more complete picture of the human ESCRT pathway, the 
remainder of my thesis research focused on understanding mechanistic details of the final 
fission step of vesicle formation or virus budding.  VPS4 is the only known enzyme in 
the ESCRT pathway and its ability to hydrolyze ATP is thought to be required for 
recycling the assembled ESCRT machinery (Babst et al., 1998; Bishop & Woodman, 
2000; Fujita et al., 2003; Garrus et al., 2001; Martin-Serrano et al., 2003; Wollert et al., 
2009; Yoshimori et al., 2000).  VPS4 interacts with at least a subset of the large ESCRT-
III family of proteins (Bowers et al., 2004; Scott et al., 2005b; von Schwedler et al., 
2003), which are believed to form lattices on endosomal membranes (Babst et al., 2002; 
Muziol et al., 2006; Scott et al., 2005b).  These interactions, together with the enzymatic 
activity of VPS4, are both required for endosomal protein sorting and recycling of 
ESCRT pathway components (Babst et al., 1998; Kieffer et al., 2008; Lata et al., 2008b; 
Lin et al., 2005; Nickerson et al., 2006; Shim et al., 2008; Stuchell-Brereton et al., 2007).  
The final research goal of my thesis was to understand the interaction between ESCRT-
III and the VPS4 complex.   
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 Biochemical and structural studies have helped us to understand how the VPS4 
AAA (ATPases associated with diverse cellular activities) ATPases, can bind ESCRT-III 
proteins and help facilitate recycling of the assembled ESCRT machinery.  In 2005, 
VPS4 was reported to be composed of three different regions: an N-terminal microtubule 
interacting and trafficking (MIT) domain, a C-terminal AAA ATPase cassette, and a 
three-stranded, anti-parallel β -domain that is inserted into the small domain of the 
ATPase cassette (Scott et al., 2005a; Scott et al., 2005b; Takasu et al., 2005).  The crystal 
structure of monomeric VPS4A revealed that the protein resembled another AAA 
ATPase, p97, and allowed us to model the hexameric rings formed by VPS4 by analogy 
to the structurally characterized p97 ring (Scott et al., 2005a; Zhang et al., 2000).  This 
model also suggested that VPS4 might act like other known protein unfolding ATPases 
by feeding substrates, the ESCRT-III components, through the central pore of the VPS4 
ring (Sauer et al., 2004).  Other AAA ATPases recognize their substrates using N-
terminal domains, suggesting that the N-terminal MIT domain might bind ESCRT-III 
proteins (Sauer et al., 2004; Scott et al., 2005a).  This model was tested, as described in 
Appendix A, by showing that the isolated MIT regions of the VPS4 proteins could bind 
directly with ESCRT-III proteins (Scott et al., 2005b).  These studies also revealed that 
the MIT domains were unusual three helix bundles.  Finally, mapping studies revealed 
that the VPS4A MIT domain bound the C-terminal half of CHMP1B (charged 
multivesicular body protein 1B) (Scott et al., 2005b).   
To ascertain exactly how VPS4/MIT domains recognize their ESCRT-III 
substrates, I mapped the MIT binding sites on ESCRT-III proteins more precisely and 
determined two ESCRT-III/VPS4 co-structures using NMR spectroscopy (Stuchell-
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 Brereton et al., 2007).  Chapter 4 and Appendix B of this dissertation mapped MIT 
binding sites to amphipathic helices, termed MIT-interacting motifs 1 (MIM1), at the C-
termini of a subset of the ESCRT-III proteins (Obita et al., 2007; Stuchell-Brereton et al., 
2007; Zamborlini et al., 2006).  The C-termini of both CHMP1A and CHMP2B each 
formed helices that bound between helices 2 and 3 of the MIT domain, in an orientation 
parallel to MIT helix 3 (Obita et al., 2007; Stuchell-Brereton et al., 2007).  Similar MIM 
elements were also identified in a subset of the CHMP proteins (CHMP1A, CHMP1B, 
CHMP2A, CHMP2B, and CHMP3) based on biochemical analyses (Obita et al., 2007; 
Shim et al., 2007; Stuchell-Brereton et al., 2007).  Following the publication of the 
VPS4/CHMP1-3 co-structures, the MIM1 elements in ESCRT-III proteins were also been 
shown to bind other MIT-domain containing proteins, including AMSH, UBPY and 
Vta1/LIP5 (Agromayor & Martin-Serrano, 2006; Azmi et al., 2008; Lata et al., 2008a; 
Lottridge et al., 2006; McCullough et al., 2006; Row et al., 2007; Xiao et al., 2008; 
Zamborlini et al., 2006).  Thus MIM1-MIT interactions are a ubiquitous feature of the 
ESCRT pathway.  In addition, a second distinct MIM element, termed MIM2, was 
identified in a second subset of CHMP proteins, and a structure of the CHMP6 MIM2 – 
VPS4 MIT complex was determined (Kieffer et al., 2008).  The MIM2 element is an 
extended strand that binds between MIT helices 1 and 3, again in an orientation parallel 
to helix 3.  MIM2 binding was also shown to be necessary for VPS4 recruitment as well 
as efficient protein sorting and HIV-1 budding, indicating that the MIT-MIM2 
interactions are also important components of the ESCRT pathway (Kieffer et al., 2008; 




 Current Models for ESCRT-III and VPS4 Function 
 Significant progress has been made in the past ten years in understanding the 
molecular mechanism by which the ESCRT pathway facilitates vesicle formation at the 
late endosome, HIV-1 budding and the abscission step of cytokinesis.  The current model 
for MVB formation suggests that cargo is recognized by ESCRT-0 and ESCRT-I is 
subsequently recruited to protein sorting sites on late endosomes through direct 
interactions with the HRS/Vps27p subunit of ESCRT-0 (Bache et al., 2003; Bilodeau et 
al., 2003; Katzmann et al., 2003; Pornillos et al., 2003).  ESCRT-I sequentially recruits 
ESCRT-II (Gill et al., 2007; Pineda-Molina et al., 2006; Teo et al., 2006), which interacts 
with the CHMP6/VPS20 subunit of ESCRT-III to initiate polymerization of the ESCRT-
III subunit CHMP4/Snf7p into a ring that forms within the neck of the newly forming 
vesicle (Hanson et al., 2008; Im et al., 2009; Saksena et al., 2009; Teis et al., 2008; 
Wollert et al., 2009).  It is believed that ESCRT-I/ESCRT-II and ESCRT-III polymers 
can stabilize membrane curvature at the bud neck (Fabrikant et al., 2009; Hanson et al., 
2008; Im et al., 2009; Saksena et al., 2009; Wollert et al., 2009).  CHMP4/SNF7 
polymerization, in turn, recruits the remaining ESCRT-III components, CHMP3/VPS24 
and CHMP2/VPS2 (Nickerson et al., 2006; Saksena et al., 2009; Teis et al., 2008).  These 
ESCRT subunits may then from an enclosing “dome” that juxtaposes the membranes for 
fission (Fabrikant et al., 2009; Lata et al., 2009).  Finally, the VPS4 AAA ATPases are 
recruited and utilize ATP hydrolysis to recycle ESCRT components, allowing for 
multiple rounds of vesicle formation (Fabrikant et al., 2009; Ghazi-Tabatabai et al., 2008; 
Im et al., 2009; Lata et al., 2008b; Wollert et al., 2009). 
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 Although the characterization of the ESCRT pathway has come a long way in the 
past 10 years, there are still many unanswered mechanistic questions.  Reconstitution of 
vesicle formation using pure recombinant yeast ESCRT proteins offers a powerful tool 
for mechanistic studies.  For example, recent in vitro reconstitution assays indicate that 
the ESCRT-III components can facilitate the membrane scission event without the aid of 
VPS4 ATP hydrolysis (Wollert et al., 2009).  This model suggests that VPS4 is not 
required for vesicle fission; but is required to remove ESCRT-III from the membrane and 
recycle the subunits for further rounds of vesicle formation (Wollert et al., 2009).  The 
precise roles of the different ESCRT-III subunits are also emerging.  The ESCRT-III 
subunits are recruited in a sequential manner, both in vitro and in vivo.  CHMP6/Vps20 
recruits CHMP4/Snf7, which polymerizes and recruits CHMP3/Vps24, leading to 
CHMP2/Vps2 binding (Saksena et al., 2009; Teis et al., 2008).  CHMP2/Vps2 and 
CHMP3/Vps24 can form closed tubes, even dome shaped caps on tubes, in vitro 
(Fabrikant et al., 2009; Ghazi-Tabatabai et al., 2008; Lata et al., 2008b).  A recent 
computational analysis argues that these domes have sufficient binding energy to deform 
the tubular membrane to the point where the tube closes and ultimately fuses, releasing 
the newly formed vesicle (Fabrikant et al., 2009).  Future studies will focus on testing the 
“dome” model for membrane fission, and the detailed mechanisms by which VPS4 
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The VPS4 AAA ATPases function both in endosomal vesicle forma-
tion and in the budding of many enveloped RNA viruses, including
HIV-1. VPS4 proteins act by binding and catalyzing release of the
membrane-associated ESCRT-III protein lattice, thereby allowing
multiple rounds of protein sorting and vesicle formation. Here, we
report the solution structure of the N-terminal VPS4A microtubule
interacting and transport (MIT) domain and demonstrate that the
VPS4A MIT domain binds the C-terminal half of the ESCRT-III
protein, CHMP1B (Kd  20  13 M). The MIT domain forms an
asymmetric three-helix bundle that resembles the first three heli-
ces in a tetratricopeptide repeat (TPR) motif. Unusual interhelical
interactions are mediated by a series of conserved aromatic resi-
dues that form coiled-coil interactions between the second two
helices and also pack against the conserved alanines that interdig-
itate between the first two helices. Mutational analyses revealed
that a conserved leucine residue (Leu-64) on the third helix that
would normally bind the fourth helix in an extended TPR is used to
bind CHMP1B, raising the possibility that ESCRT-III proteins may
bind by completing the TPR motif.
HIV  budding  vacuolar protein sorting  multivesicular body  NMR
Proteins targeted for lysosomal degradation are sorted intovesicles that bud into late endosomal compartments called
multivesicular bodies (MVB). Once formed, multivesicular bod-
ies can undergo several different fates, either serving as long-
term storage compartments, fusing with lysosomes to deliver the
internal vesicles and their contents for degradation, or fusing
with the plasma membrane to release the vesicles as extracellular
‘‘exosomes.’’ The MVB functions in a number of important
biological processes, including receptor down-regulation, anti-
gen presentation, intercellular communication, and develop-
ment (for reviews, see refs. 1–4). Moreover, a number of
enveloped RNA viruses, including HIV-1, usurp cellular pro-
teins involved in MVB biogenesis to facilitate virus budding, a
process that shares many similarities with MVB vesicle forma-
tion (5, 6).
MVB vesicle formation and protein sorting require a complex
set of protein machinery (the class E proteins) originally iden-
tified in yeast genetic screens (2, 7). Subsequent studies have
identified at least one human homolog for every yeast class E
protein (5), indicating that theMVB pathway is conserved across
eukaryotes. Most class E proteins function as components of one
of three endosomal sorting complexes required for transport
(ESCRT-I, -II, and -III), which are sequentially recruited to sites
of MVB protein sorting and vesicle formation (8). The ESCRT-
III proteins are the last to assemble, and are thought to form a
membrane-associated lattice that functions in the final stages of
protein sorting and vesicle formation (2, 8). Humans have a total
of 10 ESCRT-III-like proteins (the ‘‘CHMP’’ proteins) that can
be subdivided into six families corresponding to the six ESCRT-
III proteins in yeast (5, 9). Four of the ESCRT-III protein
families (corresponding to CHMP-2, -3, -4, and -6) are consid-
ered core ESCRT-III components, whereas the other two fam-
ilies (CHMP-1 and CHMP-5) may play regulatory or peripheral
roles (8). The ESCRT-III proteins, in turn, recruit the VPS4
AAA ATPases to sites of MVB vesicle formation (10). This
recruitment appears to occur through direct protein–protein
interactions, because both human and yeast ESCRT-III proteins
bind directly to VPS4 proteins (11–13). Subsequent release of
ESCRT complexes from the membrane requires the ATPase
activity of the VPS4 proteins (9, 10, 14–17). Thus, the VPS4
ATPases allow the ESCRT machinery to recycle through mul-
tiple rounds of vesicle formation andmay also provide the energy
necessary for protein sorting andor vesicle formation.
Humans and other mammals have two highly related VPS4
proteins (designated VPS4A and VPS4BSKD1) that are 80%
identical to one another and 60% identical to the yeast VPS4
protein (17). Like other AAA ATPases, the VPS4 proteins have
modular structures, with an N-terminal substrate recognition
domain preceding the canonical AAA ATPase cassette (Fig. 1)
(18, 19). Although the catalytic domains are highly conserved,
distinct substrate specificities are created through the use of
different N-terminal domains. The N-terminal domains of the
VPS4 proteins belong to a family called MIT (microtubule
interacting and trafficking) domains (20, 21). MIT domains are
found in other AAA ATPases, such as spastin, and are also
present in proteins that lack ATPase domains, such as SNX15
and PalBcalpain-7. Several recent yeast two-hybrid studies have
indicated that at least some MIT domains may act as protein
recognition modules that bind ESCRT-IIICHMP proteins (13,
22). However, detailed biochemical or structural analyses have
not yet been performed for any MIT domain. Here, we describe
the structure and protein–protein interactions of the VPS4A
MIT domain.
Experimental Procedures
Supporting Information. Further details can be found in Tables 1
and 2 and Figs. 5–7, which are published as supporting infor-
mation on the PNAS web site.
MIT Domain Alignments. The MIT domain sequence alignment
(Fig. 1) matches that presented previously (21, 23), except that
the third helices in spastin, spartin, and tobacco mosaic virus
(TMV) helicase were manually adjusted by first aligning spastin
with VPS4A and VPS4B by using CLUSTALW (24), and then
aligning spartin and TMV helicase with spastin. This procedure
optimized the alignment of highly conserved residues without
altering the 50% consensus sequence.
Cloning. DNA encoding VPS4A residues 1–84, 1–122, or 1–437
(full length) or VPS4B 1–129 or 1–444 (full length) was amplified
from EST templates (ATCC 81449 and 6216963) (25). The 5
PCR primer also reintroduced the first five amino acids that were
missing from the VPS4A EST sequence. DNA fragments were
cloned into NdeIBamH1 sites of pET16b (Novagen), modified
This paper was submitted directly (Track II) to the PNAS office.
Abbreviations: MVB, multivesicular body; TPR, tetratricopeptide repeats.
Data deposition: The model coordinates and assignments have been deposited in the
Protein Data Bank, www.pdb.org (PDB ID code 1YXR).
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to encode a TEV protease site after the N-terminal His-10 tag.
Site directed mutants were created by using the QuikChange
method (Stratagene). DNA fragments encoding CHMP1B res-
idues 65–196 and 1–196 (full length) were amplified from aHeLa
cDNA library (Stratagene) (26), and cloned into the NdeI
BamHI sites of a modified pGEX2T vector that encoded a TEV
protease cleavage site. All constructs were verified by DNA
sequencing.
Protein Expression and Purification. Protein expression and purifi-
cation protocols were similar for the different VPS4 proteins,
and are described for VPS4A1–122. His-10-VPS4A1–122 was ex-
pressed in 2-liter cultures of BL21(DE3) Escherichia coli cells
grown in LB or in M9 media supplemented with either 2 gliter
15NH4Cl or 2 gliter 15NH4Cl and 2 gliter 13C6-glucose. Ex-
pression was induced (4 h at 27°C) with 0.5 mM IPTG (A600 
0.65). Subsequent steps were performed at 4°C. Cells were
harvested and resuspended in lysis buffer (50 mM Tris, pH
8.050 mM imidazole500 mM NaCl) supplemented with pro-
tease inhibitors (Roche Diagnostics) and lysed with 1 mgml
lysozyme followed by sonication. The lysate was clarified by
centrifugation (45 min, 35,000  g), and the soluble protein
purified by nickel Sepharose chromatography (Amersham Phar-
macia). His-10-VPS4A1–122 eluted at 400 mM imidazole from
a linear gradient of 50–750 mM imidazole in lysis buffer. Protein
fractions were pooled and dialyzed sequentially against two
changes of cleavage buffer (20 mM TrisHCl, pH 8.0100 mM
NaCl5 mM EDTA), with 1 mM DTT replacing EDTA in the
second change. The His-10 tag was removed by incubation with
TEV protease (1 mg per 100 mg of protein, 12 h, 27°C) followed
by anion exchange chromatography (Q Sepharose, Amersham
Pharmacia). Flow-through fractions containing VPS4A1–122
were concentrated to 4 ml, and the protein was purified to
homogeneity by gel filtration chromatography (S75, Amersham
Pharmacia). This procedure typically yielded 30 mg of
VPS4A1–122. TEV cleavage left two nonnative residues at the N
terminus (Gly–His), which are not included in our numbering
scheme. The protein was verified by N-terminal sequencing
(G-H-M-T-T-S-T) and electrospray mass spectrometry (MWexp.
 14,168 Da, MWcalc.  14,167 Da).
GST Pull-Down Experiments. E. coli (30-ml cultures) expressing
either GST or GST-CHMP1B65–196 were pelleted, resuspended
in 5 ml of lysis buffer (50 mM TrisHCl, pH 7.450 mM NaCl5
mM 2-mercaptoethanol), and lysed with 75 l of 10 mgml
lysozyme (20 min, 4°C) followed by addition of 100 l of 5%
deoxycholate (20 min) and sonication. Soluble proteins were
collected after centrifugation for 45 min at 13,200  g. Binding
reactions (1 h at 4°C) contained 35 M GST or GST-
CHMP1B65–196, 60 M VPS4A or 300 M VPS4A1–84, and 100
l glutathione agarose slurry (Amersham Pharmacia ) in 190 ml
total volume buffer (20 mM TrisHCl, pH 8.0100 mM NaCl2
mMMgCl22 mMCaCl25 mM 2-mercaptoethanol0.02%Non-
idet P-405% glycerol). Unbound proteins were removed in
three 1.2-ml buffer washes. Bound proteins were eluted from the
matrix by boiling in 100 l of 2 SDSPAGE buffer and
detected by SDSPAGE.
Biosensor Binding Experiments. Biosensor binding experiments
used a BIACORE 2000 with research-grade CM4 sensor chips.
Approximately 5 kRU of anti-GST Ab was immobilized by
amine-coupling, and GST-CHMP proteins or GST alone (ref-
Fig. 1. Sequences and features of VPS4A, CHMP1B, and MIT domains. (A) Schematic illustrations of human VPS4A (19) and CHMP1B. The predicted coiled-coil
(CC) of CHMP1Bwas identifiedat aprobability of 0.17byusingMULTICOIL (41). (B) Sequence alignmentof knownMITdomains fromeight humanproteins (Upper)
and two proteins lacking human homologs. The ‘‘consensus’’ sequence (Lower) was derived from all 116 MIT domains in the SMART database (23). Highly
conserved residues (50% identity) are shown in blue, and residue types conserved in 50% of the sequences are shown in lowercase (h, hydrophobic; ,
positively charged; -, negatively charged; u, Ala or Gly; l, Ile, Val, or Leu). Numbering corresponds to VPS4A.
13814  www.pnas.orgcgidoi10.1073pnas.0502165102 Scott et al.
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erence) were captured in running buffer (0.5 kRU, 20 mM
Tris, pH 8.0100 mMNaCl1 mMDTT0.2 mg/ml BSA0.005%
P20). GST-CHMP proteins were either purified by glutathione
affinity chromatography or captured directly from soluble E. coli
lysates (no difference in binding was noted). Purified VPS4A
MIT proteins were injected in running buffer (0–450 M, 50
lmin, 20°C). Data were collected at 2 Hz during 30-s associ-
ation and dissociation phases and equilibrium binding isotherms
fit to simple 1:1 binding models (27). VPS4A MIT proteins in
running buffer were injected in duplicate or triplicate. Sensor-
grams for wild-type VPS4A1–84 and L64A mutant VPS4A1–84
binding immobilized GST-CHMP1B65–196 are given in Fig. 7B.
NMR Spectroscopy. NMR samples were 3 mM protein in 20 mM
sodium phosphate (pH 5.5), 50 mM NaCl, 90% H2O10% D2O.
Spectra were recorded at 25°C on a Varian Inova 600 NMR
spectrometer equipped with a triple-resonance 1H13C15N
probe and z axis pulsed-field gradients. Data were processed
with FELIX (Accelrys, San Diego), and resonances were assigned
by using standard approaches within the SPARKY program (T. D.
Goddard and D. G. Kneller, University of California, San
Francisco) (see Tables 1 and 2). Complete resonance assign-
ments were obtained, with eight exceptions: H48 HN, F39 H,
K83 H H H, and M1, M114, and M119 H. Stereospecific
assignments were obtained from GLOMSA (28) for six pairs of
methylene protons: E18H, E18H, N24H, E27H, Y38H, and
E39H. Backbone torsion angles were estimated from 13C chem-
ical shifts by using TALOS (42). All prolines were in the trans
conformation, as confirmed by intense Xxx(H)-Pro(H) se-
quential NOESY cross peaks and 13C and 13C chemical shifts
typical of trans-Pro (29).
Structure Calculations. NOE coordinates and intensities were
obtained by using the tools in SPARKY. NOE assignments were
obtained and initial structures calculated by using automated
NOE assignment together with torsion angle dynamics as im-
plemented in CYANA (28). A total of 100 randomized conformers
were ‘‘folded’’ into 3D structures by introducing NOE con-
straints in a step-wise manner by using the criteria of chemical
shift agreement, network anchoring, and consistency with an
initial fold. Each conformer was subjected to 10,000 steps of
torsion angle dynamics per cycle (seven cycles). The 20 structures
with the lowest final CYANA target function values were then
subjected to restrained energy minimization in CNS (30) using the
final CYANA NOE and torsion angle constraints, as well as helical
hydrogen bond restraints based upon chemical shift indices and
local NOE patterns (Fig. 5). Structures were validated by using
PROCHECK-NMR and AQUA (31) and visualized by using PYMOL
(DeLano Scientific).
Results and Discussion
VPS4A MIT Domain Structure Determination. N-terminal fragments
of VPS4A and VPS4B were screened for their feasibility for
NMR structural studies. The two fragments tested, VPS4A1–122
and VPS4B1–129, were designed to span the entire region of
VPS4B that was disordered in our recent crystal structure of the
full-length protein (residues 1–122) (19). Both VPS4A1–122 and
VPS4B1–129 exhibited reasonable amide proton and nitrogen
chemical shift dispersion, but VPS4B1–129 NH resonance line-
widths and intensities varied, whereas the VPS4A1–122 spectrum
was of uniformly high quality. Therefore, this protein was
selected for high-resolution structural studies.
Essentially complete proton resonance assignments were ob-
tained for VPS4A1–122 by using a standard suite of NMR
experiments (Table 1). Analyses of short- and medium-range
NOE patterns, 3JHNHA couplings, and 13C chemical shift indices
indicated the presence of three well defined helices (residues
5–20, 25–45, and 50–76), a fourth region with helical propensity
(105–114), and random coil secondary structure elsewhere (Fig.
5). VPS4A1–122 residues 77–122, including the final nascent helix,
lacked any detectable long-range NOEs, and were therefore
excluded from structure calculations. VPS4 residues 5–76
formed a tightly packed, well ordered structure as judged by the
excellent agreement between different structures (0.26-Å back-
bone heavy atom rms deviation for 20 calculated structures),
good geometries, low residual energies, and a lack of NOE
violations (see Table 2 and Fig. 6).
Structure of the VPS4A MIT Domain. The MIT domain of VPS4A
(residues 5–76) forms an antiparallel three helix bundle (Fig.
2A). The three helices wrap with a left superhelical twist, and are
disposed asymmetrically onto three corners of a square (Fig.
2B). The third helix is longer than the first two, and has an 10°
bend centered about residue Tyr-63. Helices 2 and 3 form a
two-stranded, antiparallel coiled coil, and interact with canon-
ical ‘‘knobs in holes’’ side chain interactions (32, 33) (Fig. 3). This
interaction explains the predicted coiled-coil propensity of the
third helix (10), and also explains the conservation of hydro-
phobic residues across MIT domains at helix 2 positions 25, 29,
32, 36, 39, and 43 and helix 3 positions 56, 60, 63, 67, 70, and 74
(see Fig. 1), because these residues correspond to the alternating
a (1) and d (4) positions in the heptad repeats of the coiled
coil. However, the coiled coil formed between helices 2 and 3 is
unusual in that it is mediated by conserved aromatic (as opposed
to aliphatic) side chains at positions 25, 32, 39, and 63.
In contrast, helices 1 and 2 do not form a canonical coiled coil,
but rather interact through a motif that could be described as an
‘‘alanine zipper.’’ As shown in Figs. 2C and 3, the closest contacts
between the two helices are mediated by five alanine residues,
two from helix 1 (Ala-9 and Ala-16), and three from helix 2
(Ala-28, Ala-35, and Ala-42). Each set of alanines is separated
by seven residues, and the side chains therefore project from the
same side of the helix with a spacing of two helical turns.
However, unlike the side chains in a coiled coil, the alanines
project directly toward the partner helix, and form an interdig-
itating strip between the two helices (Fig. 2C). As shown in Fig.
3, all of these alanines sit between hydrophobic residues that
project from the 4 and 5 positions on the partner helix
(numbering relative to the preceding alanine). The distance
between helices 1 and 2 in the MIT domain of VPS4A is not
unusual (10 Å), but this packing distance can only readily
accommodate small side chains such as Ala and Gly at the five
zipper positions (9, 16, 28, 35, and 42). Importantly, these
alanines or glycines are highly conserved, particularly within the
center of the zipper, with 93% conservation of Ala or Gly at
Fig. 2. VPS4A5–76 MIT domain structure. (A) Ribbon diagram of the VPS4A
MIT domain (residues 5–76). (B) View down the three helix bundle of the MIT
domain, emphasizing theasymmetry in thedispositionof the threehelices. (C)
‘‘Alanine zipper’’ connectingVPS4A5–76MIThelices 1 and2. Thefive conserved
alanine side chains within this motif are shown explicitly.










positions 9, 16, 28, and 35 in the 116 known MIT domain
sequences (23). Therefore, analogous interhelical packing inter-
actions likely exist in all MIT domains.
Importantly, the alanine zipper formed between the first two
helices is linked structurally to the aromatic coiled coil formed
between the second two helices, so that the entire three-helix
bundle of the MIT domain can be considered a single structural
motif. Specifically, the two alanines from helix 1 (Ala-9 and
Ala-16) pack between conserved central aromatic residues from
helix 2 (Tyr-32 and Phe-39). Similarly, the three alanines on helix
2 (Ala-28, Ala-35, and Ala-42) pack against aromaticlarge
hydrophobic side chains from the heptad repeat of helix 3
(Leu-70, Tyr-63, and Ile-56). Thus, the central strip of aromatic
residues between helices 2 and 3 simultaneously buttresses the
alanine zipper and participates in coiled-coil formation, and
apparently serves to hold the three helices at a proper angle (see
Figs. 2B and 3).
The closest known structural matches to the VPS4A MIT
domain occur for two distinct classes of helical bundles (34). The
first class corresponds to the first three helices within canonical
four helix bundles. In the best matches, the three MIT domain
helices align with the first three helices of the four helix bundles
with backbone atom rms deviations of 2 Å (e.g., -1 catenin;
Protein Data Bank ID 1h6g, Dali z score  8.1, backbone atom
rms deviation  2.0 over 74 residues). However, as emphasized
above, the interhelical side chain packing interactions of the
VPS4A5–76 MIT domain are quite distinct from those of canon-
ical four helix bundles, and it therefore seems unlikely that MIT
domains bind their partners by completing the four helix bundle.
The second class of similar structures correspond to helices
within tetratricopeptide repeats (TPR). For example, the three
MIT domain helices align well with the first three helices in the
TPR of FKBP51 (Protein Data Bank ID 1kt0, Dali z score 8.7,
backbone atom rms deviation  2.1 over 70 residues in helices
1–3, see Fig. 4D and E). TPRmotifs are repeats of paired helices
composed of two different types of interhelical interactions: an
AB interaction within each helical pair and a BA interaction
that links one helix pair to the next (35). TPR and MIT domain
helices are similar in that: (i) the helices have similar spatial
dispositions, (ii) an AlaGly zipper pairs the first two helices (the
AB interaction), and (iii) conserved aromatic residues perform
similar roles in helping to bridge the first helix pair and the
following repeat (the BA interaction). In a TPR, the fourth
(B) helix, which is absent in the MIT domain, binds the third
helix and we envision that an analogous interaction could
mediate the intermolecular interaction with CHMP1B (see
below).
The VPS4A MIT Domain Binds the C-Terminal Region of CHMP1B. To
begin to define how the VPS4 ATPases interact with the
assembled ESCRT-III lattice, we mapped the sites of interaction
between the VPS4A and CHMP1B proteins. The 10 different
human CHMP proteins exhibit only modest pairwise sequence
identities (12–65%), but nevertheless share a number of com-
mon features, including similar sizes (210  20 residues), pre-
dicted coiled-coil motifs, and highly asymmetric charge distri-
butions (9). CHMP1B is typical of other CHMP proteins in that
the first 64 residues are highly basic [predicted isoelectric point
(PI) of 10.1] and contain a predicted coiled coil (see Fig. 1),
whereas the C-terminal 132 residues are highly acidic (predicted
PI of 4.5) and lack predicted coiled-coil motifs. We have
previously used GST pull-down assays to demonstrate that both
VPS4A and VPS4B bind to a series of full-length ESCRT-III
proteins, including CHMP1B (12). As shown in Fig. 4A, the
full-length recombinant VPS4A protein also bound a C-terminal
fragment of GST-CHMP1B (residues 65–196), but not GST
alone (compare lanes 4 and 5). Thus, VPS4A does not interact
with the CHMP1B coiled-coilbasic region as had been pre-
Fig. 3. Side chain interactions at the different layers of the VPS4A MIT
three-helix bundle. Sequential amino acid layers in the three helix bundle of
the VPS4A MIT domain. Note that side chain interactions between helices 2
(H2) and 3 (H3) follow canonical alternating ‘‘knobs into holes’’ interactions
between residues at helix positions 1 (A) and 4 (D), whereas side chain
packing between helices 1 (H1) and 2 (H2) is different because alternating
alanine residues (highlighted in green) project almost directly at the pairing
helix and are sandwiched between hydrophobic side chains from the4 and
5 positions (relative to the preceding alanine) in the pairing helix.
13816  www.pnas.orgcgidoi10.1073pnas.0502165102 Scott et al.
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dicted (10), but instead binds the protein’s acidic C-terminal
region. These data are consistent with other recent experiments
showing that C-terminal regions of other CHMP proteins bind
VPS4 in extracts (13, 36).
As discussed above, the ESCRT-III proteins are apparently
substrates for the VPS4 ATPases (9, 10, 14–17) and AAAATPase
substrate recognition is typically meditated by the N-terminal
domain (reviewed in ref. 18). Therefore, we tested whether the
N-terminal MIT domain of VPS4A alone (VPS4A1–84) could bind
CHMP1B proteins. As shown in Fig. 4A, VPS4A1–84 bound GST-
CHMP1B65–196, but not GST alone (compare lanes 6 and 7). Thus,
the VPS4AMIT domain alone contains CHMP1B binding activity.
This observation was confirmed and quantitated in biosensor
binding experiments, in which soluble monomeric VPS4A1–84
bound specifically to immobilizedGST-CHMP1B proteins. VPS4A
MIT domain binding and dissociation were rapid at 20°C, and
dissociation constants were therefore obtained by analyzing equi-
libriumbinding phases (seeFig. 7B for representative sensorgrams).
As shown in Fig. 4B, the MIT domain bound with equal affinity to
both full-length GST-CHMP1B (Kd  20  13 M) and GST-
CHMP1B65–196 (Kd  13  6 M). Thus, a C-terminal CHMP1B
fragment that contains the acidic region but lacks the predicted
coiled-coil contributes all of the energetically significant VPS4A
MIT binding contacts.
Biosensor binding assays were also used to map the interaction
surface on the VPS4A MIT domain. We reasoned that the
binding site might feature a cluster of conserved, surface-
exposed residues, particularly hydrophobic residues. As dis-
cussed above, interhelical packing interactions rationalize the
conservation of all hydrophobic residues found with 50%
frequency in the MIT domain, with the sole exception of Leu-64,
which is exposed on the surface of helix 3 (see Figs. 1 and 4C).
Most of the remaining hydrophobic residues that lack strict
sequence conservation also appear to perform structural roles,
as do a conserved pair of charged residues, Asp-20 and Arg-66,
which approach one another across the interface between helices
1 and 2, where they may interact to form a salt bridge. This leaves
nine solvent-exposed residues that are conserved at 50%
identity and that appear unlikely to perform important structural
roles within the three helix bundle (LysArg-15, GluAsp-26,
GluAsp-37, ArgLys-53, ArgLys-57, Lys-59, Leu-64, Glu-68,
and LysArg-71). We created an ensemble of proteins that
contained single alanine substitution mutations at each con-
served position, as well as in the exposed Ile-10 residue. Al-
Fig. 4. Interactions between VPS4A and CHMP1B proteins. (A) GST pull-downs demonstrating that both full-length VPS4A and its isolated MIT domain
(VPS4A1–84) bind GST-CHMP1B65–196 (denoted GST-1B65–196, lanes 5 and 7) but not GST alone (lanes 4 and 6). Molecular weight standards (MW, lane 1), pure GST
(lane 2), and pure GST-CHMP1B65–196 (lane 3) are shown for reference. (B) Biosensor binding isotherms showing wild-type (WT) and L64A mutant VPS4A1–84
proteins bindingGST-CHMP1BandGST-CHMP1B65–196. Filled circles,WTVPS4A1–84 binding full-lengthGST-CHMP1B captured fromE. coliextracts; filled triangles,
WT VPS4A1–84 binding GST-CHMP1B65–196 captured from E. coli extracts; filled squares, WT VPS4A1–84 binding affinity purified GST-CHMP1B65–196; open squares,
VPS4A1–84 L64A binding affinity purified GST-CHMP1B65–196. Binding to the GST control surface was negligible (not shown). Dissociation constants (M) for WT
VPS4A1–84 bindingwere: CHMP1B 20 13 and CHMP1B65–196 13 6 M; andwere500 M for VPS4A1–84 L64A binding to both constructs (minimum three
independent measurements). (C) VPS4AMIT surface renderings showing the locations and identities of conserved residues. Conserved residues are color-coded
based on the reduction in CHMP65–196 binding affinity for alanine substitution mutations: dark blue,3-fold change; light blue, 3- to 30-fold reduction; green,
30-fold reduction. Dissociation constants were: WT, 13 6 M; I10A, 17 1 M; K15A, 14 1 M; E26A, 8 1 M; E37A, 16 2 M; K53A, 20 2 M; R57A,
34  4 M; K59A, 9  1 M; L64A, 500 M; E68A, 55  4 M; K71A, 18  2 M (minimum of two independent measurements). (D) Overlays of the first four
helices of the TPRdomainof FKBP51 (gray)with theMITdomainofVPS4A. Theoverlay shows the similarity of the structures and thepositionof the secondpaired
helix (fourth overall) in the FKBP51 TPR domain, which is missing in the VPS4A MIT domain. (E) Side view of the overlay in D, but with the VPS4A MIT domain
shown in a space filling model and color coded as in C. The figure emphasizes that residues required for CHMP1B binding (green, light blue) map to the same
surface as the binding site for the second paired helix of the FKBP51 TPR domain.










though Ile-10 is 50% conserved across all MIT domains, this
position is typically hydrophobic and lies on the face opposite
Leu-64.
As summarized in Fig. 4 B–E, the affinity of CHMP1B (and
CHMP1B65–96) binding was reduced very substantially (30-
fold) by the VPS4A1–84 L64A mutation. An alanine substitution
mutation in the adjacent Glu-68 residue also reduced CHMP1B
binding affinity, albeit modestly (3.5-fold). None of the other
mutants altered the CHMP1B binding affinity significantly
(3-fold). Importantly, an [1H,15N] HSQC spectrum of the
VPS4A1–84 L64A protein confirmed that this mutation did not
alter the overall fold of theMIT domain (see Fig. 7A). Therefore,
we conclude that CHMP1B contacts the Leu-64Glu-68 patch
directly. As shown in Fig. 4E, this patch corresponds to the
surface of helix 3 that would normally interact with the fourth
helix in a TPR motif. Thus, the short TPR in the MIT domain
has adapted to bind a target protein in trans, rather than a fourth
helix in cis, raising the intriguing possibility that helices from the
ESCRT-III proteins may bind by completing or extending the
TPR.
Potential Biological Implications. MIT domains are found in pro-
teins that function in important biological processes such as
endosomal protein sorting (VPS4, SNX15, spastin) (10, 20, 22),
virus budding (VPS4) (25), microtubule organization (spastin)
(21, 22, 37, 38), and maintenance of motor neuron function
(spastin and spartin) (22, 39). The general conservation of key
structural residues indicates that all MIT domains will form
three-helix bundles that are similar to the VPS4A MIT domain
structure presented here.
Our data also demonstrate that the MIT domain of VPS4A
binds directly to the C-terminal acidic region of the ESCRT-III
protein, CHMP1B, and to analogous regions on other human
CHMP proteins (data not shown). These interactions seem
functionally important because recruitment of VPS4 proteins to
endosomal membranes requires both the C-terminal half of
CHMP proteins (40) and the MIT domains of VPS4 proteins
(10). Interestingly, another MIT domain-containing protein,
spastin, is also a CHMP1B-binding protein and the MIT domain
is again required for this interaction (22). As shown in Fig. 1, the
key Leu-64 residue in helix 3 critical for the VPS4ACHMP1B
interaction is also conserved in the spastin MIT domain. This
domain again precedes a AAA ATPase cassette, raising the
possibility that spastin may perform at least some functions that
are analogous to those of the two better characterized human
VPS4 proteins. Indeed, although the binding partners for most
MIT domain proteins have not yet been determined experimen-
tally, the apparent conservation of the exposed leucine on helix
3 suggests that other human MIT domain proteins such as
SNX15, which again seems to function in endosomal protein
sorting (20), may also interact functionally with ESCRT-III
proteins.
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VPS4B MIT VPS4B MIT-
CHMP2B195-213
NMR distance and dihedral constraints
Distance constraints
Total NOE 1311 1769 1625
Intra-residue 309 426 338
Inter-residue 1002 1343 1287
Sequential (|i – j| = 1) 333 418 403
Medium-range (2 |i – j| 5) 391 538 487
Long-range (|i – j| > 5) 215 387 336
Intermolecular (MIT – CHMP) 63 61
Hydrogen bonds 59 55 61





Distance constraints (Å) 0.002, 0.002 0.003, 0.005 0.003, 0.004
Dihedral angle constraints (º) 0.030, 0.025 0.035, 0.025 0.034, 0.027
Max. distance constraint violation (Å) 0.017 0.065 0.026
Max. dihedral angle violation (º) 0.1 0.103 0.125
Deviations from idealized geometry
(r.m.s.deviation)
Bond lengths (Å) 0.0003 0.0003 0.0004
Bond angles (º) 0.29 0.25 0.25
Impropers (º) 0.08 0.79 0.81
Average pairwise r.m.s. deviation1 (Å)
All heavy atoms 1.25 ± 0.14 1.07 ± 0.08 1.16 ± 0.10
Backbone atoms (C , C, N, O) 0.63 ± 0.26 0.37 ± 0.07 0.64 ± 0.10
1Average pairwise r.m.s. deviation was calculated using the 20 lowest energy CNS structures.
Structures were superimposed using residues 5-75 and 185-196 for VPS4A MIT-CHMP1A180-
196, 10-81 for VPS4B MIT, and 10-81 and 200-213 for VPS4B MIT-CHMP2B195-213.
Ramachandran statistics (most favored%, additionally allowed%, generously allowed%) are:
VPS4A MIT-CHMP1A180-196 (93.7, 6.3, 0); VPS4B MIT (95.1, 4.9, 0); and VPS4B MIT-
CHMP2B195-213 (94.7, 5.1, 0.2).
Structure coordinates have been deposited in the PDB with the following codes: VPS4A MIT-
CHMP1A180-196, rcsb100153 and PDB ID code 2jq9; VPS4B MIT, rcsb100161 and PDB ID
code 2jqh; and VPS4B MIT- CHMP2B195-213, rcsb100164 and PDB ID code 2jqk.
SUPPLEMENTARY INFORMATION










1A Homo Sapiens Q9HD42 SQEDQLSRRLAALRN
1B Homo Sapiens AAG01449 AEQDELSQRLARLRDQV
2A Homo Sapiens NP_940818 DADADLEERLKNLRRD
2B Homo Sapiens NP_054762 ISDEEIERQLKALGVD
3 Homo Sapiens NP_057163 EALEAMQSRLATLRS
1 Macaca mulatta XP_001103984 SQEDQLSRRLAALRN
2 Macaca mulatta XP_001104442 ISDEEIERQLKALGVD
3 Macaca mulatta XP_001086438 AAEMEIDRILFEITADVFHNT
1A Mus musculus NP_663581 SQEDQLSRRLAALRN
1B Mus musculus NP_077152 AEQDELSQRLARLRDQV
2A Mus musculus NP_081161 DADADLEERLKNLRRD
2B Mus musculus NP_081155 ISDEEIERQLKALGVD
3 Mus musculus NP_080059 EDLEAMQSRLATLRS
1A Rattus norvegicus NP_001076782 SQEDQLSRRLAALRN
1B Rattus norvegicus XP_001067633 AEQDELSQRLARLRDQV
2A Rattus norvegicus XP_344861 DADADLEERLKNLRRD
2B Rattus norvegicus XP_001063932 ISDEEIERQLKALGVD
3 Rattus norvegicus NP_758834 EDLEAMQSRLATLRS
1 Caenorhabditis elegans NP_490974 SEDKDLTERLAALRNM
2A Caenorhabditis elegans NP_496717 DVDDDLQARLDQLRRE
2B Caenorhabditis elegans NP_493357 ADFDDLEAQLARLRS
3 Caenorhabditis elegans NP_494919 EDFEGMAQRLAELRD
1A Xenopus laevis AAH68657 TQEDQLSRRLASLRN
1B Xenopus laevis Q7SZB5 TEQDELSQRLARLRDQV
2A Xenopus laevis Q6IP52 DADADLEERLNNLRRD
2B Xenopus laevis Q7SYR0 ISDEEIERQLKALGVD
2B Xenopus laevis Q66IV6 ISDEEIERQLKALGVD
3 Xenopus laevis Q6NRM7 EDLEAMHSRLAALRS
1 Drosophila melanogaster NP_649051 QEQDELTQRLARLRQAE
2A Drosophila melanogaster NP_651455 DADADLQARLDKLRKD
2B Drosophila melanogaster NP_647947 RTEKDIADQLAKLRSS
3 Drosophila melanogaster NP_649451 EELQEMQSRLASLRS
1 Anopheles gambiae XP_316550 TEQDELTARLARLRQAE
2 Anopheles gambiae XP_321862 DADADLQARLDNLRRE
3 Anopheles gambiae EAA05411 DDMKEMQNRLQALRS
1 Arabidopsis thaliana AAF99815 VEEDDLTRRLAELKAR
2A Arabidopsis thaliana NP_565336 GIDSDLQARLDNLRKM
2B Arabidopsis thaliana ADD10675 SGIDELEKRLAALR
2B Arabidopsis thaliana NP_563696 SGIDELEKRLAALR
3 Arabidopsis thaliana NP_197686 EELEEIRARLAKVRS
1A Leishmania infantum JPCM5 XP_001468271 VDEDDIAERLKALQAL
1B Leishmania infantum JPCM5 XP_001469249 VEEDDLEAKFAQLRGR
2 Leishmania infantum JPCM5 XP_001466503 ETDEELDARLAALKASM
3 Leishmania infantum JPCM5 XP_001469672 --EDELMEKFNALRNS
1 Saccharomyces cerevisiae NP_012961 EKEDKLAQRLRALRG
2 Saccharomyces cerevisiae NP_012924 NPDDDLQARLNTLKKQT
3 Saccharomyces cerevisiae CAA81876 RMVNEMRERLRALQN
1 Schizosaccharomyces pombe NP_596562 VEDDNLQERLRALRS
2 Schizosaccharomyces pombe CAB90130 KTEDNLQARLDELAKR
3 Schizosaccharomyces pombe NP_594587 EQLLDIRDKLDALKS




Supplemental Figure 1 NMR Spectra of the VPS4A MIT-CHMP1A180-196 Complex.
a, Overlay of 2D [15N, 1H] HSQC spectra for 15N-labeled VPS4A MIT titrated with unlabeled
CHMP1A180-196 peptide. Spectra are colored according to the number of molar equivalents
CHMP1A180-196 added: red, 0 equivalents; cyan, 0.35 equivalents; purple, 0.65 equivalents;
and blue, 1.15 equivalents. Aliased arginine N H resonances are shown in green, yellow,
white, and cyan, respectively. Right panels show expanded regions of the left spectrum.
b, Comparative NH backbone chemical shifts from the 0 and 1.15 equivalent titration points in
a mapped on the VPS4A MIT–CHMP1A180-196 structure. Red denotes NH signals with
composite > 5, where =25(( HN)2 + ( N/5)2)0.5.
c, Strip plots from 3D [1H,13C/15N, 1H] NOESY (blue) and 3D F1-13C15N-filtered [1H,13C/15N,1H]
NOESY (red) for six different CH strips from residues within the VPS4A MIT–CHMP1A
interface. Horizontal lines denote assigned inter-molecular NOEs and assignments are given
to the right of the corresponding strips.
Supplemental Figure 2 Structure of the VPS4A MIT-CHMP1A180-196 Complex.
Superposition of the twenty lowest penalty structures of the VPS4A MIT-CHMP1A180-196
complex. Structure statistics are given in Supplemental Table 1. Color coding here and
throughout is the same as in Fig. 2b.
Supplemental Figure 3 Structures and Comparisons of the VPS4B MIT Domains
a, Superposition of the twenty lowest penalty structures of the free VPS4B MIT Domain.
Structure statistics are given in Supplemental Table 1.
b, Ribbon diagrams showing the superposition of the free VPS4B MIT domain (colored) and
the free VPS4A MIT domain (grey), rmsd = 1.14 Å. Superpositions in parts b-d were on all
heavy atoms within the three helices of the VPS4A and VPS4B MIT domains (VPS4A
residues 6-22, 25-45, 50-75 and VPS4B residues 8-24, 27-47, 52-83).
c, Ribbon diagrams showing the superposition of the free VPS4A MIT domain (colored) and
the same domain within the VPS4A MIT-CHMP1A180-196 complex (grey), rmsd = 0.86 Å.
d, Ribbon diagrams showing the superposition of the free VPS4B MIT domain (colored) and
the same domain within the VPS4B MIT-CHMP2B195-213 complex (grey), rmsd = 0.73 Å.
Supplemental Figure 4 Structure of the VPS4B MIT-CHMP2B195-213 Complex.
a, Superposition of the twenty lowest penalty structures of the VPS4B MIT-CHMP1A195-213
complex. Structure statistics are given in Supplemental Table 1.
b, Ribbon diagram of the VPS4B MIT-CHMP2B195-213 complex, with the three conserved
leucine residues shown explicitly.
c, Structure of the VPS4B MIT-CHMP2B195-213 complex. The MIT domain is shown in a space
filling model with the Leu66 residue highlighted in blue, and with important residues on both
sides of the interface shown explicitly. Arrows denote the approximate orientations of the
three leucine binding pocket views shown in parts d-f.
d-f, Close up views of the three leucine binding pockets of the VPS4B MIT domain showing
the hydrophobic pockets in detail, as well as salt bridge and hydrogen bonding interactions
between D200-R59 and Q206-E70 (CHMP2B residues listed first).
Supplemental Figure 5 VPS4A MIT-CHMP1B Binding Interactions
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Biosensor binding isotherms showing wild type and mutant VPS4A MIT binding to
immobilized GST-CHMP1B180-196 proteins. The data demonstrate that mutation of the VPS4A
Leu64 residue severely inhibits CHMP1B binding and that the L64D mutation is even more
detrimental than the L64A mutation. Duplicate data points are shown for each condition, and
estimated dissociation constants derived from fits to single site binding models (curves) were
wt VPS4A MIT = 19.0 ± 0.1μM and VPS4A MITL64A ~3.36 ± 0.2 mM. VPS4A MITL64D binding
was undetectable at the highest concentration tested (250 μM). Estimated errors in
dissociation constants were derived from statistical fits of duplicate binding data to 1:1
binding models and the dissociation constant for the VPS4A MIT-CHMP1B180-196 interaction
(KD=19 μM, M buffer) was in good agreement with previous measurements for VPS4A
binding to full length CHMP1B (KD=20 ±13 μM, M buffer)2.
Supplemental Figure 6 The Yeast Vps4p MIT Leu64Asp Mutation Inhibits Recruitment
of GFP-Vps4p to Class E Compartments.
a, Confocal fluorescence slices showing localization of GFP-Vps4pK179Q (top row), and GFP-
Vps4pL64D/K179Q (bottom row) in yeast. FM4-64 staining (red) was used to define the limiting
vacuolar membrane (open circles) and to visualize class E compartments (intense puncta).
Overlaid and differential interference contrast (DIC) images are shown in the final two rows
for reference and the scale bar is 5 μm.
b, Graphic quantification of the experiment shown in a, demonstrating that the Vps4pK179Q
protein localizes to Class E compartments and that the secondary L64D mutation
redistributes the Vps4pL64D/K179Q protein back into the cytoplasm.




As expected, the VPS4A and VPS4B MIT domains adopt similar structures, and all three
helices overlayed with rmsd values that were only slightly larger than their coordinate errors
(Supplemental Figure 3). Furthermore, neither domain changed structure significantly upon
CHMP peptide binding, indicating that MIT domains are preformed binding modules. Both
CHMP peptides exhibited some helical character prior to binding, but changes in chemical
shift indices indicated that the peptides became substantially more helical when they bound
the MIT domain. Both complexes exhibit a similar amount of total buried surface area
(VPS4A MIT-CHMP1A180-196 = 1040Å2, VPS4B MIT- CHMP2B195-213 = 1007Å2).
Previous studies of isolated VPS4 MIT domains have provided structural explanations
for the sequence conservation at a number of positions that stabilize the TPR-like disposition
of the three helix bundle1,2. The MIT-CHMP complex structures now rationalize the weaker
sequence conservation at several additional positions that help define the three binding
pockets for the conserved CHMP leucines, including: L29 and Q33 (Leu194 binding pocket),
Val36 (Leu191 binding pocket), and Leu40 (Leu187 binding pocket) (VPS4A MIT/CHMP1A
numbering). Although the VPS4A MIT-CHMP1A180-196 and VPS4B MIT-CHMP2B195-213
complexes adopted very similar structures, the VPS4B MIT- CHMP2B195-213 interaction was
approximately 50-fold weaker (Fig. 1b). To a large extent, this appears to be because the
CHMP1A tail conforms perfectly to the 187LxxRLAALR195 core consensus sequence, whereas
the CHMP2B tail differs from the consensus at four positions (204IxxQLKALG211). As a result:
1) the Arg195-Glu37 salt bridge in the VPS4A MIT-CHMP1A complex is lost in the VPS4B
MIT-CHMP2B complex (Gly211-Gln39), 2) the Arg190-Glu68 salt bridge in the VPS4A MIT-
CHMP1A complex is replaced by a simple hydrogen bonding interaction in the VPS4B MIT-
CHMP2B complex (Gln206-Glu70), 3) the conserved Leu187 residue of CHMP1A is replaced
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by an isoleucine in CHMP2B (Ile203), and 4) the consensus Ala-Ala motif (192AA193 in
CHMP1A) may augment the binding affinity indirectly by contributing to helical propensity,
(vs. the 208KA209 sequence in CHMP2B), even though these residues do not directly contact
the MIT domain. Similarly, the weaker binding typically seen for the VPS4B MIT domain
appears to reflect substitutions at VPS4A Val61 (Leu187 binding pocket) vs. VPS4B Thr63,
VPS4A Ile43 (Leu184 binding pocket) vs. VPS4B Val45, and VPS4A Glu37 (salt bridge with
Arg195 salt bridge, CHMP1A numbering) vs. VPS4B Gln39. Thus, the complex structures
explain the sequence conservation on both sides of the interface, and can also rationalize the
gradient of binding affinities observed for different MIT-CHMP complexes.




ESCRT-III Protein Sequence Alignments
50 different CHMP1-3 protein sequences from 12 model organisms were identified using
BLAST searches3 (Supplemental Table 2). C-terminal sequence alignments were created in
Clustal W (http://align.genome.jp) by aligning the final 14-21 residues of each sequence.
Yeast Strains
Standard yeast genetic methods were used for the construction, transformation, and growth
of yeast4,5. The VPS4 open reading frame (ORF) was replaced with the KanMX cassette
generated from pFA6-KanMX46 using homologous recombination7 in the SEY6210 genetic
background8 (MATa; leu2-3,112 ura3-52 his3- 200 trp1- 901 lys2-801 suc2- 9).
Expression Constructs and Plasmids
VPS4 MIT Domains. DNA encoding residues 1-84 of human VPS4A and 1-86 of VPS4B were
amplified from EST templates (ATCC 81449 and 6216963)9,10 and cloned into the
(5’)NdeI/(3’)BamHI sites of a pET16b (Novagen) plasmid modified to encode a TEV protease
site after the N-terminal His10 tag (WISP00-71). The resulting expression constructs were
designated WISP05-43 (VPS4A) and WISP04-153 (VPS4B). Expression constructs for the
VPS4A MITL64A2 (WISP07-119) and VPS4A MITL64D (WISP07-120) were made by the
QuikChange method (Stratagene). The wt VPS4 MIT constructs were also subcloned into the
(5’)NdeI/(3’)BamHI sites of pGEX-2T (Amersham) plasmid modified to encode a TEV
protease site after the N-terminal GST tag, to create expression constructs for GST-VPS4A1-
84 (WISP07-60) and GST-VPS4B1-86 (WISP04-155).
CHMP1B. Expression constructs for GST-CHMP1B1-196 (full length) and GST-CHMP1B65-196
have been described2. Analogous expression constructs for GST-CHMP1B180-196 (WISP06-
22) and GST-CHMP1B65-180 (WISP06-12), GST-CHMP1BL189A (WISP06-23), and GST-
CHMP1BL192A (WISP06-24) were created by the QuikChange method using the CHMP1B and
CHMP1B65-196 expression constructs as templates.
CHMP1A180-196 and CHMP2B195-213. Expression constructs for (His)10-Trp LE-CHMP1A180-196
(WISP06-62) and Trp LE-CHMP2B195-213 (WISP07-61) fusions were initially created by the
QuikChange method using the Trp LE-Pro- -MVIIA-Gly template plasmid11.
Yeast Vps4p Expression Constructs. Expression constructs for yeast Vps4p were created by
amplifying a fragment containing the yeast VPS4 ORF and ~250 bases up and downstream
using wild-type yeast genomic DNA as a template. The amplified fragment was inserted at
(5’)BamH1/(3’)Sal1 sites of pRS416 (ATCC) to create WISP07-95, and this plasmid was
mutated using the QuikChange method to create an expression construct for Vps4pL64D
(WISP07-97).
GFP-Vps4p. The yeast VPS4 ORF was amplified from wild-type yeast genomic DNA and
cloned into (5’)BamH1/(3’)Xho1 sites of pRS415MET25-GFP12. A single base pair was
removed from the multiple cloning site using QuikChange mutagenesis to generate the in-
frame GFP fusion construct (WISP07-90). vps4 mutations were introduced using the
QuikChange method to create expression constructs for Vps4pK179Q (WISP07-92) and
Vps4pK179Q,L64D (WISP07-93).
GFP-CPS Constructs. The gene for carboxypeptidase S was amplified from wild-type yeast
genomic DNA and cloned into (5’)BamH1/(3’)Xho1 sites of WISP07-90 in place of the ORF
for VPS4 to create WISP07-94.
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GFP-VPS4 Constructs. The mammalian expression constructs for EGFP-VPS4A and EGFP-
VPS4AK173Q have been described9, and mutations were introduced using the QuikChange
method to create constructs for VPS4L64A (WISP07-98), VPS4L64D (WISP07-99), VPS4K173Q/
L64A (WISP07-100), and VPS4K173Q/L64D (WISP07-101).
Protein Expression and Purification
Wild type and mutant VPS4A and VPS4B MIT domains were expressed in BL21(DE3) E. coli
cells grown in 2-liter cultures of LB or M9 media (2 g/liter 15NH4Cl or 2 g/liter 15NH4Cl and 2
g/liter 13C6-glucose). Protein expression was induced (4-12 h, 23 C) with 0.5 mM IPTG (A600
= 0.65). Cells were harvested and resuspended in 50 mM Tris pH 8.0, 50 mM imidazole, 500
mM NaCl, and protease inhibitors (Roche Diagnostics) and lysed with 1 mg/mL lysozyme
followed by sonication. Lysates were clarified by centrifugation (45 min., 17,000 rpm), and the
soluble MIT domains purified by nickel affinity chromatography (chelating sepharose,
Amersham Pharmacia). His10-VPS4 MIT domains eluted at ~500 mM imidazole from a linear
gradient of 50-750 mM imidazole in the lysis buffer. Protein fractions were collected and
dialyzed against two changes of 20 mM Tris pH 8.0, 100 mM NaCl, and 5 mM EDTA
replacing EDTA in the second change with 1 mM DTT. The His10 tag was removed by
incubation with TEV protease (1 mg TEV per 100 mg VPS4 protein, 12 h, 23 C) followed by
anion exchange chromatography (Q sepharose, Amersham Pharmacia). Flow-through
fractions containing VPS4 MIT were concentrated to ~2 ml, and the proteins were purified to
homogeneity by gel filtration chromatography (S75, Amersham Pharmacia). This procedure
typically yielded ~30 mg of VPS4A MIT and ~20 mg of VPS4B MIT. TEV cleavage left two
nonnative residues at the N-terminus of VPS4A MIT (Gly-His) and three nonnative residues
at the N-terminus of VPS4B MIT (Gly-His-Met), which are not included in our numbering
scheme. Proteins were verified by N-terminal sequencing and electrospray mass
spectrometry.
Peptide Synthesis/Expression and Purification
Unlabeled CHMP1A180-196 and CHMP2B195-213 were prepared by solid phase synthesis and
purified by reversed phase HPLC. CHMP1A180-196 and CHMP2B195-213 were also expressed in
bacteria as Trp LE peptide fusions for isotopic 13C- and 15N-labeling. The recombinant
peptides were purified from inclusion bodies, with an additional nickel affinity chromatography
step (6M urea) for (His)10-Trp LE-CHMP1A180-196. The fusion peptides were then cleaved
using cyanogen bromide in 70% formic acid13,14, and the desired peptides were purified by
reversed phase HPLC purification. Expected masses were confirmed by mass spectrometry,
and final peptide concentrations were determined by amino acid analysis.
Biosensor Analyses
Biosensor binding experiments used BIACORE 2000 and 3000 instruments. Research-grade
CM4 sensor chips were derivatized with anti-GST antibody by amine-coupling (5-6000
response units (RU) in Fig. 1a, 15 kRU in Fig. 1b). GST-CHMP1B proteins (Fig. 1a) or GST-
VPS4 MIT proteins (Fig. 1b) or GST alone (reference) were captured directly from soluble E.
coli lysates for 10 minutes at a flow rate of 10 l/min in running buffer (~0.77 kRU GST-
CHMP1B proteins in Fig. 1a, ~2-3 kRU GST-MIT proteins in Fig. 1b, and ~3 kRU GST-
CHMP1B180-196 protein in Supplemental Figure 5). Running buffers were: 20 mM Tris pH
8.0, 100 mM NaCl, 1 mM DTT, 0.2 mg/mL BSA, 0.005% P20 surfactant (Fig. 1a and “M”
buffer in Fig. 1b and Supplemental Figure 5) or 20 mM sodium phosphate pH 5.5, 0.05%
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P20, 0.4 mg/mL BSA (“L” buffer in Fig. 1b). Pure VPS4B MIT (Fig. 1a), CHMP peptides (Fig.
1b), or VPS4A MIT proteins (Supplemental Figure 5) at the designated concentrations were
injected in duplicate (running buffer, 50 L/min, 20ºC) and binding data were collected at 2
Hz during the 30 s association and dissociation phases. All interactions reached equilibrium
rapidly and dissociated within seconds during the dissociation phase. To obtain equilibrium
constants, the responses at 15 s were fit to a 1:1 binding interaction isotherm15. Note that
although the estimated dissociation constant for the VPS4A MITL64A-CHMP1B180-194
interaction is not reliable owing to weak binding (KD~3.3 mM, see Supplemental Figure 5),
this interaction is clearly stronger than the VPS4A MITL64D-CHMP1B180-194 interaction, where
binding was undetectable even at 250 μM VPS4A MITL64D.
NMR Sample Preparation and Screening
NMR titration experiments were initially used to screen different VPS4 MIT-CHMP peptide
complexes, salt conditions, and temperatures to identify optimal complexes and solution
conditions. Samples used for structure determinations were in NMR buffer (20 mM sodium
phosphate pH 5.5, 90% H2O, and 10% D2O) except where noted. The following NMR
samples were prepared and used for complex structure determinations: 1) 1.4 mM uniformly
labeled 15N-/13C-labeled VPS4A MIT + 1.6 mM unlabeled CHMP1A180-196 (NMR structure of
bound VPS4A MIT and ID of intermolecular NOEs, KD=4.6 M, 98% occupancy) 2) 1.6 mM
unlabeled VPS4A MIT in complex with 1.4 mM uniformly 15N-/13C-labeled CHMP1A180-196
(NMR structure of bound CHMP1A180-196 and ID of intermolecular NOEs, 98% occupancy), 3)
2.9 mM uniformly 15N-/13C-labeled VPS4B MIT in NMR buffer + 50 mM NaCl (NMR structure
determination of free VPS4B MIT), 4) 0.48 mM uniformly 15N-/13C-labeled VPS4B MIT + 4.8
mM unlabeled CHMP2B195-213 (NMR structure of bound VPS4B MIT and ID of intermolecular
NOEs, KD=273 M, 94% occupancy) 5) 2.84 mM unlabeled VPS4B MIT in complex with 0.26
mM uniformly 15N-/13C-labeled CHMP2B195-213 (NMR structure of bound CHMP2B195-213 and
and ID of intermolecular NOEs ,94% occupancy). All complexes were in fast exchange.
Data Collection and Resonance Assignment
Assignments were made using a standard suite of triple resonance NMR experiments16
recorded at 25 ºC on Varian Inova 600 or 800 MHz NMR spectrometers equipped with triple-
resonance 1H/13C/15N probes (cryogenic probe, 600 MHz; room temperature probe, 800 MHz)
and z-axis pulsed-field gradients. Data were processed with FELIX (Accelrys, San Diego),
and resonances assigned using standard approaches within the SPARKY program (T.D.
Goddard and D.G. Kneller, University of California, San Francisco).
Nearly complete resonance assignments were obtained for VPS4A MIT-CHMP1A180-
196 (96.4%, 13 stereospecific assignments), free VPS4B MIT (94.7%, 31 stereospecific
assignments), and bound VPS4B MIT-CHMP2B195-213 (98%, 14 stereospecific assignments).
Backbone phi and psi torsion angles were estimated from 13C chemical shifts using
TALOS17. All prolines were in the trans conformation, as confirmed within CYANA by 13C
and 13C chemical shifts typical of trans-Pro18 as part of the CYANA program19. The chemical
shifts of CHMP1A180-196 resonances in samples 1 and 2 (see above) were not identical due to
slightly different VPS4A MIT-CHMP1A180-196 molar ratios (and fast exchange conditions).
Sample 1 CHMP1A resonance assignments were required for proper interpretation of
intermolecular NOEs. These assignments were determined by adjusting the assignments in
sample 2 using a combination of 2D F1/F2-13C15N filtered [1H, 1H] NOESY20,21 (60 ms mix
time), 2D F1/F2-13C15N filtered [1H, 1H] TOCSY (35, 55, 70 ms mix times), and analysis of 2D
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[15N, 1H] HSQC (Supplemental Figure 1) and 2D [13C, 1H] HSQC titration curves. Double
edited NOESY experiments were unnecessary owing to the small size of the system.
These procedures resulted in nearly complete resonance assignments for the bound
CHMP1A180-196 peptide in both samples 1 and 2. Chemical shift differences for bound VPS4A
MIT in these samples were tracked using the titration data exclusively (Supplemental Figure
1).
Structure Calculations
Intra and intermolecular NOEs were obtained using 3D [1H,13C/15N,1H] NOESY and 3D F1-
13C15N-filtered [1H,13C/15N,1H] NOESY experiments (60 msec mixing times). Intermolecular
NOEs were obtained from the F1-13C15N-filtered [1H,13C/15N,1H] NOESY while intramolecular
NOEs were obtained from differences between the 3D [1H,13C/15N,1H] NOESY and 3D F1-
13C15N-filtered [1H,13C/15N,1H] NOESY. NOE coordinates (1H, 15N/13C, 1H) and intensities
were obtained by using the tools in SPARKY (from T.D. Goddard and D.G. Kneller), and
exported into CYANA19 for structure calculations. NOEs were assigned and structures
calculated using the automated NOE assignment module implemented in CYANA (Version
2.1)19. Intermolecular NOEs for both complexes were manually assigned and incorporated
into the complex structure calculations using the “Keep” subroutine in CYANA. A number of
additional peaks were present in the 3D [1H,13C/15N,1H] F1-13C15N-filtered NOESY spectra of
VPS4B MIT-CHMP2B195-213 owing to the very high excess of CHMP2B195-213 peptide required
to saturate this weaker-binding complex. The assigned VPS4A MIT-CHMP1A180-196 structure
was therefore used as a general “distance filter” to select the subset of NOE’s kept.
Final CYANA calculations started with 1000 randomized conformers that were “folded”
into 3D structures by introducing NOE constraints in a step-wise manner by using the criteria
of chemical shift agreement, network anchoring, and consistency with an initial fold. Each
conformer was subjected to 10,000 steps of torsion angle dynamics per cycle (seven cycles
total). Final CYANA calculations included helical hydrogen bond restraints, derived from the
preliminary structures. The 20 lowest energy CYANA structures were refined in CNS using a
low temperature simulated annealing protocol. Structure statistics for VPS4A MIT-
CHMP1A180-196, free VPS4B, and VPS4B MIT-CHMP2B195-213 are summarized in
Supplemental Table 1. Structures were visualized, superimposed, and figures made using
PYMOL (DeLano Scientific).
GFP-CPS Cargo Sorting Assays
vps4 yeast cells harboring pRS415MET25+GFP-CPS22 and either pRS416+VPS4,
pRS416+vps4L64D, or an empty control vector were grown to log phase in selective media at
30 C or 37 C and scored for the presence of vacuolar GFP fluorescence primarily: 1) at the
limiting vacuolar membrane, or 2) within the vacuolar lumen.
Yeast Class E compartments and vacuolar membranes were simultaneously
visualized using FM4-64 staining23. Log phase cultures were incubated with 10 mg/μl FM4-
64 dye (Molecular Probes)) at 30 C or 37 C for 15 min, washed, and incubated at 30 C or
37 C in selective media for 0.5-2 h prior to observation.
Vps4p Localization (Yeast)
For GFP-Vps4p localization studies, vps4 cells harboring pRS415MET25+GFP-VPS4
or mutant alleles were grown to log phase at 30 C, stained with FM4-64, and scored for one
of three different phenotypes: 1) diffuse cytoplasmic, 2) diffuse + punctate, or 3) exclusively
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punctate GFP fluorescence. FM4-64 staining was performed as described above. Equivalent
expression levels of the wt and mutant GFP-Vps4p proteins were confirmed by western
blotting (not shown).
Fluorescence Imaging (Yeast)
Yeast cells were visualized and protein localization was scored using a Zeiss Axioplan 2
Imaging microscope. Images used for figures were collected on an Olympus FV300 confocal
fluorescence microscope using Fluoview 2.0.3.9 software. Quantified data shown in Fig. 3
and Supplemental Figure 6 are both from three independent data sets of 100 cells, and error
bars reflect standard deviations.
Fluorescence Imaging (Mammalian Cells)
COS7 cells were seeded on collagen-coated glass coverslips in a 12-well plate at 8x104
cells/well. 2 μg pEGFP-VPS4A DNA or mutant construct was transfected using 2.5 μl of
lipofectamine 2000 (Invitrogen) per well according to the manufacturers instructions. Cells
were fixed ~18 h post-transfection in 3% paraformaldehyde in phosphate buffered saline
(PBS), washed once with 50 mM NH4Cl in PBS, washed twice in 1% BSA in PBS and placed
onto a microscope slide containing Fluoromount-G (Southern Biotech). Images were
collected on an Olympus FV300 confocal fluorescence microscope using Fluoview 2.0.3.9
software. Data shown in Fig. 4a are from two independent experiments ( 100
cells/experiment), and errors reflect standard deviations.
Infectivity Assays
293T cells were seeded in 6-well plates at 8x105 cells per well and co-transfected with the
pEGFP-VPS4 expression construct and an HIV-1 vector system (packaging and transfer
plasmids kindly provided by D. Trono, and envelope plasmid by J. Burns). Briefly, 12 μl
FuGene 6 Transfection Reagent (Roche Diagnostics) was combined with 1 μg pCMV R8.2,
1μg pWPTS-nlsLacZ, 0.36 μg phCMV-VSVG, and 0.5 μg pEGFP-VPS4A plasmid per well
according to manufacturer’s instructions. Supernatants containing virions were harvested 48
h post-transfection, and used to infect HeLa-M cells24 or used in virion release assays. Titers
reported in Fig. 4b are from triplicate measurements, and errors reflect standard deviations.
Virion Release Assays
Viral supernatants and cell-associated proteins were prepared25 and analyzed by western
blotting was as described26. Primary antibodies used were rabbit anti-HIV-1 MA (1:50,000,
from D. Trono), rabbit anti-HIV-1 CA UT415 (1:1000, Covance), rabbit anti-VPS4A UT289
(1:000, Covance), and mouse anti- -Tubulin GTU-88 (1:5000, Abcam). Proteins were
detected using fluorescent secondary antibodies: 1) goat anti-rabbit ALEXA680nm (1:20,000,
Molecular Probes) or 2) donkey anti-mouse IR800nm (1:10,000, Rockland) and visualized on
an Odyssey scanner (LiCor Inc.).
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